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Abstract 
Tennekès, H.A. (1979) The relationship between microsomal enzyme induction and liver 
tumour formation - A study on the effects of xenobiotic and naturally occurring microsomal 
enzyme inducers on livers of male CF-1 mice. Agric. Res. Rep. (Versl. landbouwk. Onderz.) 
890, ISBN 90 220 0707 3, (viii) + 127 p., 5 figs, 69 tables, 193 refs. 
Also: Doctoral thesis, Wageningen. 
The effects of naturally occurring microsomal enzyme inducers on important hepato-
cellular pathways for the metabolism of foreign compounds (xenobiotics) and also upon the 
incidence of liver tumours in CF-1 mice treated or not with 10 mg dieldrin.kg diet were 
investigated using animals maintained on semi-synthetic diet and filter paper bedding as 
controls. The results of the study indicate that dieldrin administration to mice results 
in a generalized liver enlargement predominantly due to hyperplasia. Liver enlargement in 
dieldrin-treated mice was followed by the appearance of nodular liver tumours, first 
observed at the age of 43 weeks. Conventional rodent diet and sawdust bedding were shown 
to contain agents that induce the microsomal mono-oxygenase system of mouse liver. However, 
the extent of mono-oxygenase induction by these factors was less pronounced than that 
caused by dieldrin. In contrast to the effects of dieldrin, conventional diet and sawdust 
bedding did not cause any significant induction of secondary drug-metabolizing enzyme 
systems, e.g. epoxide hydratase, glutathione S-epoxide transferase and UDP-glucuronyl 
transferase. Histopathological examination of livers demonstrated a low incidence of 
tumours in the livers of mice not treated with dieldrin. These tumours were generally 
benign in character although a few showed morphological characteristics associated with 
malignant liver cell tumours. The overall incidence of liver tumours was significantly 
increased in dieldrin-treated animals. Both benign and malignant liver tumours were found 
in dieldrin-treated mice; the latter type of lesion showing evidence of lung metastasis. 
Conventional diet and sawdust bedding did not exert any obvious influence on the develop-
ment of 'spontaneous' tumours in the livers of male CF-1 mice. 
It is concluded that microsomal enzyme inducers such as dieldrin act by facilitating 
the expression of a pre-existing oncogenic factor, probably by inducing hyperplasia. 
Free descriptors: liver enlargement, environmental components, dieldrin, drug-metabolizing 
enzymes. 
This thesis will also be published as Agricultural Research Report 890. 
© Centre for Agricultural Publishing and Documentation, Wageningen, 1979. 
No part of this book may be reproduced or published in any form, by print, photoprint, 
microfilm or any other means without written permission from the publishers. 
Stellingen 
1. Er zijn geen aanwijzingen dat de tumor-inducerende effecten van microsomale enzyminductoren 
het directe gevolg zijn van de door deze stoffen veroorzaakte verhoging van de activiteit 
van leverbiotransformatie-enzymen. 
Dit proefschrift. 
2. Voor de schatting van een" "no toxic effect level" van microsomale enzyminductoren mag 
het enzyminducerend effect niet worden beschouwd als de meest gevoelige variable. 
Dit proefschrift. 
3. De promoverende werking van microsomale enzyminductoren op de ontwikkeling van lever-
tumoren is terug te voeren op het hyperplastische effect dat deze stoffen in de lever 
teweeg kunnen brengen. 
Dit proefschrift. 
4. De histochemische identificatie van pre-neoplastische levercellen biedt de mogelijkheid 
tot de ontwikkeling van een toets op tumor-promoverende eigenschappen van lichaamsvreemde 
stoffen. 
5. Er zijn geen aanwijzingen dat het toenemende gebruik van chemische hulpstoffen bij de 
produktie van voedingsmiddelen heeft geleid tot een waarneembare stijging in het voorkomen 
van kwaadaardige nieuwvormingen (kanker). 
D.L. Levin et al. Cancer Rates and Risks, DHEW Publications, U.S. Government 
Printing Office (1974). 
Ministerie van Volksgezondheid en Milieuhygiene. Trends in de sterfte aan kwaad-
aardige nieuwvormingen, Nederland, 1950-1972. 
6. De door Crampton et al. met histochemische methoden waargenomen depressie van centrilo-
bulaire glucose-6-fosfatase-activiteit in levers van ratten die met fenobarbital of 
butylhydroxytolueen werden behandeld, vormt een afspiegeling van hepatocellulaire hyper-
trofie. 
R.F. Crampton, T.J.E. Gray, P. Grasso & D.V. Parke, Toxicology 7: 289-306 (1977). 
7. Het aanprijzen van een levensmiddel op een wijze waarbij de indruk wordt gewekt dat de 
consumptie ervan noodzakelijk is voor het bereiken van een optimale gezondheidstoestand 
moet als misleidend worden gekwalificeerd. 
8. Bij het achterwege laten van onderzoek naar het werkingsmechanisme van tumor-induce-
rende lichaamsvreemde stoffen kan de chronische dierproef geen uitsluitsel geven over de 
door de Gezondheidsraad voorgestelde classificering van carcinogene stoffen. 
Gezondheidsraad, Advies inzake de beoordeling van carcinogeniteit van chemische 
stoffen (1978). 
9. De opleidingsmogelijkheden op het gebied van de toxicologie dienen te worden uitgebreid. 
Hierbij kan gedacht worden aan de instelling van een post-doctorale opleiding van enkele 
jaren waaraan de belangrijkste toxicologische instellingen hun medewerking verlenen. 
10. De huidige straf voor het "neerleggen" van een in kansrijke positie verkerende voet-
balspeler voordat deze het strafschopgebied heeft bereikt staat in geen verhouding tot de 
overtreding en dient te worden vervangen door een strafschop vanaf de 16-meterlijn. 
Proefschrift van H.A. Tennekes 
The relationship between microsomal enzyme induction and liver tumour formation. 
Wageningen, 17 oktober 1979 
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AAF 2-acetylaminofluorene 
BHC benzenehexachloride (all isomers) = HCH 
BHT butylated hydroxytoluene 
CD conventional rodent diet 
CPA. cyproterone acetate 
D 10 mg dieldrin.kg diet 
DDT dichlorodiphenyltrichloroethane 
DNA deoxyribonucleic acid 
DTNB 5,5'-dithiobis-(2-nitrobenzoic) acid 
F filter paper bedding 
G-6-Pase glucose-6-phosphatase 
G-6-PDH glucose-6-phosphate dehydrogenase 
GSH glutathione 
Y-GT Y"glutamyltranspeptidase 
HCB hexachlorobenzene 
HCH hexachlorocyclohexane (all isomers) = BHC 
HEOD dieldrin 
3-MC 3-methylcholanthrene 
NADPH nicotinamide-adenine dinucleotide phosphate 
NS not significant 
PCA perchloric acid 
PCB polychlorinated biphenyl(s) 
PCN pregnelonone-16a-carbonitrile 
RLW relative liver weight, i.e. liver weight.100 g~' bodyweight 
RNA ribosenucleic acid 
S sawdust bedding 
SER smooth, i.e. ribosome-free endoplasmic reticulum 
SSD semi-synthetic diet 
TCA trichloroacetic acid 
TCDD 2,3,7,8,-tetrachlorodibenzo-p-dioxin 
TX-100 octylphenoxypolyethoxyethanol 
UDPGA uridine-diphosph'oglucuronic acid 
1 Introduction 
I . 1 OBJECTIVES OF THE STUDY 
A variety of xenobiotic compounds are known to induce characteristic changes in the 
livers of laboratory animals. These changes include liver enlargement (hepatomegaly), 
usually as a result of cell enlargement (hypertrophy) or cell replication (hyperplasia), 
induction of drug metabolising enzymes, and proliferation of the smooth endoplasmic 
reticulum (SER). Such changes may not be accompanied by evidence of liver damage and in 
such cases are reversible upon withdrawal and elimination of the compound (Schulte-Hermann 
et al., 1971; Schulte-Hermann, 1974a; Wright et al., 1972, 1977; Depierre & Ernster, 1976; 
Bolender & Weibel, 1973; Böhm & Moser, 1976).Consequently, most authors regard this pheno-
menon as an adaptive response of the organ to increased functional demands. However, chro-
nic exposure of various strains of mice to dieldrin (HEOD), phenobarbitone, DDT and a-, 
ß- and Y- stereoisomers of hexachlorocyclohexane (HCH, also known as benzenehexachloride, 
BHC) may lead to the development of liver tumours (Davis & Fitzhugh, 1962; Walker et al., 
1973; Thorpe & Walker, 1973; Tomatis et al., 1972, 1974; Turosov et al., 1973; Terracini 
et al., 1973a, 1973b; Peraino et al., 1973a; Ponomarkov and Tomatis, 1976; Nagasaki et 
al., 1971, 1972; Ito et al., 1973). 
There is no apparent relationship in chemical structure between these compounds 
(Figure 1). Their main common features are that they are lipophilic at a physiological 
pH and induce the microsomal mono-oxygénase system of mammalian liver (Conney, 1967). 
This latter feature has led to the suggestion that a common property of microsomal enzyme 
inducers may be to enhance the incidence of liver tumours in susceptible animal species 
(Wright et al., 1972, 1977). 
Present experimental evidence supports the hypothesis that these compounds act by 
facilitating or exacerbating the expression of pre-existing oncogenic factors in 
susceptible animal species. Reports that microsomal enzyme inducers, such as phénobarbi-
tal, DDT, a-HCH and butylated hydroxytoluene (BHT) may also promote the formation of rat 
liver tumours from lesions previously initiated by liver carcinogens (Peraino et al., 
1971, 1973b, 1975, 1977; Schulte-Hermann, 1978) are consistent with this hypothesis. 
The contention that xenobiotic microsomal enzyme inducers may promote rather than 
initiate liver tumourigenesis is also supported by the observation that strains of mouse 
with a spontaneous incidence of liver tumours, e.g. CF-1 and C3H mice, are particularly 
susceptible to the tumourigenic effects of microsomal enzyme inducers (Walker et al., 
1973; Thorpe & Walker, 1973; Thorpe & Hunt, 1975; Tomatis et al., 1972, 1974; Turosov et 
al., 1973; Peraino et al., 1973a). 
Several reports (Ferguson, 1966; Vessel, 1967; Loub et al., 1975; Babish & Stoesand, 
1975, 1977) indicate that diets and bedding employed in toxicological studies with rodents 
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Fig. 1. Chemical formula, nomenclature and trade name(s) of microsomal enzyme inducers 
shown to be tumourigenic in mouse liver. 
may contain naturally occurring and, possible, adventitious microsomal enzyme inducers.If 
apparently unrelated xenobiotic microsomal enzyme inducers can enhance the incidence of 
liver tumours in various strains of mice, similar effects might be expected as a consequen-
ce of exposure to such naturally occurring or adventitious microsomal enzyme inducers in 
the animals' environment. Accordingly, the principal objectives of the current study were 
to determine the capacity of diets and bedding employed in this laboratory, to induce mi-
crosomal mono-oxygenases and related enzyme systems and to study the relationships between 
these effects and tumour incidence in the livers and other tissues of a susceptible strain 
of mouse, CF-1. 
The effects of a conventional rodent diet (CD) and of bedding material, e.g. soft-
wood sawdust (S), were studied using animals maintained on semi-synthetic diet (SSD) and 
filter paper bedding (F) as controls. The administration of 10 mg dieldrin.kg diet to 
some of the experimental treatment groups served as a positive control, i.e. a potent 
microsomal enzyme inducer with tumourigenic properties in various strains of mouse. 
In addition, commercial diet may contain traces of carcinogenic agents, e.g. nitro-
samines and aflatoxin Bj, (Schoental, 1974) and softwood sawdust is frequently contamina-
ted with certain wood preservatives, e.g. pentachlorophenol, dieldrin, HCB, DDT or endrin 
(Baldwin, unpublished observations). The presence of highly toxic and carcinogenic substan-
ces in the animals' environment might be a major cause of the development of 'spontaneous' 
liver tumours in tumour-susceptible strains of mouse. As a result, the administration of 
a purified semi-synthetic diet and maintenance on purified bedding, such as shredded 
filter paper, might significantly reduce the initiation of liver carcinogenesis in tumour-
susceptible strains of mouse. It was also decided to study the possible implications of 
such effects in mice treated with a potent microsomal enzyme inducer (dieldrin). The 
studies with this latter compound served as both a positive control and as an aid to 
perspective. The experiments entailed both biochemical investigations of the liver and 
histopathological assessment of the incidence of liver tumours in the various treatment 
groups. 
1.2 INDUCTION OF LIVER ENLARGEMENT BY XENOBIOTIC AGENTS 
Many drugs, insecticides, food additives and other chemicals are known to induce 
liver enlargement (Barka & Popper, 1967; Schulte-Hermann, 1974a). The chemical structures 
of the substances that induce liver enlargement vary widely and their only common feature 
is their lipid solubility at a physiological pH. Furthermore, many inducers of liver 
enlargement are substrates of the microsomal mono-oxygénase system of mammalian liver and 
are able to induce the activity of these enzymes (Conney, 1967; Schulte-Hermann, 1974a; 
Wright et al., 1977). . 
The quantities of xenobiotic inducers required to produce a measurable enlargement 
of the liver vary widely. Threshold doses observed with some compounds are shown in Table 
1. It should be noted that a considerable variation of liver sensitivity has been 
observed from one study to the other (Hodge et al., 1967). In most of the studies reported 
so far, the increment of liver weight ranged from 10°s to approximately 501, but increases 
of 100% or more have been reported (Fitzhugh & Nelson, 1947; Fitzhugh et al., 1950; Kunz 
et al., 1966a; Schlicht et al., 1968; Schulte-Hermann et al., 1974b). The capacity of a 
compound to induce liver enlargement is related to the rate of its elimination from the 
body. Kunz and co-workers (1966a) showed that hexobarbital, which is rapidly metabolized 
and excreted, produced only a small gain in liver weight, whereas the long-acting 
barbiturates phénobarbital and N-methylphenobarbital led to striking increases in relative 
liver weight (i.e. liver weight per 100 g bodyweight, RLW). 
In the course of liver enlargement, the proportions of the main cell constituents wa-
ter, protein, lipid, glycogen and RNA appear to remain unchanged. This has been shown in 
experiments in rats and mice treated with phénobarbital (Conney et al., 1960; Kunz et al., 
1966b; Schlicht et al., 1968; Agryris & Magnus, 1968), halothane (Kunz et al., 1966b), 
thiourea (Doljanski et al., 1956), a-HCH (Schlicht et al., 1968), pyrethrum (Springfield 
et al., 1975), BHT (Pascal et al., 1970), or polycyclic aromatic hydrocarbons (Arcos et 
al., 1961; Argyris & Layman, 1969). 
Enzymic profiles during the course of xenobiotic-induced hepatomegaly have also been 
studied. Stier et al. (1972) and Kunz & Schnieders (1970) measured the activities of 
several mitochondrial, microsomal and hyaloplasmic enzymes during the course of liver 
enlargement in rats exposed to barbiturates and halothane. Most enzymes catalysing inter-
mediary metabolism increased in proportion to liver size. However, microsomal NADPH-oxidase 
was more than proportionally increased after phénobarbital treatment and this finding was 
considered indicative of stimulation of drug-metabolising enzymes. 
The cellular composition of the enlarged liver was analysed by quantitative histolo-
gical procedures. Kunz et al. (1966b) and Preis et al. (1966) observed that parenchymal 
space increased from 82 to 871 and that the extra-parenchymal space was reduced from 
18 to 131 in the livers of phenobarbital-treated mice. Likewise, rat liver also showed 
decreases in extrahepatocytic space after phénobarbital treatment (Stäubli et al.,1969). 
These studies indicate that the parenchymal fraction contributed to a predominant extent 
to the enlargement of the liver by the compounds tested. 
Several inducers of liver enlargement have been shown to induce disproportionate 
increases of certain hepatocyte organelles. Remmer & Merker (1963) demonstrated that the 
exposure of rats to phénobarbital leads to a considerable augmentation of the smooth, 
i.e. ribosome-free, membranes of the endoplasmic reticulum (SER). Subsequent studies re-
vealed that hepatocellular SER was increased by many of the compounds that induce liver 
growth, including a-HCH (Koransky et al., 1966), DDT (Ortega, 1966), chlordane (Fouts & 
Rogers, 1965), BHT (Lane and Lieber, 1967; Botham et al., 1970), dieldrin (Wright et al., 
1972), and others (Meldolesi, 1967). In some studies (Ortega, 1966; Meldolesi, 1967; 
Wright et al., 1972) formation of concentric whorls of SER was observed. A quantitative 
electron microscopic analysis of the liver of phenobarbital-treated rats, performed by 
Stäubli et al. (1969), revealed the quantitative importance of cytoplasmic changes in 
liver enlargement with endoplasmic reticulum accounting for more than half of the in-
crease in cytoplasmic volume. 
1.2.1 Hyperplasia and hypertrophy 
Liver enlargement may involve an increase in cell size or cell number or a combina-
tion of the two. The terms 'hypertrophy' and 'hyperplasia' are commonly used to describe 
these events. Conventionally, 'hypertrophy' means an increase in cell volume and 'hyper-
plasia' an increase in cell number. However, this morphological definition has limited 
usefulness in the liver, which contains cells of different ploidy (Barka & Popper, 1967; 
Epstein et al., 1967). Enlargement of a cell, without changes in cell ploidy, clearly 
represents hypertrophy. However, when cell enlargement is associated with an increase 
in cell ploidy - which requires DNA replication - there is no change in the ratio of 
nuclear volume to cytoplasmic volume and the only deviation from conventional hyperplasia 
is the absence of cell division, i.e. an increase in ploidy may be regarded as an arrested 
form of cell replication. 
For this reason, Barka & Popper (1967) have defined hypertrophy as an increase in 
cell size without an increase of cell ploidy and hyperplasia as any increase in genetic 
material of the liver, whether derived from an increase in cell ploidy or from cell 
division. This definition simplifies the description of liver enlargement. In morphologic 
terms, the characteristic of hypertrophy is a decrease in the ratio of nuclear volume to 
cellular volume; in biochemical terms it is a relatively decreased DNA concentration per 
cell. Hyperplasia per se, on the other hand, is characterised by a constant ratio of nu-
clear and cellular volume and a constant DNA concentration. 
The relative contribution of hypertrophy and hyperplasia to chemically induced liver 
enlargement appears to depend on various factors, such as the dose and properties of the 
inducer, and species and strain of the animals. In studies with rats, dieldrin and phéno-
barbital are reported to induce predominantly liver cell hypertrophy, while a-HCH and BHT 
elicited predominantly hyperplasia (Wright et al., 1972; Schulte-Hermann, 1971, 1974a, 
1974b, 1979). The results of studies with dieldrin and phenobarbltone in various species 
(Wright et al., 1972, 1977, 1978) indicated that liver cell hypertrophy occurred in rats, 
mice and dogs exposed to these compounds. In the case of dieldrin-treated rhesus monkeys, 
only the first indications of hepatocellular hypertrophy, as evinced by marginal increases 
in microsomal protein were present in the absence of obvious liver enlargement. No in-
creases in the DNA content of the liver were detected in rats or dogs when these animals 
were exposed to high doses of dieldrin or phénobarbital, indicating that hyperplasia does 
not make a significant contribution to the dieldrin- or phenobarbitone-induced liver en-
largement in these species. Total liver DNA was also unaltered in rhesus monkeys fed 
dieldrin at concentrations of up to 5 mg.kg-1 for 6.5 years (Wright et al., 1978). In the 
mouse, however, liver DNA content was increased from the outset of exposure to both 
dieldrin and phénobarbital. Hyperplasia and hypertrophy were reported to make a similar 
contribution to the overall enlargement of the liver. 
1. 2. 2 Intralobular differences 
Fitzhugh and his associates (1947, 1950) reported that administration to rats of DDT 
or a-HCH led to marked enlargement of centrilobular hepatocytes while periportal cells 
were not enlarged. Similar observations were made later in studies with DDT (Ortega, 1966; 
Thorpe & Walker, 1973), other chlorinated hydrocarbon insecticides (Ortega et al.,1957) 
and phénobarbital (Kunz et al., 1966b). Increases in diameter or number of nuclei were 
not observed in the centrilobular cells (Fitzhugh & Nelson, 1947; Fitzhugh et al., 1950; 
Kunz et al., 1966b) indicating that hypertrophy was the cause of enlargement rather than 
increased ploidy. 
Electron microscopic analysis revealed that proliferation of SER occurred predomi-
nantly in the vicinity of the central vein of the liver lobule (Burger & Herdson, 1966; 
Becker & Lane, 1968). These observations support findings (Stäubli et al., 1969) indi-
cating that SER multiplication is an important factor in cell hypertrophy after phéno-
barbital administration. 
While hypertrophy predominates in the centrilobular area, proliferating cells have 
been found in all parts of the lobule, but preferentially in the periportal and midzonal 
areas (Grisham, 1973). 
1.2.3 Dose-dependence ' 
The extent of liver enlargement clearly depends on the dose of the inducer used. 
This relationship has been demonstrated in studies with barbiturates (Kunz et al., 1966a), 
pyrethrum (Springfield et al., 1973), a-HCH (Schulte-Hermann et al., 1974b), DDT (Hoff-
man et al., 1970), BHT (Gilbert & Golberg, 1965) and dieldrin (Wright et al., 1972). 
Above the range of the respective threshold doses, a linear relationship appears to 
exist between the increase of liver mass and the logarithm of the dose. This relationship 
appears valid when the inducing compound is administered only once (Schulte-Hermann et 
al., 1974b) but also upon daily administration for several days or weeks (Kunz et al., 
1966a; Hoffman et al., 1970; Gilbert & Golberg, 1965). Likewise, hepatic DNA is increased 
in proportion to the logarithm of the dose (Schulte-Hermann, 1974b). Toxic effects of 
the inducers have limited attempts to determine maxima of the growth responses of the 
liver (Kunz et al., 1966a; Hoffman et al., 1970; Schulte-Hermann et al., 1974b). Studies 
with a-HCH (Schlicht et al., 1968; Schulte-Hermann et al., 1974b) revealed that this 
compound can increase RLW by more than 1001. An even higher increase in RLW, i.e. almost 
2001, was observed in rats bearing pituitary tumours that excreted excessive amounts of 
pituitary hormones (Epstein et al., 1967; Milkovic et al., 1964). 
1,2.4 Reversibility of liver enlargement 
Liver weight returns to normal when the administration of the inducing substance 
ceases. This observation was made in studies with barbiturates (Kunz et al., 1966a; 
Schlicht et al., 1968; Owen et al., 1971), pyrethrum (Springfield et al., 1973), a-HCH , 
(Schlicht et al., 1968; Schulte-Hermann et al., 1971), DDT (Fitzhugh & Nelson, 1947), 
dieldrin (Ferrigan et al., 1965) and BHT (Schulte-Hermann et al., 1971; Gilbert & Gol-
berg, 1967). 
The rate at which liver enlargement recedes seems to be closely related to the rate 
of elimination of the inducer. Hence, liver weights in rat and mouse return to normal 
levels within a few days when compounds with relatively short biological half-lives, 
such as phénobarbital (Kunz et al., 1966a; Schlicht et al., 1968) or BHT (Gilbert & Gol-
berg, 1967) are used. A return to normal liver weight may take weeks when chlorinated 
hydrocarbons such as DDT (Fitzhugh & Nelson, 1947) or a-HCH (Schlicht et al., 1968) are 
used. 
The increased amount of endoplasmic reticulum also returns to normal when administra-
tion of the inducer is discontinued (Bolender & Weibel, 1973). Excess membranes, induced 
by phénobarbital treatment, were removed within 5 days after the end of treatment. During 
the regression phase an increase in the number of autophagic vacuoles occurred which 
suggests that, in addition to a biochemical turnover, specific cellular mechnisms may be 
responsible for the bulk-removal of phenobarbital-induced membranes (Bolender & Weibel, 
1973). 
Conflicting results have been reported on the fate of the excess of liver cells (due 
to hyperplasia) in the regression period. After discontinuation of phénobarbital treat-
ment of rats, the increased number of nuclei was found to be reduced (Argyris & Magnus, 
1968). In contrast, experiments with a-HCH and BHT indicated.that the elevation of the 
total DNA content persisted throughout the period of regression of the increased liver 
size (Schulte-Hermann et al., 1971). Schulte-Hermann (1974a) suggested that the apparent 
reduction in the differences between the liver DNA content of control and experimental 
animals, observed in some studies, might be due to developmental growth of control livers 
during the regression period. It would seem that, in contrast to other changes in the li-
ver, there is no certainty at present about the fate of the induced excess of liver cells 
during regression. 
1.3 ENZYME INDUCTION BY XENOBIOTIC COMPOUNDS 
1.3.1 Mono-oxygenase 
The oxidative catabolism of lipophilic substrates is catalysed by an enzyme system 
which requires both NADPH and molecular oxygen and is designated mono-oxygenase(s) or 
mixed-function oxidase (s). This membrane-bound system is one of the most versatile enzyme 
complexes known. It metabolizes not only endogenous substrates such as steroids and fatty 
acids but also a variety of foreign compounds, e.g. drugs, insecticides, and carcinogens. 
Reactions catalysed include aromatic and aliphatic hydroxylation, N-, 0-, and S- dealkyla-
tion, sulfoxidation, deamination, epoxidation, desulfuration and dehalogenation (Conney, 
1967; Gillette et al., 1972). 
The system consists of a flavoprotein referred to as NADPH -*• cytochrome c-reductase 
and a hemoprotein (cytochrome); in addition phosphatidyl-choline is required for catalytic 
activity (Lu et al., 1969; Lu & Levin, 1974). Substrate specificity resides in the hemo-
protein moiety, and it has been found that at least six different forms of these cyto-
chromes exist in the liver which differ in catalytic activity towards various substrates 
as well as in molecular weight and in immunological and spectral properties (Thomas et al., 
1976). On the basis of spectral properties the hemoproteins are frequently referred to as 
cytochrome P-450 or cytochrome P-448. It is quite likely that the activity of each of the 
various hemoproteins is under different genetic control and may, therefore, be influenced 
differently by various groups of xenobiotic inducers. 
The concentration of cytochrome P-450 exceeds that of the mitochondrial cytochromes 
(Estabrook et al., 1971) and comprises approximately 11 of the total liver proteins 
(Schulte-Hermann, 1974a). Cytochrome P-450 may increase several-fold after treatment with 
xenobiotic compounds (Conney, 1967). 
There are two 'classical' groups of xenobiotic inducers of hepatic mono-oxygénas es. 
The first group, represented by phénobarbital, stimulates the degradation of many sub-
strates (e.g. ff-demethylation of aminopyrine, ethylmorphine, benzphetamine), the second, 
exemplified by 3-methylcholanthrene (3-MC), stimulates the hydroxylation of benzpyrene 
but has little or no effect on most other oxidative pathways (Conney, 1967; Gillette et 
al., 1972). These observations have now been explained by the preferential synthesis of 
catalytically different cytochromes (P-450 and P-448) induced by the two groups of in-
ducers (Haugen & Coon, 1976a; Haugen et al., 1976b; Thomas et al., 1976). 
More recent evidence suggests that there are probably more than two groups of micro-
somal enzyme inducers. Thus, ethanol was found to stimulate microsomal mono-oxygenase(s) 
with a high capacity for aniline hydroxylation (Villeneuve et al., 1976). Pregnelenone-
16ct-carbonitrile' (PCN) and other steroids may represent another group of enzyme inducers 
(Lu et al., 1972) and polychlorinated biphenyls (PCB) and hexachlorobenzene (HCB) produce 
a pattern of induction that resembles a mixture of the changes produced by phénobarbital 
and 3-MC (Alvares et'al., 1973; Stonard & Greig, 1976). 
1.3.2 Epoxide hydratase, glutathione transferase and UDP-glucuronyl transferase 
Induction of hepatic mono-oxygenases is frequently associated with increased activi-
ties of other enzyme systems, which also serve to metabolise lipophilic substrates. 
Epoxide hydratase catalyses the hydration of epoxides, highly reactive and toxic 
intermediates which may arise from aromatic hydrocarbons and other substrates by mono-
oxygenase action. Hepatic epoxide hydratase activity is elevated substantially by pre-
treatment of rats and mice with phenobarbitone and to a lesser extent by pre-treatment 
with 3-MC (Oesch et al., 1971, 1973). PCN has also been reported to induce a slight in-
crease in hepatic epoxide hydratase activity (Oesch, 1975). 
The glutathione transferases which employ glutathione (GSH) as a co-substrate also 
play a prominant role in the inactivation of toxic intermediates. A broad spectrum of 
structural types may undergo spontaneous or enzyme-mediated conjugation with glutathione 
in vivo leading ultimately to the formation of ff-acetyl cysteine conjugates (mercapturic 
acids) which may be excreted via the bile or as urinary metabolites (Boyland & Chasseaud, 
1969; Chasseaud, 1973, 1976). Rat liver cytosol contains at least 6 different GSH trans-
ferases of broad and overlapping specificities, including the anion-binding ligandin or 
transferase B (Jakoby et al., 1976). 
Glutathione transferases are inducible by common inducers of hepatic mono-oxygenases, 
such as phénobarbital, TCDD (2,3,7,8-tetra chlorodibenzo-p-dioxin) and PCN (Klassen & 
Plaa, 1968; Darby and Grundy, 1975; Kaplowitz et al., 1975; Jenna & Bend, 1977). 
The liver microsomal UDP-glucuronyl transferase system constitutes another group of 
enzymes which can be induced by treatment with foreign compounds. Glucuronidation is a 
major pathway by which the body inactivates and eliminates a wide variety of lipid-soluble 
endogenous and exogenous compounds such as phenols, carboxylic acids, aliphatic and aroma-
tic alcohols and certain aromatic amines (Dutton, 1966). There is accumulating evidence 
for the existence of a number of UDP-glucuronyl transferases each possessing different sub-
strate specificities. These enzymes can be selectively induced by different types of indu-
cing agents. For example, treatment of rats with phénobarbital induces the glucuronidation 
of chloramphenicol and bilirubin whereas pretreatment of the animals with 3-MC induces 
the glucuronidation of 1-naphthol and p-nitrophenol (Dutton, 1966; Bock et al., 1973). 
Interpretation of these data is somewhat complicated by the latency of the enzymes, i.e. 
glucuronyl transferases can be activated up to 10-fold in vitro by addition of detergents 
(Bock & White , 1974). Latency may be due to conformational restraints within the intact 
endoplasmic reticulum. 
1.4 INDUCTION OF LIVER TUMOURS BY MICROSOMAL ENZYME INDUCERS 
1. 4.1 Carcinogenicity studies in mice 
The first carcinogenicity studies conducted in mice exposed to a microsomal enzyme 
inducer (dieldrin) were reported by Davis & Fitzhugh (1962). The results of this study 
were inconclusive because the majority of animals were not available for pathological 
examination. However, in a second study, the feeding of 10 mg dieldrin.kg"1 diet shortened 
the life-span of C3HeB/Fe mice by 2 months and increased the incidence of liver tumours. 
It should be noted, however, that the latter study showed a very poor survival time 
(average survival time: S1.4 weeks in treated mice compared with 59.8 weeks in controls) 
and that a substantial proportion of the animals was discarded at autopsy: 70/218 dieldrin-
treated mice and 83/217 control animals. Thus, these experiments failed to provide conclu-
sive evidence on the tumourigenicity of the compound in this species. 
Another series of experiments with dieldrin in the CF-1 mouse were reported by Walker 
et al. (1973) and Thorpe & Walker (1973). In the main experiment, 87 - 297 mice of each 
sex were fed diets containing either 0, 0.1 , 1.0 or 10.0 mg dieldrin.kg-1 for 132 
weeks (Table 2). Fifty percent mortality was reached at 15 months among mice fed 10 mg 
dieldrin.kg diet and at 20 months in the other groups. The liver tumour incidence (Table 
2) was enhanced in all of the three dieldrin treatment groups. The highest incidence of li-
ver tumours was observed in mice exposed to 10 mg dieldrin.kg diet: 94°s in males and 
92°6 in females. CF-1 mice fed on 0.1 and 1.0 mg dieldrin.kg" diet showed a similar inci-
dence of liver tumours (25-351 in both males and females). The results of a second dose-
response study, in which exposure lasted for 128 weeks, showed that the incidence of liver 
tumours was enhanced in all of the five dieldrin treatment groups (1.25, 2.5, 5.0, 10.0 
and 20.0 mg dieldrin.kg-1 diet, both in male and female CF-1 mice). 
Neither of these studies with dieldrin in the CF-1 mouse produced a clear-cut dose-
response relationship. However, it was clearly demonstrated that high doses of dieldrin 
invariably induced a high incidence of liver tumours. Furthermore, clear dose-response 
relationships may never be established when the survival of the animals is adversely 
affected by continuous exposure of mice to high doses of the test compound. On the other 
hand, it is interesting to note that, in the main experiment (Table 2), dieldrin enhanced 
the incidence of liver tumours when ingested at a dietary concentration of 0.1 mg kg . 
This concentration is below the reported threshold dose for the induction of liver enlar-
gement (Fitzhugh et al., 1964; Walker et al., 1969). 
It would seem, therefore, that even though high doses of dieldrin are required to 
produce a maximum increase of the incidence of liver tumours in CF-1 mice, this compound 
may exert tumourigenic effects in livers of this strain of mouse at very low levels of 
exposure. 
In a subsequent study (Walker et al., 1973), groups of male CF-1 mice were fed on 
10 mg dieldrin.kg diet for up to 64 weeks and allowed to live until 104 weeks. The re-
sults of this study (Table 3) show that short-term exposure of mice to dieldrin, e.g. 
8 weeks, produced a highly significant increase in the incidence of liver tumours (404 
in treated mice versus 11% in controls). However, the highest incidence of liver tumours 
(1001) was found in mice receiving the compound for the longest period of time (64 weeks). 
In an unpublished experiment (Thorpe & Hunt, 1975) a study was made of the patholo-
gical changes in three strains of mice (CF-1, LACG and CF-1 x LACG ) following chronic 
dieldrin administration (10 mg.kg-1 in the diet). The results of this study (Table 4) 
suggest considerable strain differences in susceptibility to the tumourigenic effects of 
dieldrin. Hybrid (LACG x CF-1) mice responded with liver tumour formation in a somewhat 
similar fashion to CF-1 mice, but fewer liver tumours were found in treated LACG mice 
and in males the increased risk was only marginally significant. 
Among several hundred mice with liver tumours, metastases were found in only 15. 
Unpublished studies (Thorpe, 1973) showed that liver cell tumours from mice that had 
received prolonged oral exposure to dieldrin were capable of autonomous growth as sub-
cutaneous transplants without recourse to the use of immuno-suppressive agents. This 
latter finding was highly suggestive of the malignant character of the liver tumours. 
In recent years, a number of reports have been published showing that certain other 
microsomal enzyme inducers also exerted tumourigenic effects on mouse liver. 
A 2-generation dose-response study on the feeding of DDT to CF-1 mice involving a 
total of 881 treated and 224 control mice was reported by Tomatis et al. (1972). Dietary 
concentrations of 2, 10, 50 and 250 mg technical DDT.kg-1 were administered for life-
span. In both parent (P) and Fi generation mice an increased incidence of liver tumours 
was observed in all males exposed to DDT particularly in those exposed to the highest 
concentration (Table 5). The administration of 2 and 10 mg DDT.kg" diet to parent and 
Fi generation female mice, however, did not result in a significant excess over control 
levels of liver-cell tumours. An incidence of 131 was observed in (P + Fj) females given 
50 mg DDT.kg diet (significant at the 5% level only). A high incidence of liver tumours 
was observed in females of both generations exposed to 250 mg DDT.kg" diet (63$ in P and 
71'o in F^. A later study by the same group of workers, reporting on the effects of DDT 
on 6 consecutive generations of CF-1 mice (Turosov et al., 1973), confirmed these results. 
The results of both studies with DDT in the CF-1 mouse (Tomatis et al., 1972; Turo-
sov et al., 1973) suggest that the tumourigenic potential of this compound is more easily 
expressed in males than in females. However, it is interesting to note that in these ex-
periments females showed a lower background incidence of liver tumours. In experiments 
with CF-1 mice showing no clear sex difference in spontaneous liver tumour incidence 
(Walker et al., 1973; Thorpe & Walker, 1973), the tumourigenic effects of DDT were found 
to be similar in males and females. 
A 2-generation study with DDT involving a total of 515 female and 431 male BALB/c 
mice was reported by Terracini et al. (1973a, 1973b). DDT was administered at dietary 
concentrations of 2, 20 or 250 mg.kg-1 for life-span. A comparison of the results from 
this study with those from studies conducted with DDT in the CF-1 strain of mouse (Toma-
tis et al., 1972; Turosov et al., 1973; Walker et al., 1973; Thorpe & Walker, 1973) 
strongly suggests that the latter strain, which generally exhibits a relatively high in-
cidence of spontaneous liver tumours, is more susceptible to the tumourigenice effects 
of DDT than BALB/c mice. The occurrence of spontaneous liver tumours in BALB/c mice is 
rare (Andervont & Dunn, 1948; Deringer, 1965; Madison et al., 1968; Smith & Pilgrim, 
1971; Terracini et al., 1973a). 
In more recent experiment, reported by Tomatis et al. (1974), groups of 60 male and 
60 female CF-1 mice were given 250 mg DDT.kg"1 diet for 15 or 30 weeks after which the 
mice were killed at different time intervals (at 65, 95 and 120 weeks after initiation of 
the experiment. The results of this study are similar to those reported by Walker et al. 
(1973) on the tumourigenicity of dieldrin in the CF-1 mouse and suggest that a limited 
period of exposure to microsomal enzyme inducers results in an increased appearance of 
liver tumours similar to that caused by life-span exposure. The shorter the period of ex-
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posure the lower the incidence of liver tumours. In this context, it is interesting to no-
te that life-span exposure of CF-1 mice to 250 mg DDT.kg" diet resulted in a higher inci-
cence of liver tumours than 30-weeks exposure. 
Several recent carcinogenicity studies with phenobarbitone have shown that this 
'classical' microsomal enzyme inducer may also enhance the incidence of liver tumours 
in mice (Table 6). This effect has been demonstrated in strains of mice that are known 
to be susceptible to 'spontaneous' development of liver tumours, e.g. CF-1 mice (Thorpe 
& Walker, 1973; Ponomarkov et al., 1976) and C3H mice (Peraino et al., 1973a). 
Similarly, several stereo-isomers of HCH have now been found to possess tumourigenic 
potential in mice (Table 7). The results of two studies by Ito and co-workers indicate 
that a-HCH may induce liver tumours in male dd mice within 6 months of exposure (Nagasaki 
et al, 1971, 1972; Ito et al., 1973). This group found no evidence for tumourigenic 
potential of other stereo-isomers. However, a study by Thorpe & Walker (1973) showed 
that ß- and -y-HCH may enhance the incidence of liver tumours in CF-1 mice. 
CONCLUSIONS 
The carcinogenicity studies discussed above have clearly established that various 
microsomal enzyme inducers, such as dieldrin, DDT, phenobarbitone, a, 8 and y HCH are 
tumourigenic in livers of various strains of mouse. 
The tumourigenic effects of microsomal enzyme inducers have been shown to be pronoun-
ced in strains of mouse that show a relatively high incidence of spontaneous liver tumours 
(Thorpe & Walker, 1973; Walker et al., 1973; Tomatis et al., 1972; Turosov et al., 1973; 
Peraino et al., 1973a; Ponomarkov et al., 1976) whereas strains of mouse with a low 
background incidence of liver tumours appear to be less susceptible (Thorpe & Hunt, 1975; 
Terracini et al., 1973a, 1973b). 
The tumourigenic effects of the inducer were most pronounced when high doses of the 
compound were used. Moreover, a positive relationship appears to exist between the 
duration of treatment with an inducer and the incidence of liver tumours (Walker et al., 
1973; Tomatis et al., 1974). On the other hand, it has been demonstrated that microsomal 
enzyme inducers may enhance the incidence of liver tumours at exposure levels below the 
threshold doses for the induction of liver enlargement (Walker et al., 1973; Turosov et 
al., 1973; Tomatis et al., 1972). 
Therefore it would seem that some compounds exert tumourigenic effects at very low 
levels of exposure, even though maximum enhancement of the incidence of liver tumours in 
susceptible strains of mouse may require protracted treatment with high doses of a micro-
somal enzyme inducer. 
1.4.2 Carcinogenicity studies in rats 
The first chronic feeding study with a microsomal enzyme inducer (DDT) in rats was 
published by Fitzhugh et al. (1947). A total of 228 animals (Osborne-Mendel Strain) re-
ceived diets containing technical DDT at concentrations of 0, 100, 200, 400, 600 and 800 
mg.kg" . The mortality in DDT-treated groups was very high and of the initial 192 rats ex-
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posed to the compound only 81 survived at least 18 months. After 18-24 months of feeding, 
four rats were reported to have 'low-grade' hepatic cell carcinomas and eleven rats showed 
nodular adenomatoid hyperplasia (nodules measuring up to 3 mm). Although no liver tumours 
were found in control rats, hepatic-cell tumours have been reported to occur spontaneously 
in H of the rats in this colony (Fitzhugh et al., 1947). The authors concluded that 'DDT 
showed a minimal tendency to cause formation of hepatic cell tumours'. 
A second carcinogenicity study with DDT in Osborne-Mendel rats was reported by 
Radomski et al. (1965) and Deichmann et al. (1970). Thirty males and 30 females were 
exposed for 24-27 months to either 80 or 200 mg DDT.kg-1 diet and compared with two con-
trol groups of 30 animals of each sex. Two liver tumours were found in the experiment: 
one occurred in a control female and the other in a female given 200 mg DDT.kg diet. 
Incidences of other tumours were similar in control and treated rats. 
Weisburger & Weisburger (1968) reported an experiment in which a group of 15 male 
and 15 female Fisher rats were given a dose of 10 mg DDT per rat by stomach tube, 5 times 
a week starting at weaning. Treatment lasted one year, and survivors were observed for 
a further 6 months. No liver tumours were found. However, the duration of this study was 
too short and the number of rats per treatment group too small to warrant any firm con-
clusion. 
Recently Rossi et.al. (1977) reported an experiment in which 37 male and 35 female 
Wistar rats were fed on diets containing 500 mg DDT.kg-1 for life-span (Table 8)- Thirty-
six male and 35 female rats served as controls. Of the animals that survived the time at 
which the first liver nodule was observed in a DDT-treated female (at 80 weeks), 9 out of 
26 treated males (34.64) and 15 out of 27 females (55.H) were found to bear liver nodules 
at death. No liver nodules occurred in controls. There was no evidence of metastases to 
the lungs or any other organ. The authors classified these lesions as neoplastic nodules 
even though there was no evidence of invasive properties. Furthermore, the observed nodu-
les occurred - very late in life - in the presence of liver damage including centrilobular 
necrosis and fatty degeneration. The occurrence of nodular hyperplasia in rats chronically 
exposed to very high doses of DDT could thus represent a form of regenerative liver growth. 
Consequently, this study provides no convincing evidence for the tumourigenicity of DDT in 
rats. 
Rossi et al. (1977) also investigated the effects of chronic treatment of Wistar 
rats with another potent microsomal enzyme inducer, phenobarbital-Na (Table 8). The 
compound was administered at a concentration of 500 mg/1 in the drinking water to 36 
male and 34 female seven-week-old Wistar rats for life-span. Twenty-two males and 28 
females were still alive when the first liver nodule was reported at about 99 weeks. At 
the termination of this experiment, when the animals had reached an age of 152 weeks, 
13 males and 9 females had developed hepatic nodules. No hepatic nodules were observed 
in a group of 36 male and 35 female control rats. The incidences of non-hepatic neo-
plasms were comparable in the test and control groups of rats. The effects of phenobar-
bitone were thus similar to those observed with DDT. 
In a recent study reported by Butler (1978), male inbred Fisher rats were fed on 
diets containing 1000 mg phenobarbitone-Na.kg"1 for 103 weeks. Of 33 treated rats survi-
ving 80 weeks and more, 11 showed foci of nodular hyperplasia in the liver. The foci 
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were usually small, but one rat killed at 102 weeks had a lesion of 0.75 cm diameter, 
which compressed the surrounding liver. In no case was evidence of local invasion or meta-
stasis found. Thus this experiment provided no evidence to suggest that phenobarbitone-
Na induced neoplasms in rat liver. 
The studies by Rossi et al. (1977) and Butler (1978) both failed to establish that 
phenobarbital-induced liver nodules possessed invasive properties, even though the 
observation period in one of these studies (Rossi et al., 1977) lasted nearly 3 years. 
Consequently, it would seem incorrect to classify these lesions as neoplastic growth. As 
both studies yielded evidence of liver damage in phénobarbital-treated rats, it is not 
unlikely that the observed liver nodules represent a hyperplastic response to compound-
induced liver necrosis. 
Several carcinogenicity studies with dieldrin in the rat have been published in the 
last 15 years (Table 9). Fitzhugh et al. (1964) reported an experiment in which groups 
of 12 male and 12 female Osborne-Mendel rats were fed on diets containing 0, 0.5, 2, 10, 
50, 100 or 150 mg dieldrin.kg for two years. Survival rates were decreased at 50 mg 
dieldrin.kg" and higher doses and the tumour incidences in these groups have little com-
parative value. In groups of rats given 0.5, 2 or 10 mg dieldrin.kg , the number of tu-
mour-bearing (= all tumours) animals were 8/22, 8/23 and 4/18 at 0.5, 2 and 10 mg dieldrin. 
kg , respectively, compared with 3/17 in the controls (Table 9). In these groups, the 
survival rate was comparable with that in the controls (75°s at 18 months). The authors 
claimed that there was evidence of 'some general type of effect that increased tumour pro-
duction, without causing any single type of tumour to predominate'. However, the diffe-
rence between 20/63 tumour-bearing rats in the treated groups and 3/17 in the controls is 
not significant (x2= 0.71, P ^  0.05). The authors did not observe any liver tumours in 
this study. 
A subsequent carcinogenicity study performed by Walker et al. (1969) also failed 
to demonstrate an increased overall tumour incidence in rats exposed to dieldrin (Table 9). 
Diets containing 0.1, 1.0 and 10.0 mg dieldrin.kg"1 were administrated to groups of 25 
male and 25 female CFE rats for two years. A group of 45 males and 45 females served as 
controls. The authors reported that 3 female rats on 10 mg dieldrin.kg" and one control 
female rat showed focal proliferation of liver parenchymal cells to form microscopic no-
dules. Liver tumours were not observed. 
Two studies with dieldrin in rats were published recently (National Cancer Institute, 
1978a) (Table 9). In the first study, dieldrin was administered to groups of 50 Osborne-
Mendel rats of each sex at either a low or a high dieldrin concentration. Time-weighted 
average doses were 29 (low dose) or 65 mg dieldrin.kg diet (high dose). Low-dose rats 
were treated for 80 weeks, followed by 30-31 weeks of observation. Treatment of high-dose 
rats was terminated after 59 weeks and followed by an observation period of 51-52 weeks. 
Matched controls consisted of groups of 10 untreated rats of each sex. Pooled controls 
consisting of the matched control groups combined with untreated animals from similar bio-
assays of other chemicals (58 male and 60 female rats) were used for statistical evalua-
tion. All surviving rats were killed at 110-111 weeks. A low incidence of hepatocellular 
carcinomata was observed with no increased frequency for treated groups over controls 
(males: one control and one 'high-dose' animal; females: one 'low-dose' and one 'high-
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dose' animal). 
In the second study (National Cancer Institute, 1978b) groups of 24 Fisher 344 rats 
of each sex were administered either 0, 2, 10 or 500 mg dieldrin.kg" diet for 104-105 
weeks (Table 9). Survival was not adversely affected by treatment. A variety of neoplasms 
occurred in control and treated rats, but incidence was not related to treatment. No 
liver tumours were observed. However, 2 control males (81) and four males on 50 mg dieldrin 
.kg-1 diet showed evidence of nodular hyperplasia. These lesions were classified as non-
neoplastic. 
The four studies with dieldrin described above have thus failed to demonstrate 
tumourigenic effects of the compound on rat liver. 
The results of an early study with the a-,6-and y-stereoisomers of hexachlorocyclo-
hexane (HCH), published by Fitzhugh et al. (1950), indicated that these compounds were 
not tumourigenic in the rat..However, the validity of this study is questionable. The 
experimental group sizes were small (10 male and 10 female rats per group) and the survi-
val rates were very poor: mean age was 58 weeks in a group of 40 controls and 33-70 weeks 
in experimental groups. 
Recently, Ito et al. (1975) observed hepatocellular carcinomas in a few Wistar rats 
fed on a diet containing 1,000 or 1,500 mg a-HCH.kg"1 for 72 weeks (Table 10). There 
was also a high incidence of nodular hyperplasia in these treatment groups. Other isomers 
of HCH were tested for periods up to 48 weeks, which is far too short to warrant any 
conclusions on the (non-)tumourigenicity of these compounds in rats. 
CONCLUSIONS 
Long-term studies in rats with DDT, phénobarbital and dieldrin have provided no evi-
dence of carcinogenicity of these compounds in this species (Fitzhugh et al., 1964; 
Walker et al., 1969; NCI studies, 1978a, 1978b; Radomski et al., 1965; Deichmann et al., 
1970; Rossi et al., 1977; Butler, 1978). 
The apparent non-tumourigenicity of these microsomal enzyme inducers in rats has 
led to the opinion that the tumourigenic effects of these agents on mouse liver constitute 
species-specific events and may consequently bear no relevance to other mammalian spe-
cies, including man (van Raalte, 1973). This has resulted in a considerable controversy 
regarding the use of the laboratory mouse in carcinogenicity testing (Tomatis et al., 1973; 
Grasso & Crampton, 1972). In the case of a-HCH, however, there are indications that this 
compound may possess tumourigenic potential in mice (Nagasaki et al., 1971, 1972; Ito 
et al., 1973) and rats (Ito et al., 1975). Consequently, the contention that the tumouri-
genic effects of microsomal enzyme inducers in various strains of mouse are species-
specific events per se may not be a valid generalization. On the other hand, there can 
be little doubt that some strains of mouse are highly sensitive to the tumourigenic effects 
of these compounds. 
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1.4.3 Carcinogenicity studies in other mammalian species 
To date, there are only a few long-term studies with microsomal enzyme inducers in 
mammalian species other than rats and mice. 
Two long-term feeding studies with DDT were conducted in hamsters by Agthe et al. 
(1970) and Graillot et al. (1975), respectively. The results of these studies provided no 
evidence of tumourigenicity of DDT in this species. 
Agthe et al. (1970) fed groups of 30 male and 30 female Syrian Golden Hamsters on 
diets containing 500 or 1000 mg DDT.kg-1 for 44 weeks. Survivors at 50 weeks were 70/115 
treated versus 59/79 control animals. All treated animals and 62/79 controls had died 
by the 90th week. Eleven treated hamsters developed tumours at different sites (including 
one liver tumour) as did 8 controls. 
Graillot et al. (1975) fed groups of 30 male and 40 female hamsters on diets con-
taining 0,- 250, 500 or 1000 mg DDT.kg for a period of 78 weeks and observed no lesions 
which could be attributed to DDT-treatment. 
A study with DDT in the dog was published by Lehmann (1965). A total of 22 animals 
approximately equally divided by sex were fed either 0 (2 dogs), 400 (2 dogs), 2000 (4 
dogs) or 3200 (14 dogs) mg DDT.kg" diet. Only the control dogs, the 2 dogs given 400 mg 
DDT.kg and 2 of the dogs receiving 2000 mg DDT.kg" survived until they were killed 
(39-49 months). This study, in which no liver tumours were observed in any of the dogs, 
was clearly too short to warrant any conclusions on the chronic toxicity of the compound. 
Similarly, a chronic study reported by Walker et al. (1969) with dieldrin (daily 
oral doses of 0, 0.005 and 0.05 mg.kg-1 body weight) in dogs was terminated after only 
two years - no liver tumours were found - and provides no indications on the tumourigeni-
city of dieldrin in the dog. 
In a study reported by Wright et al. (1978) Rhesus monkeys were fed on diets contai-
ning 0 mg dieldrin.kg-1 (5 animals), 0.01 mg dieldrin.kg-1 (4 animals), 0.1 mg dieldrin. 
kg"1 (5 animals), 0.5 mg dieldrin.kg"1 (5 animals), 1.0 mg dieldrin.kg"1 (4 animals), 
1.75 mg dieldrin.kg"1 (2 animals) and 5.0 mg dieldrin.kg"1 (1 animal) for periods up to 
6.5 years. Although at the end of this period no obvious alteration in general structure, 
colour or texture was observed in the livers of dieldrin-treated animals, this study can-
not be regarded as a valid carcinogenicity study in a primate species. 
CONCLUSIONS 
The results of two chronic feeding studies with DDT in hamsters indicate that this 
compound is not tumourigenic in this species (Agthe et al., 1970; Graillot et al., 1975). 
However, non-rodent studies conducted to date with dieldrin (Walker et al., 1969; 
Wright et al., 1978) and DDT (Lehmann, 1965) cannot be regarded as valid carcinogenicity 
studies and warrant no conclusions on the tumourigenicity of these agents in these spe-
cies . 
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1.4.4 Epidemiological observations in man 
Microsomal enzyme inducers such as phenobarbitone (an anti-convulsant drug used in 
the treatment of epilepsy), DDT (agricultural pesticide, also successfully applied in 
anti-malaria programs) and dieldrin (agricultural pesticide) have been in use for more 
than three decades and retrospective epidemiological studies may thus provide evidence 
on the hazards of these compounds to man. 
The first study on plant workers exposed to DDT was reported by Ortelee (1958). 
Forty men engaged in the manufacture or formulation of DDT were medically examined. 
Twenty-eight of the men were under 39 years of age, 7 between 40 and 49, and 5 over 50. 
The length of exposure at the time of the study was less than 1 year for 2 workers, 1-4 
years for 21 workers and 5-8 years for 17 workers. The clinical and laboratory studies 
conducted (history, physical and neurological examination, blood counts and haemoglobin, 
sulfobromophtalein, Cholinesterase, urinary excretion of DDA) revealed no ill effects 
attributable to DDT. No evidence of neoplasia was found among the 40 workers at the time 
of investigation. However, this study cannot, for a variety of reasons, provide evidence 
on the tumourigenicity of DDT in man. The experimental group was small and the majority 
of the patients were at an age at which the occurrence of human cancer would not be ex-
pected. Furthermore, the observation period was limited to 8 years at maximum, which 
•would seem far too short. 
In 1966 a study was made of 35 plant workers with 11-19 years (average 15 years) of 
exposure to high concentrations of DDT (Laws et al., 1967). The ages of these workers 
ranged between 30 and 63 years (mean: 43 years). Findings from medical history, physical 
examination, routine clinical laboratory tests, and chest X-ray film did not reveal ill 
effects attributable to exposure to DDT. No cancer was reported in any of the workers. 
A follow-up study on liver function utilizing the same group of men was initiated in 1972 
(Laws et al., 1973). By that time the duration of exposure to DDT ranged from 16-25 years 
with a mean and median of 21 years. No clinical indications of hepatotoxicity, hepatic 
enlargement or liver dysfunction were observed. The results of serum a-fetoprotein analy-
ses were negative in all 20 of the men for whom the test was performed. This study was 
also based on a small group of occupational^ exposed workers. The fate of workers who 
had left the mdustry was not investigated. Liver cancer is relatively rare in the Western 
world and a study of a small group of occupationally exposed workers does not constitute 
a sufficiently sound basis for the prediction of safety of the compound in the human si-
tuation. 
Di6ld
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were still employed by the firm at the time of the study, and their average age was 41 
years (range 22-64). Only 2 deaths had occurred, and one had been caused by stomach can-
cer. Fifty-two workers who had left the company have been the subject of a subsequent re-
port (Versteeg & Jager, 1973). The average age of this group was 47.4 (range 29-72) years, 
average occupational exposure was 6.6 years (4.0-12.3) and average time since the end of 
exposure was 7.4 years (4.5-16). Only one death was recorded, and this had not been caused 
by cancer. 
The results of these studies - so far - indicate that dieldrin causes no liver tu-
mours in occupationally exposed workers. Again, the size of the experimental group is 
relatively small for a thorough epidemiological study (233 patients) and the occurrence 
of only one case of liver cancer would result in serious problems of interpretation. 
The carcinogenicity of anti-convulsant drugs (including phénobarbital) in man was 
studied by Clemmesen et al. (1974) in a retrospective investigation conducted on 9,136 pa-
tients admitted to the Danish epilepsy centre "Filadelfia" between 1933 and 1962. The 
patients were treated with phénobarbital (100-300 mg), Phenytoin (100-400 mg) or primi-
done (500-1500 mg) daily. In patients treated for up to 10 years, the incidence at all 
sites except the liver was the same as or lower than that expected when compared with the 
incidence of the general population in Denmark. In patients treated for more than 10 
years, 3 cases of liver cancer were observed in males, whereas 1.1 were expected, and 1 
liver cancer was observed in a female where 0:7 was expected. In males, treated for less 
than 10 years, 1 liver cancer was observed where 0.4 was expected. Clemmesen et al. (1974) 
reported that one man with liver cancer had been treated with thorotrast, a known liver-
carcinogen, 18 years before death. In patients treated for more than 10 years, tumours of 
brain and nervous system were observed in 10 males (expected 3.5) and 6 females (expec-
ted 2.9). 
Schneidermann (1974) reconsidered these results with respect to liver tumours and 
suggested that the cases of liver cancer might represent an increased incidence, but 
Clemmesen (1975) reported that 3 out of the 4 liver cancers seen in male patients had pre-
viously been treated with thorotrast which is known to induce liver tumours in man 
(Kiely et al., 1973; Macmahon et al., 1947; Mann et al., 1976 ; Smoron et al., 1972). 
CONCLUSIONS 
The epidemiological evidence obtained with dieldrin and DDT is not sufficiently 
strong to indicate safety of these compounds in the human situation (Ortelee, 1958; Laws 
et al., 1967, 1973; Hoogendam et al., 1962, 1965; Jager, 1970; Versteeg & Jager, 1973). 
In contrast, the epidemiological studies conducted by Clemmesen and his associates 
(1974, 1975) with phénobarbital have established that pharmacological doses of the com-
pound have no adverse effect on human health. The epidemiological evidence obtained with 
phénobarbital, which was shown to be tumourigenic in mice (Walker et al., 1973; Peraino 
et al., 1973a; Ponomarkov et al. 1976), supports the contention that 'no toxic effect 
levels' of xenobiotic inducers in humans exist. 
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1.5 MECHANISTIC ASPECTS OF LIVER TUMOUR FORMATION BY MICROSOMAL ENZYME INDUCERS 
Several mechanisms can be envisaged by which xenobiotic enzyme inducers may exert 
tumourigenic effects in mammalian liver. 
1. Homeostatic mechanisms might gradually be deranged by chronic treatment with xeno-
biotic inducers. It has been suggested that prolonged exposure to excessive functional 
demands favours the development of tumours and there is evidence from studies with va-
rious organs to support this concept (Becker, 1971). If this were so in the case of micro-
somal enzyme inducers, one would expect to find signs of autonomy of growth and enzyme 
production in mammalian liver during protracted treatment with these compounds. Present 
evidence from several studies indicates that the short-term increases in liver size, DNA 
synthesis and enzyme activities produced by a-HCH (Schulte-Hermann, 1979), phénobarbi-
tal (Crampton et al., 1977), BHT (Crampton et al., 1977) or dieldrin (Wright et al., 1972, 
1977) did not increase any further by protracted treatment with these enzyme inducers. 
Even after 80 weeks, the changes induced by phénobarbital in rat liver were reversible on 
cessation of treatment and re-induced by phénobarbital to the same extent as by the 
initial treatment (Crampton et al., 1977). 
2. Microsomal enzyme inducers or their metabolites might induce somatic mutations, 
i.e. alterations in the nucleotide sequence in the DNA genome. Such alterations may re-
sult from covalent attacks of ultimate carcinogens on DNA or conceivably from indirect 
mechanisms involving covalent binding to RNA or specific proteins (Miller, 1970). This 
concept of chemical carcinogenesis assumes that somatic mutations are primary events in 
carcinogenesis and, therefore, ultimate carcinogens are considered to be mutagens. 
The possibility that dieldrin or one of its metabolic products exerts its tumouri-
genic action on mouse liver by a direct interaction with DNA has been explored by study-
ing the extent of binding of radioactivity to the liver DNA of rodents exposed to | l H Cj-
dieldrin in vivo (Wright et al., 1977). The results of these studies indicated that very 
small amounts of an unidentified biotransformation product of dieldrin became tightly 
bound to the liver DNA of the CFE rat, the CF-1 mouse and the LACG mouse (Table 11). The 
extent of binding correlated with the rate of dieldrin metabolism in these animals (Hutson, 
1976); the more rapid the metabolism the greater the binding. Thus, binding was highest 
in the CFE rat, intermediate in the CF-1 mouse and lowest in the male LACG mouse. However, 
the CFE rat has been reported to be resistent to the induction of liver tumours by diel-
drin (Walker et al., 1969) and consequently, there would seem to be no correlation be-
tween the extent of binding to liver DNA and susceptibility to liver tumour formation. 
The possibility that in vivo exposure to dieldrin might cause DNA strand breakage 
has been investigated in the livers of rats and mice. No single strand breakage was detec-
ted in the livers of either species after acute exposure to high doses of dieldrin 
(Wright et al., 1977). 
Dieldrin has also been evaluated for mutagenic activity in a variety of test systems. 
The compound gave negative results in the Salmonella-microsome test system (Bidwell et 
al., 197S). Dominant lethal assays and host-mediated assays with dieldrin on male CF-1 
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mice have also yielded negative results (Dean & Doak, 1975). A mutagenic event due to in-
tercalation can be ruled out because of the globular structure of dieldrin. It would thus 
seem that dieldrin is devoid of mutagenic activity or potential, which makes it unlikely 
that an interaction between the compound and liver DNA could be responsible for the liver 
tumours. 
3. The induction of hepatic mono-oxygenases by microsomal enzyme inducers could render 
the liver more susceptible to tumour formation as a result of an increased capability 
to synthesise proximate or ultimate carcinogenic forms of exogenous or endogenous pre-
carcinogens. 
In many instances, co-administration of carcinogens with microsomal enzyme inducers 
has been reported to result in reduced rather than in enhanced carcinogenesis (Kunz et 
al., 1969; Peraino et al., 1971). These reports suggest that other cellular factors may 
also influence the generation of carcinogenic reactivity from pre-carcinogens. These 
factors could include rates and modes of transport to the enzyme(s), levels and affini-
ties of physiological and foreign substrates, e.g. inducer, and activities of enzyme sys-
stems which catalyse the subsequent metabolism of the primary products of mono-oxygénase 
action, e.g. epoxide hydratase, glutathione s-epoxide transferase and UDP-glucuronyl 
transferase. An assessment of the relative contributions of these factors to the overall 
rate of in vivo activation of pre-carcinogens is very difficult, which may explain some 
of the contradictory results which have been obtained to date. 
The relationship between microsomal enzyme induction and liver tumour formation is 
a central theme of this thesis and will be subject of further discussion in Chapter 4. 
4. The induction of cell replication sensitises liver cells to initiating effects 
of carcinogenic chemicals. Increased susceptibility of dividing cells to experimentally 
administered carcinogens appears well documented (Pound & Lawson, 1975; Craddock, 1975; 
Delia Porta & Terracini, 1969). However, the relevance of this mechanism for situations 
in which no carcinogen is deliberately administered is difficult to assess (Schulte-
Hermann, 1979). 
5. Microsomal enzyme inducers promote the expression of a pre-existing oncogenic 
factor in susceptible animal species. The high incidence of 'spontaneous' liver tumours 
in some strains of mice (Walker et al., 1973; Thorpe & Walker, 1973; Tomatis et al., 
1972; Turosov et al., 1973; Tomatis et al., 1974; Peraino et al., 1973a; Ponomarkov & 
Tomatis, 1976) strongly suggests the existence of such a factor in these animals. Promo-
ting effects by xenobiotic inducers on hepatocarcinogenesis have, in fact, been demon-
strated. The administration of phénobarbital to rats previously treated with 2-acetylamino-
fluorene, a known liver carcinogen, accelerated the appearance/ of liver tumours and in-
creased the number and growth rate of tumor foci' (Peraino et al., 1971, 1973b, 1975, 1977). 
The promoting effect of phénobarbital on liver tumour formation was confirmed using 
diethyl-nitrosamine (DENA) as a tumour-initiating agent (Weisburger et al., 1975). 
Several other microsomal enzyme inducers including DDT (Peraino et al., 1975), 
BHT (Peraino et al., 1975), PCB (Kimura et al., 1976) and a-HCH (Schulte-Hermann, 1978) 
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were also found to promote the formation of liver tumours from previously induced lesions 
by hepatocarcinogens. 
CONCLUSIONS 
There is no evidence at present to indicate that microsomal enzyme inducers have muta-
genic activity or potential [Wright et al., 1977; Bidwell et al., 1975; Dean & Doak, 1975) 
and it appears unlikely that an interaction between microsomal enzyme inducers and liver 
DNA could be responsible for the induction of liver tumours in various strains of mouse. 
However, microsomal enzyme inducers, such as phénobarbital, DDT, BHT, PCBs and a-HCH, 
were found to promote the formation of liver tumours in rats previously treated with liver 
carcinogens such as 2-MF or DENA (Peraino et al., 1971, 1973b, 1975, 1977; Weisburger 
et al., 1975; Kimura et al., 1976 Schulte-Hermann, 1978). 
This experimental evidence suggests that the tumourigenic effects of various micro-
somal enzyme inducers in susceptible strains of mouse could be due to promotion of the 
expression of pre-existing oncogenic potential in these animals. This hypothesis is 
supported by the observation that susceptible strains of mouse possess a background inci-
dence of 'spontaneous' liver tumours (see Section 1.4.1). 
1.6 RATIONALE OF EXPERIMENTATION 
Experimental evidence indicates that the susceptibility of various strains of mouse 
to the tumourigenic effects of microsomal enzyme inducers could well be related to the 
presence of pre-existing oncogenic potential in these animals: firstly, susceptible 
strains of mouse, e.g. CF-1 and C3H mice, show a relatively high incidence of 'spontaneous' 
liver tumours (see Section 1.4.1) and, secondly, there is evidence to indicate that va-
rious microsomal enzyme inducers promote the development of liver tumours in rats pre-
viously treated with liver carcinogens such as 2-MF or DENA (see Section 1.5). 
Consequently, the formation of liver tumours in mice exposed to microsomal enzyme 
inducers could well be due to promotion of the expression of pre-existing oncogenic fac-
tor(s) in these animals. 
The aim of the present study was to investigate the effects which environmental 
factors, e.g. the animal diet and bedding, might have on the 'spontaneous' incidence of 
liver tumours in a tumour-susceptible strain of mouse (CF-1). Both environmental factors 
are known to contain naturally occurring microsomal enzyme inducers (Ferguson, 1966; Ves-
sell 1967; Loub et al., 1975; Babish
 & Stoewsand, 1975, 1977). Additionally, commercial 
t l ?rL^tain traCeS ° f C a r C i n°e e n i c « ' e.g. nitrosamines or aflatoxin Bx 
(Schoental, 1974) and softwood sawdust (S) is frequently contaminated with 'moth proofing' 
wood preservatives, e.g. pentachlorophenol, dieldrin, HCB, DDT or endrin (Baldwin, un-
published publications). 
éiceTjTTti0nr ^ if aPParently Unrelated Xen0hi°U° •*="»«*1 -zyme in-
tf ts I h V l ^incidence of liver tumours in various strains of mouse, similar 
eff c s might be expected from naturally occurring microsomal enzyme inducers in the 
mouse's environment. 
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In addition, the presence of carcinogenic substances in the animal's environment 
might be a major cause of the development of 'spontaneous' liver tumours in tumour-
susceptible strains of mouse. The administration of a purified semi-synthetic diet and 
maintenance on purified bedding, such as shredded filter paper, might, therefore, signi-
ficantly reduce the initiation of liver carcinogenesis in tumour-susceptible strains of 
mouse. It was decided to study the possible implications of such effects in mice treated 
with a potent microsomal enzyme inducer (dieldrin). 
1.7 SELECTION OF PARAMETERS FOR BIOCHEMICAL INVESTIGATIONS IN MOUSE LIVER 
One of the main objects of the present study was to investigate the relationship 
between microsomal enzyme induction (by naturally occurring agents in diet and bedding 
and by a xenobiotic inducer) and liver tumour formation in a susceptible strain of mouse 
(CF-1). The activities of four drug-metabolizing enzyme systems were selected for assay: 
1. Mono-oxygenase p-Nitroanisole O-demethylation was used as an index of liver mono-
oxygenase activity. As was described in Section 1.3.1, several substrates should ideally 
be used to achieve proper perspective in the type of mono-oxygenase induction caused by 
the various experimental factors. However, practical considerations i.e. that such assays 
could be conducted only at the expense of assays of other drug-metabolizing enzyme systems, 
imposed limitations on the number of substrates used for the determination of liver mono-
oxygenase activity. 
2. Epoxide hydratase This enzyme catalyses the hydration of epoxides, highly reac-
tive and toxic intermediates which may arise from aromatic hydrocarbons and other sub-
strates by mono-oxygenase action (see Section 1.3.2). Epoxide hydratase may be induced 
by classical inducers, such as phenobarbitone and 3-MC. Enhancement of the enzyme activity 
by experimental factors could affect the generation of proximate and ultimate carcinogenic 
forms of environmental pre-carcinogens. Interaction between epoxide hydratase and diel-
drin was considered likely because of the epoxide ring in the dieldrin molecule. 
3. Glutathione S-epoxide transferase This enzyme system also plays a prominant role 
in the inactivation of toxic intermediates formed by mono-oxygenase action and may, simi-
lar to the activity of epoxide hydratase, affect the formation of proximate and ultimate 
carcinogens. The enzyme activity is inducible by microsomal enzyme inducers such as phéno-
barbital (see Section 1.3.2). 
4. UDP-Gluowonyl transferase This enzyme system is implicated in the metabolism 
of dieldrin in mammals (Hutson, 1976). In addition, glucuronidation constitutes a major 
pathway by which the body inactivates a wide variety of lipid-soluble endogenous and exo-
genous compounds. The activity of these enzymes may, therefore, be relevant to the fate 
of reactive metabolites formed by mono-oxygenase action. The enzyme(s) are inducible by 
common microsomal enzyme inducers such as phénobarbital and 3-MC. (see Section 1.3.2). 
21 
Information on the type of liver enlargement in the various experimental treatments 
was provided by livev DNA assays. As described in Section 1.2.1, changes in the liver DNA 
concentration and in the total DNA content of the liver are indicative of the occurrence 
of hypertrophy or hyperplasia or a combination of the two. In addition, many of the re-
sults were expressed on a liver DNA weight basis in an attempt to relate the measurements 
directly to number of liver cells. 
Gluoose-6-phosphatase (G-6-Pase) activity was measured in whole liver homogenates 
and liver microsomes. G-6-Pase being located exclusively in the endoplasmic reticulum of 
hepatocytes was used as a marker enzyme for the microsomal fraction. The recovery of micro-
somal protein after subcellular fractionation was based on the retention of G-6-Pase in 
the microsomal fraction. In addition, depression of G-6-Pase activity has been observed 
after treatment with a range of liver toxins and liver carcinogens (Feuer et al., 196S). 
Consequently, G-6-Pase assays also served to monitor toxic effects of experimental fac-
tors on hepatocytes. 
Similarly, glutathione assays were conducted to provide further information on the 
effects of reactive, i.e. electrophilic, metabolites formed from naturally occurring or 
synthetic compounds in diet and bedding. 
The concentration of dieldrin was routinely assayed in livers of dieldrin-treated 
mice and mice not treated with dieldrin (hereafter referred to as non-dieldrin treated 
mice). The results of these assays served to indicate to what levels of dieldrin the li-
vers of dieldrin-treated mice had been exposed and also provided a check on the possibili-
ty that dieldrin-containing diets might, at some stage, have been erroneously given to 
non-dieldrin treated mice. 
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2 Animal experiments, methods and materials 
2.1 ANIMAL EXPERIMENTS 
2.1.1 Design 
The effects of a conventional rodent diet were studied using a purified (semi-
synthetic) diet, compounded in this laboratory, as control. Shredded filter paper was 
used as an alternative bedding to softwood sawdust and dieldrin was chosen as a model 
xenobiotic microsomal enzyme inducer known to increase the incidence of liver tumours in 
the CF-1 mouse (Walker et al., 1973; Thorpe & Walker, 1973). Investigation of each of 
these factors, singly and in combination resulted in 8 experimental treatments (Table 12). 
2.1.2 Breeding schedule 
The purpose of the schedule was to produce male CF-1 mice that had been continually 
exposed to specific experimental regimes during both the pre-natal and post-natal periods. 
Practical considerations, i.e. liver biochemistry in sufficient animals of equal age per 
treatment group, necessitated a phased breeding schedule: male CF-1 mice were bred and 
reared during each week of a 6-week period. 
Each week over a 6-week period, 32 virgin female CF-1 mice (8 weeks old at a time 
of allocation) were randomly allocated to eight different treatments (= 4 female mice 
per treatment). The females were housed individually. Two weeks after allocation to 
treatments, a randomly chosen virgin male CF-1 mouse of the same age was assigned to each 
female. The males remained with the females until the presence of vaginal plugs indicated 
that the females had been mated. Individual females and their offspring were maintained 
on the specific pre-mating treatments during gestation and pre-weaning phases. After 
weaning, each male offspring was maintained on the same treatment as his female parent. 
Males from the same treatment group and of the same age were housed together (up to 5 
mice per cage). Parent females and female offspring were discarded. Numbers of male CF-1 
mice weaned off in each treatment group are shown in Table 13. 
Dieldrin-treated parent females showed signs of hyper-irratability which resulted 
in an increased occurrence of litter destruction. As a consequence the size of some of 
the dieldrin treatments was smaller than anticipated. Mice were killed at intervals for 
biochemical and morphological investigations of their livers. 
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2.1. S Maintenance 
The animals were housed in plastic cages approximately 30 x 13 x 12 'cm with a wire 
mesh top and a layer of sawdust or shredded filter paper on the bottom. The cages were 
cleaned twice weekly. The temperature of the animal room was maintained at 20 + 2°C and 
both feed and water (local mains supply) were offered ad libitun. Throughout the trial, 
the animals were inspected daily and killed when moribund. 
2.2 METHODS 
2. 2.1 Préparation of liver homogenates and subcellular fractions 
The animals were killed by cervical dislocation. The livers were quickly excised, 
the gall bladder was removed and the tissue was chilled in ice-cold 0.25 M (isotonic) 
sucrose solution, pH 7.4, for a few minutes. In livers with macroscopic nodules, the no-
dular tissue was separated from host liver tissue whenever the size of the lesion(s) 
would allow all of the biochemical measurements to be carried out (ca. 500 mg tissue). 
Nodular tissue was then worked up as a separate sample at the expense of one of the 
control livers. Small nodule(s), comprising not more than a total of a few hundred mg 
were not separated from the rest of the tissue and results were classified as those ob-
tained in non-nodular liver tissue. The livers and where appropriate, host tissue and 
nodular tissue, were weighed. Weighed samples of tissue were pressed into a homogenising 
tube and homogenised in approximately 6-7 ml of ice-cold isotonic sucrose solution, pH 
7.4. Fifteen passes of the pestle with a clearance of 0.01 inch (0.252 mm) were used at 
1452 rev/min. The final volume of the homogenate was adjusted to 101 w/v by the addition 
of ice-cold isotonic sucrose (PH 7.4). Ten ml of liver homogenate was fractionated by 
centrifugation at 11,000 * for 15 minutes to remove cell debris, nuclei and mitochondria 
and subsequently at 200,000
 g for 40 minutes to obtain the microsomal and soluble frac-
tion. The microsomal pellet was resuspended in 5 ml 0.25 M sucrose solution (pH 7.4). 
2.2. 2 Enzyme assays 
2.2.2.1 p-Nitroanisole O-demethylase 
P-Nitroanisole O-demethylase activity was assayed to monitor mono-oxygénase activity 
in accor ance with the method described by Netter
 & Seidel 0964). For the standard assay 
btff H T T ; ln ' t0tal V O l m e ° f 4 - ° 4 5 "*• C ° n t a i n e d 5° « " * Tris-chloride 
1 7 TLLV 7? 8 C l 2' 17'2 Um01 d i S ° d i U m ^cose-6-phosphate, 1.52 pmol 
7 1 ' LT, Tl°Se-6-*h°^ dehydrogenase (1 unit will oxidise 1
 ymol of glucose-
W o 1 6 - p h ° S p h 0 8 l ™ e P - •*»*« at pH 7.4 at 25°C in the presence o N M * * ) . 
ni rlLi T 'T 1" (COntaining 1-S"3-0 ^ ° f *"***• ^ 8 - 1 * V-
k n a ^ ' f t 1< Vl ° f a œt0ne JUSt P r i ° r t0 inCUbati0n^ I» •**•« wa sha-
S 1 ml f 2 H I h;V0T 1° " ^ ln alr- ^  r e a C t i ° n - S ***** * * » édition 
of 1 ml of 20. w/v trichloroacetic acid (TCA). Enzyme activity was determined in dupli-
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cate and compared with a blank (boiled microsomal suspension). After the addition of TCA, 
the precipitated protein was removed by centrifugation and 1 ml of 201 w/v Na2CO, was 
added to the recovered supernatant. p-Nitrophenol concentration was estimated by 
ring the extinction at 420 ran in a Unicam SP 600 spectrophotometer and comparison with a 
range of standard solutions. 
2.2.2.2 Epoxide hydratase (EC. 4.2.1.63) 
The activity of this microsomal enzyme was measured as described by Oesch et al.(1971) 
using |7-3H|-styrène oxide as a substrate. Incubation mixtures in a final volume of 0.4 
ml, contained 5 ymol Tris-chloride buffer (pH 8.7 at 37°C), 100 yg Tween 80, 0.2 ml of 
microsomal suspension (containing 0.5-1.2 mg of protein), and 1.01 nmol |7-3H|-styrene 
oxide (11 x 101* disintegrations per minute, dpm) which was added in 25 yl of acetonitrile 
just prior to incubation. After incubation at 37°C for 10 minutes, the reaction was ter-
minated by the extraction of the substrate into 10 ml of light petroleum (b.p.40-60°). 
The organic phase was removed by freezing the aqueous phase in dry ice-acetone and de-
canting the light petroleum. After thawing, the extraction procedure was repeated and 
the product, |7-3H|-styrene glycol, was subsequently extracted from the aqueous phase 
into 2 ml of ethylacetate. Duplicate aliquots (0.2 ml) were counted in 10 ml of NE 260 
micellar scintillator solution. Boiled enzyme preparations (5 min, 100 C) served as con-
trol. 
2.2.2.3 UDP-glucuronyl transferase (EC 2.4.1.17) 
The activity was assayed by measuring the rate of glucuronidation of p-nitrophenol 
in the presence of uridine-diphosphoglucuronic acid (UDPGA) and Triton X-100 (octyl-
phenoxypolyethoxyethanol) as described by Pogell & Krismann (1960). The reaction mixture, 
in a final volume of 0.6 ml, contained 50 ymol of phosphate buffer (pH 7.3), 118 nmol 
UDPGA, 1.2 yl TX-100, 0.2-0.3 ml of microsomal suspension (containing 0.5-1.5 mg of pro-
tein), and 100 nmol p-nitrophenol. The incubation mixture was shaken at 37 C for 30 minu-
tes. The reaction was stopped by the addition of 0.1 N TCA (2.4 ml). Enzyme activity was 
determined in duplicate and compared with a blank which was prepared by omitting UDPGA in 
the incubation mixture. After the addition of TCA, precipitated protein was removed by 
centrifugation and 10 N potassium hydroxide (60 yl) was added to the recovered superna-
tant. The concentration of p-nitrophenol was determined by measuring the extinction at 
400 nm in a Unlearn SP 600 spectrophotometer and comparison with a range of standard solu-
tions . 
2.2.2.4 Glutathione S-epoxide transferase (EC 4.4.1.7) 
A convenient radiometric assay using styrene oxide as a substrate was described by 
James et al. (1976). Styrene oxide is known to conjugate spontaneously with glutathione, 
and therefore the feasibility of this assay was checked under conditions of optimal sub-
strate concentrations. Incubation mixtures contained 100 ymol Tris-chloride buffer (pH 
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7.4, 37°C), 7.5 ymol reduced glutathione, 0.25 mg soluble fraction protein and water in 
a total volume of 1.5 ml. The tubes were placed in a shaking water bath at 37 C for a few 
minutes to attain this temperature. The reaction was started by adding the substrate 
(styrene oxide) in solution in acetonitrile (50 yl). Three different substrate concentra-
tions were employed: 5 ymol | 7-3H|-styrene oxide (5.5 x 105 dpm) per incubation mixture 
(3.33 mM), 10 ymol (1.1 x 106 dpm) per incubation mixture (6.67 nM), and 25 ymol (2.75 x 
106 dpm) per incubation mixture (16.67 mM). Boiled enzyme preparations served as controls. 
After an incubation time of 5 minutes the reaction was terminated by adding 4 ml ethyl-
acetate and vigorous mixing. Unreacted styrene oxide and any styrene glycol formed (by 
non-enzymic hydration) were extracted in the organic phase leaving the glutathione 
conjugate, in this case S-(2-hydroxy-1-phenylethyl)glutathione, in the aqueous phase. The 
ethylacetate layer was removed and the extraction repeated twice. Duplicate aliquots of 
the aqueous phase (0.5 ml) were subsequently counted in 10 ml NE 260 scintillation 
mixture. 
The results indicated that spontaneous conjugation increased linearly with substrate 
concentration (Figure 2). The optimal substrate concentration under these assay conditions 
was in the region of 15 mM. When the highest substrate concentration (16.7 mM) was em-
ployed, the spontaneous conjugation accounted for approximately 35»o of the total reaction. 
Spontaneous conjugation occurred exclusively with glutathione. Omission of the soluble 
protein fraction in the incubation mixture or replacement by an equivalent amount of bo-
vine serum albumin resulted in identical rates of spontaneous conjugation. On the basis 
of this evaluation it was decided to employ styrene oxide at a concentration of 16 irM 
for routine assays. For these assays, the soluble fraction was diluted ten times with 
0.25 M sucrose (pH 7.4), yielding a protein 
concentration of approximately 0.5 mg.ml 
PRODUCT 
(nmoles per 
minute) 
100 (109.1) 
3.33 6.67 16.67 
SUBSTRATE CONCENTRATION (mM) 
epoxide ^12«.1 . ' tSS1«^^^ t ^|~,SrT a ^ e 3nd UVer *"• thion**-
v i t ro . Details of assay conditions are Z,r.A Z ^ ~ s ^ ^ e <*"« with glutathione in 
enZ y m i c conjugation, /non-enzyï ïc c o ^ u g a t l o n l b o U e d ' ' * * ' * T ° t a l ^ ^ ^ ' • 
i-uujugacion (.boiled enzyme suspension). 
26 
2.2.2.S Glucose-6-phosphatase (EC 3.1.3.9) 
G-6-Pase activity was measured in whole liver homogenates and in liver microsomal 
fractions. The enzyme activity was determined by a modification of the method described 
by Harper (1965). Samples were diluted with 0.25 M sucrose solution (pH 7.4) and to dupli-
cate portions (0.2 ml) was added a solution of disodium glucose-6-phosphate (0.2 ml; 
0.08 M) in 0.1 M citrate buffer, pH 6.5. The mixtures were incubated for 10 minutes at 
37 C. Enzymic reaction was stopped by the addition of 10.81 v/v TCA (5 ml). Boiled liver 
homogenates or liver microsomes served as controls. After the addition of TCA, liberated 
inorganic phosphate was determined in the protein-free supernatant by a method described 
by Fiske & Subbarow (1925). 
2. 2. 3 Chemical assays 
2.2.3.1 Protein 
Homogenised tissue samples and samples of microsomal and soluble fractions were 
diluted with distilled water to a protein concentration of approximately 100 yg/ml and 
the protein content was determined (Lowry et al., 1951) by comparison with a series of 
standard solutions containing 0-200 yg/ml of crystalline bovine plasma albumin. 
2.2.3.2 Liver DNA 
Homogenised tissue samples (2 ml) were washed three times with 10 ml 0.2 N perchlo-
ric acid (PCA) at 0°C. Deoxyribonucleic acid was subsequently extracted in 2 x 3 ml 0.5 N 
PCA by heating at 70°C for 15 minutes. The nucleic acid extract was adjusted to 10 ml 
with 0.5 N PCA and deoxyribonucleic acid content was measured colorimetrically with the 
diphenylamine reaction described by Burton (1956). 
2.2.3.3 Reduced glutathione 
Homogenised tissue samples (1 ml) were deproteinized by the addition of absolute 
ethanol (1.9 ml) and 150 mM m2V0h, pH 5.5 (0.1 ml), and subsequent centrifugation (John-
son, 1966). Glutathione content was measured in the protein-free supernatant with 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB) as described by Beutler et al. (1963). The disad-
vantage of the DTNB-method is its non-specificity: the reagent also conjugates with 
thiols other than glutathione. Two independent groups of workers (Crowley et al., 1975; 
Moron et al., 1977) have compared the results obtained with the DTNB-method with those 
obtained with a specific enzymatic assay for reduced glutathione based on the use of 
a glutathione S-transferase. The results of these investigations indicate that for tissues 
such as lung and liver, these two methods give nearly identical results so that the use 
of the DTNB-method in the present study, seems justifiable. 
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2.2.3.4 Liver dieldrin concentration 
A sample of liver homogenate (1 ml) was stirred with acetone-washed, dried, anhydrous 
sodium sulphate until the sample was dry. The mixture was extracted with 4 x 25 ml 2 : 1 
v/v hexane : acetone over a steam hath. The extract was boiled to almost dryness and the 
residue was dissolved in approximately 2 ml hexane. Non-polar components in the extract 
were separated from dieldrin on a column containing 3 g deactivated (with 31 water) 
florisil. Hexane (25 ml) and H acetone/hexane (25 ml) were used as eluents. The latter 
fraction was analysed by gas-liquid chromatography with electron capture detection for 
dieldrin (temperature: 190°C; gas: 5$ methane, 955» argon; flow rate: 50 ml/min). The re-
covery of dieldrin was determined by spiking liver homogenate from a control animal with 
a suitable dieldrin standard (1 ml of 0.5 yg.ml-1). The recovery efficiency ('») based on 
18 separate analyses was 91.0 + 6.0 (mean + standard deviation, range 79-100%). 
2.2.4 Statistics 
Results obtained in the various treatment groups were analysed on statistical sig-
nificance with Student's t-test using mice maintained on SSD and F as controls. This 
test was also used when data obtained in dieldrin-treated mice were analysed versus data 
obtained in respective non-dieldrin treated mice. 
A comparative statistical analysis of data obtained in non-nodular and nodular liver 
tissue was performed using Student's paired t-test. 
2.3 MATERIALS 
2.3.1 Diets 
The standard laboratory feed used was Laboratory Animal Diet 2 (LAD 2) supplied by 
Spillers Ltd., Newmarket, Suffolk, U.K. The chemical composition of this diet, based on 
data supplied by the manufacturer, is shown in Table 14. Batches of diet were routinely 
analysed on the presence of aflatoxins (Bx, B2, d and C2) by the British Food Manufac-
turing Industries Research Association, Leatherhead, Surrey, U.K. The results of these 
analyses were negative throughout the trial. The possibility that other toxins, e.g. 
mtrosamines, were present in this diet was not investigated. Semi-synthetic diet was 
compounded in this laboratory on the basis of the 1969 recommendations of the Laboratory 
Animals Association (LASA) Nutrition Study Group (Dietary standards for laboratory rats 
and mice, 1969). The composition of this diet is shown in Table 15. Folic acid was not 
included m the diet since the requirement of this vitamin is satisfied through copro-
phagy (Hötzel & Barnes, 1966). Potato starch served as an indigestible diet component 
(Jelnick et al., 1952). 
Casein, sucrose and mineral components were supplied by British Drug Houses Chemicals 
Ltd Poole, Dorset, U.K. Most vitamins were purchased from Sigma Chemical Company Ltd., 
London with the exception of vitamins A, D, E and K which were supplied by Roche Pro-
ducts Ltd Dunstable, Bedfordshire, U.K. Com oil (Mazola brand) was purchased locally. 
Corn starch and potato starch were obtained from Rickards Ltd., Beckingham, Kent, U.K. 
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2. 3. 2 Bedding materials 
Sawdust bedding material was obtained from W.P. Ushers Ltd., London. This softwood 
bedding is derived predominantly from Douglas Fir (Pseudotsuga spp.) grown in the Scan-
dinavian countries. Samples of sawdust, taken at various time intervals, were analysed 
(by g.l.c. with electron capture detection) for common chemicals and pesticides used as 
'moth proofing' agents in wood preservation (Baldwin, pers. commun.). The results of 
these analyses indicated that pentachlorophenol was the main contaminant in this type of 
softwood bedding (concentrations ranging between 0-100 yg/g sawdust). The concentrations 
of dieldrin, HCB,
 Y-HCH, S-HCH, endrin, pp'DDE, pp'DDD and pp'DBT were negligible (< 0.1 
•vg/g) • 
The second type of bedding material was prepared by shredding Whatman filter paper 
No. 1 (supplied by Scientific Furnishings Ltd., Chichester, Sussex, U.K.). 
2. 3. 3 Chemicals 
|7-3H|-styrene oxide was purchased from the Radiochemical Centre, Amersham, Bucking-
hamshire, U.K. The compound was prepared by the oxidation of |7-3H|-styrene with m-
chloroperoxybenzoic acid, and purified by solvent extraction and fractional destination 
(bp 88°C, 26 mm). Radiochemical purity was demonstrated by thin layer chromatography on 
silica gel GF plates with authentic styrene oxide in four different solvent systems: 
benzene-chloroform (1 : 1 by vol.); benzene-light petroleum (1 : 1 by vol.); chloroform-
light petroleum (1 : 1 by vol.); benzene-ethylacetate-chloroform ( 1 : 1 : 1 by vol.). 
After dilution with freshly distilled styrene oxide to a specific activity of 50 uCi/mmd 
(0.42 yCi/mg), the product was stored at -15°C. p-Nitroanisole was obtained from Eastman 
Organic Chemicals, Rochester, New York. Glucose-6-phosphate (disodiumsalt), NADP, glucose-
6-phosphate dehydrogenase (from torula yeast), uridine 5'-diphosphoglucuronic acid (UDPGA), 
calf thymus DNA, bovine serum albumin, diphenylamine, p-nitrophenol, TX-100 (octylpheno-
xypolyethoxyethanol), Tween 80 (polyoxyethylene sorbitan mono-oleate), 5,5'-dithiobis-
(2-nitro-benzoic acid) (DTNB) and reduced glutathione were supplied by Sigma Chemical 
Company Ltd., London. NE 260 micellar scintillator was purchased from Nuclear Enterprises 
Ltd., Edinburgh. All reagents and solvents were of A.R. grade. 
Dieldrin (1,8,9,10,11,11-hexachloro-4,5-É»0-epoxy-2,3,7,6,-endo-2,\,7,8,-exo-
tetracyclo 6.2.1.1.3>602»7 dodec-9-ene) (von Bayer - IUPAC nomenclature), trivially known 
as HEOD, purity greater than 99»o, was supplied by the Agricultural Chemicals Division of 
Shell Biosciences Laboratory, Sittingbourne, Kent, U.K. Dieldrin was administered to diets 
in corn oil solution (10 mg in 5 g of corn oil for 1 kg diet). An identical quantity of 
corn oil was added to control diets. Randomly taken samples of the final diet were rou-
tinely analysed (by g.l.c. with electron capture detection) on dieldrin content to insure 
an equal distribution of the chemical in every batch of diet that was used. 
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3 Results 
3.1 EFFECT ON BODYWEIGHT, LIVER WEIGHT, LIVER DNA AND PROTEIN CONTENT OF LIVER AND SUB-
CELLULAR FRACTIONS OF HEPATOCYTES 
Oral exposure of CF-1 mice to dieldrin had no effect on bodyweight (Table 16). A sig-
nificant difference was observed after 68-72 weeks between dieldrin-treated and non-
dieldrin treated mice on conventional diet and sawdust bedding, but this was primarily 
due to relatively high bodyweights in the latter treatment group, of which only two mice 
were killed. This effect is, therefore, unlikely to be compound-related. Initially, mice 
fed on conventional diet showed slightly higher bodyweights than those maintained on semi-
synthetic diet, but this tendency disappeared with increasing duration of treatment. 
Bodyweights in all treatment groups increased slightly with the passage of time. 
Results ^  obtained with 15-week-old CF-1 mice showed that the administration of 10 mg 
dieldrin.kg diet resulted in pronounced generalized liver enlargement ranging from 
37.5S in mice maintained on conventional diet and filter paper bedding to 56.51 in mice 
maintained on semi-synthetic diet and sawdust bedding (Table 17). Similar effects were 
seen after 52 weeks of exposure. At this stage, however, generalized liver enlargement 
in some of the mice exposed to dieldrin was accompanied by the occurrence of advanced 
nodular liver lesions, which resulted in dramatic increases in relative liver weight 
(RLW). 
Advanced liver nodules were seen in 2/6 mice in each of three dieldrin treatment 
groups (SSD • S
 + 10 mg dieldrin.kg"1 diet, CD • F • 10 mg dieldrin.kg"1 diet, and 
CD • S • 10 mg dieldrin.kg" diet), but not in dieldrin-treated mice on semi-synthetic 
diet and filter paper bedding. However, at subsequent investigations after 68-72 weeks 
of exposure, liver nodules were observed in all of the four dieldrin-treatment groups. 
These results indicate that dieldrin exerts tuncurigenic effects on mouse liver even when 
fte animals are fed on a purified (semi-synthetic) diet and maintained on uncontaminated 
(filter paper) bedding, and thus it is unlikely that the compound causes liver tumours by 
facilitating or exacerbating the action of a potent environmental liver carcinogen. 
In the case of non-dieldrin treated mice and using data obtained from mice maintained 
ZZt^TT "* m t e r PaPer bedding " the b a S e l i n e> * » acMnistration of 
3 r 1 "^ "* eXP°SUre t0 SaWdUSt bedd**' b0th »*** « * - combination, 
r t 1 un enlargement °f *"' liVer (Table 17)- ReSUlts o b * * * * these treat-
iTe f Z
 a r 17 Sflar ^  *" Varl0US ^ ^ °f « P « ™ . a-11 nodular lesions 
e
^ t r W: ln 2/6 " ^ ° n " * - * * « « " * * " and sawdust bedding and in irrir T •* sawdust beddin§- * » — - «* -* ^ 
caused a very slight increase in mean RLW in these two treatment groups. 
Liver enlargement in mice exposed to dieldrin was found to be du! to a combination 
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of hyperplasia (increases in genetic material of the liver) and hypertrophy (increases in 
the ratio of cytoplasmic to nuclear volume). A decrease in liver DNA concentration, which 
is indicative of liver cell hypertrophy, was usually observed in mice exposed to dieldrin 
(Table 18). However, these effects were not always statistically significant (range 0-
17.5%), and invariably accounted for less than half of the enlargement of the liver. Con-
sequently, liver cell hyperplasia appeared to play a more prominant role than hypertrophy. 
This was also clearly demonstrated by the extent to which the total DNA content of the 
liver (expressed per 100 g of bodyweight) was increased in dieldrin-treated mice (Table 
19). After 15 weeks of exposure, these increases ranged from 25.81 in mice maintained 
on semi-synthetic diet and filter paper bedding to 36.8% in mice fed on a conventional 
diet and maintained on sawdust bedding. In the case of mice maintained on a conventional 
diet the increases in liver DNA were nearly proportional to the increases in liver weight. 
Similar effects were observed at later intervals of exposure. 
There was no evidence to indicate that non-nodular liver weight increased as a re-
sult of prolonged exposure of mice to dieldrin. Even in mice with advanced nodular liver 
lesions, total non-nodular liver DNA (mg per 100 g bodyweight) remained constant and was 
similar to that found in dieldrin-treated mice with no or relatively small nodular liver 
lesions (Table 20). Total nodular liver DNA (mg per 100 g bodyweight) varied widely as 
could be expected (Table 20). The concentration of DNA in nodular liver tissue was usually 
similar to that found in the non-nodular part of the liver (Table 42). A small decrease 
in nodular liver DNA concentration was observed after 68-72 weeks in dieldrin-treated 
mice on a conventional diet and filter paper bedding. This observation suggests a slight 
increase in the average size of nodular hepatocytes in these mice. 
In the case of non-dieldrin treated mice and using mice maintained on semi-synthetic 
diet and filter paper bedding as the baseline, the administration of conventional diet to 
mice and exposure to sawdust bedding caused no detectable increase in the total liver DNA 
content after 15 weeks of exposure (Table 19). Total liver DNA content in 52-week-old 
mice on semi-synthetic diet (SSD + F and SSD + S) was lower than that measured at 15 
weeks. As a result the total liver DNA content in 52-week-old mice on conventional diet 
(CD + F and CD + S) was significantly higher than baseline values (SSD + F). It is unlike-
ly that these results indicate a hyperplasiogenic effect of conventional diet on mouse 
liver. After 92 weeks of exposure, however, non-dieldrin treated mice on semi-synthetic 
diet and sawdust bedding and mice on conventional diet and sawdust bedding showed an en-
hanced total liver DNA content. Both groups of mice were exposed to sawdust, which would 
seem to implicate this factor in the observed liver cell hyperplasia. As reported earlier, 
small liver nodules were seen in the above-mentioned treatment groups (2/6 mice from 
treatment SSD + S and 1/6 mice from treatment CD + S). Total liver DNA content was clear-
ly enhanced in mice bearing liver lesions (SSD + S : 15.9; 18.5 and CD + S : 15.3), but 
these results fail to explain all of the increases in total liver DNA observed in the two 
groups of mice. When mice with liver lesions were excluded, total liver DNA was still 
significantly enhanced (SSD + S : 14.4 +1.1; 4 observations; and CD + S : 14.2 + 2.5; 
5 observations). 
Dieldrin-induced liver enlargement was not accompanied by any obvious changes in the 
concentration,i.e. per g liver, of total, microsomal or soluble protein (Tables 21-23). 
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Only a few significant differences between dieldrin and non-dieldrin treated mice were 
observed.: 
1. After 68-72 weeks of exposure, the concentration of liver protein (Table 21) was sig-
nificantly reduced (p < 0.01) in two dieldrin treatment groups (SSD + 10 mg dieldrin.kg~' 
diet + S; CD + 10 mg dieldrin.kg"1 diet + S). However, at this stage of the experiment, 
the number of mice in the non-dieldrin control groups were three and two, respectively. 
These few mice exhibited relatively high liver protein concentrations and it is, there-
fore, unlikely that the observed effects were compound-related; 
2. Fifty-two week-old dieldrin-treated mice on conventional diet and filter paper bedding 
showed a significantly increased concentration of liver microsomal protein (Table 22). 
Similar effects were not observed, however, at other intervals of exposure and the signi-
ficance of the observed effect is not very clear; 
3. After 68-72 weeks of exposure, dieldrin-treated mice on conventional diet and filter 
paper bedding showed significant decreases in the concentration of liver soluble protein 
(Table 23). However, the corresponding non-dieldrin treatment consisted of only two mice 
which showed exceptionally high concentrations of liver soluble protein and the observed 
effect is not, therefore, likely to be related to dieldrin-treatment. 
Total liver protein/liver DMA quotients (Table 24), which reflect the protein concen-
tration per liver cell, were significantly enhanced after 15 weeks of exposure in 3 out 
of 4 dieldrin treatment groups (SSD
 + F + 10 mg dieldrin.kg"1 diet, SSD + S + 10 mg diel-
dnn.kg diet and CD
 + S + 10 mg dieldrin.kg"' diet). These results confirm the occur-
rence of hypertrophy in livers of dieldrin-treated mice. However, no such effects were 
observed at later exposure intervals indicating that liver enlargement at these stages 
was probably due nearly exclusively to hyperplasia. Liver microsomal protein/liver DNA 
quotients tended to be slightly higher in dieldrin-treated mice than in the non-dieldrin 
treated controls (Table 25), but these effects were often not significant. The results 
suggest only a limited degree of proliferation of SER in livers of dieldrin-treated mice. 
Similarly, liver soluble protein/liver DNA quotients were slightly enhanced in dieldrin-
tr ated mice (Table 26). This effect was more pronounced after 15 weeks than at later 
intervals of exposure. 
with I T T ' " CSllUlar CharaCteristics * ™ ^tected that were unequaly associated 
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In contrast to the effects of dieldrin, conventional diet and sawdust caused only-
marginal enlargement of the liver. No hyperplasia was detectable at most exposure inter-
vals and any liver enlargement induced by these factors would consequently seem to be due 
to hypertrophy. Late in life (after 92 weeks of exposure), however, there was evidence of 
liver cell hyperplasia in mice exposed to sawdust. The enlargement of the liver in mice 
exposed to 10 mg dieldrin.kg-1 diet was followed by the occurrence of nodular lesions, 
which were first observed after 52 weeks. The advanced nature of the nodules suggested 
that they were macroscopically visible well before the animals were one year old. Liver 
nodules eventually occurred in all of the four dieldrin-treatments. No cellular characte-
ristics were observed that were specifically associated with nodular lesions. Total pro-
tein/liver DNA, liver microsomal protein/liver DNA and liver soluble protein/liver DNA 
quotients in nodules were similar to those observed in respective non-nodular tissue. 
3.2 EFFECT ON HEPATOCELLULAR DRUG-METABOLISING ENZYMES 
Liver enlargement induced by dieldrin was accompanied by the induction of drug-
metabolising enzymes, e.g. p-nitroanisole-O-demethylase (used as an index of mono-oxygénas e 
activity), epoxide hydratase, glutathione S-epoxide transferase and UDP-glucuronyl trans-
ferase (Tables 27-30). Conventional diet and sawdust bedding also caused induction of the 
liver mono-oxygenase system although these effects were less pronounced than that pro-
duced by dieldrin. Other drug-metabolising enzymes were only very slightly increased by 
conventional diet and sawdust bedding (Tables 28-30). 
After 15 weeks of exposure the mean percentage increase in p-nitroanisole O-demethyl-
ase activity (Table 27) due to the inclusion of dieldrin in the diet was similar in three 
of the four dieldrin treatment groups (SSD + 10 mg dieldrin.kg ' diet + S; CD + 10 mg 
dieldrin.kg-1 diet + F; CD + 10 mg dieldrin.kg ' diet + S) ranging from 1301 to 205«.. In 
the fourth dieldrin treatment group (SSD + 10 mg dieldrin.kg"1 diet + F), the activity 
of p-nitroanisole C-demethylase was increased by an average of 6601 over its respective 
control level. This massive increase was a consequence of the low activity exhibited by 
the respective control animals. In non-dieldrin treated mice and using animals maintained 
on semi-synthetic diet and filter paper bedding as the baseline, exposure to sawdust 
bedding resulted in a 267». increase in enzyme activity; conventional diet induced the en-
zyme approximately one-fold (98»). In combination, these factors caused a 133'. increase 
of p-nitroanisole O-demethylase activity. Thus the inducing effects of these factors were 
not additive. Results obtained at later intervals of exposure were similar to those ob-
tained at 15 weeks. 
After 15 weeks, a significant increase in liver epoxide hydratase activity^ (Table 28) 
was observed in three out of four dieldrin treatments (SSD • 10 mg dieldrin.kg diet • 
F, CD • 10 mg dieldrin.kg-1 diet • F and CD • 10 mg dieldrin.kg" diet * S) ranging 
from 78-871, but no evidence for induction was found in dieldrin-treated mice fed on a 
semi-synthetic diet and maintained on a sawdust bedding. Dieldrin would seem to be only 
a moderate inducer of this enzyme activity in the livers of mice. Other environmental 
• •--• „+ o-F-Fort on the activity of hepatic epoxide hydratase. factors did not exert any significant effect on tne activx , . 
™„ii ;nrrpsw<; in enzyme activity were observed as However, after 52 weeks of exposure, small increases in enzyme «*-
33 
a result of feeding a conventional diet and/or exposure of mice to sawdust. The increases 
produced by these factors were 37% as a result of exposure to sawdust, 1151 as a result 
of feeding a conventional diet and 721 by the combination of the two factors, which sug-
gests that the effects were not additive. The induction produced by the administration 
of dieldrin was more pronounced than that caused by diet and/or bedding and ranged from 
46.« to 179% over the respective non-dieldrin treated control levels. 
The activity of glutathione S-epoxide transferase (Table 29), which is located in 
the soluble fraction of hepatocytes, was induced to 70-120% over control levels in 15-
week-old mice exposed to 10 mg dieldrin.kg-1 diet. Relatively small increases of enzyme 
activity were induced by sawdust bedding (37.71), conventional diet (18.51) or a combina-
tion of the two (28.1%). The latter result suggests that the effects of diet and bedding 
were non-additive. No evidence for the induction of this enzyme system by diet and bedding 
was found at 52 weeks, but at 92 weeks non-dieldrin treated mice on conventional diet 
showed slightly higher activities than non-dieldrin treated mice on semi-synthetic diet 
(difference ca. 12%). The extent of induction of glutathione S-epoxide transferase as a 
result of dieldrin administration remained constant throughout the observation period. 
_ Fifteen-week-old CF-1 mice fed on diets containing 10 mg dieldrin.kg"! showed 
an increased activity of liver UDP-glucuronyl transferase (Table 30). The increases were 
not very pronounced, however, and ranged from 17-48%. Diet and bedding did not influence 
this enzyme activity. The effect of dieldrin after longer intervals of exposure were 
very similar to that observed at 15 weeks. 
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in nodular liver tissue (Tables 57, 58). G-6-Pase specific activity was reduced to approxi-
mately 40-50°s of the levels found in non-nodular liver tissue of the same animals (Table 
57). Similar effects were observed when the enzyme activity was expressed per unit liver 
DNA (Table 58). This indicates that nodular hepatocytes are severely G-6-Pase deficient. 
The administration of dieldrin to mice had no effect on liver glutathione concen-
tration (Tables 37 and 38). Similarly, neither the feeding of conventional diet nor expo-
sure to sawdust bedding resulted in any change in the concentration of this tripeptide. 
However, nodular liver tissue was found to be severely glutathione-deficient (approxima-
tely 60°6 of levels found in non-nodular liver tissue) as shown in Tables 59 and 60. 
3.4 RESIDUE LEVELS OF DIELDRIN IN THE LIVER 
After 15 weeks of exposure, mean concentrations of dieldrin in the liver of mice in 
the four dieldrin treatment groups ranged from 11.0 to 15.0 yg.g" liver 
(Tables 39 and 40). Similar levels were found in non-nodular livers of dieldrin-treated 
mice after 52 weeks of exposure. The concentration of dieldrin in nodular livers was lo-
wer (Tables 39 and 40) than the levels found in non-nodular livers of dieldrin-treated 
mice, but total liver dieldrin content remained unchanged (Table 41). This result suggests 
that the observed decrease in dieldrin concentration in nodular livers is due to increases 
in organ weight. No significant differences were observed between the concentration of 
dieldrin in nodular and non-nodular liver tissue of the same animal (Tables 61 and 62). 
No dieldrin could be detected in the livers of non-dieldrin treated mice (Tables 58 and 59), 
3.5 EFFECT OF DISCONTINUING THE EXPOSURE TO DIELDRIN 
The reversibility of dieldrin-mediated changes in nodular and non-nodular liver 
tissue was studied in CF-1 mice maintained on conventional diet (+ 10 mg dieldrin.kg 1) 
and filter paper bedding. After 85 weeks of exposure, some remaining mice in this treat-
ment were placed oh dieldrin-free conventional diet. After 10 weeks, four of these mice 
were killed for biochemical investigations of their liver. The results were compared with 
those obtained in non-regressed mice and also with those obtained in mice maintained 
on control conventional diet and filter paper bedding. 
Very large liver tumours were observed in dieldrin-treated mice after 95 weeks 
(Table 63) and separation of nodular liver tissue from non-nodular tissue was extremely 
difficult: most of the liver was affected by advanced lesions. Relative liver weights 
ranged from 12.63 to 22.47 (mean 17.86 + 4.10) and were similar to those found in mice 
from the same treatment group after 68-72 weeks of exposure (Table 63). Total liver weight 
was significantly reduced (P < 0.05) in regressed mice (Table 63). All of these four mice 
showed nodular liver lesions, but in a less advanced state which facilitated the separa-
tion of nodular tissue from non-nodular tissue.' No dieldrin residues were detected in 
either non-nodular or nodular liver tissues (Table 63). Total liver weights (Table 63) 
were remarkably similar in regressed mice (4.26 + 0.08, RLW: 10.36 + 0.23) as well as the 
Proportions of non-nodular liver weight (2.80 + 0.17, RLW: 6.80 +0.37) and nodular liver 
weight (1.46 + 0.22, RLW: 3.56 + 0.57). Relative non-nodular liver weights in regressed 
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mice were approximately 55'» higher than values observed in non-dieldrin treated controls. 
This difference is similar to that observed between dieldrin and non-dieldrin treated 
mice at various intervals of exposure (Table 17), which suggests that no change occurred 
in the size of non-nodular liver tissue during regression. Consequently, it would seem 
that the observed reduction of total liver weight in regressed mice was due to changes 
(decreases) in the size of liver nodules. 
An accurate assessment of total non-nodular liver DNA. in 95-week-old dieldrin-treated 
mice was prevented by the occurrence of advanced nodular lesions in many parts of the 
liver. Nevertheless, results obtained did not deviate significantly from those obtained 
at earlier intervals of exposure, e.g. after 68-72 weeks (Table 64). In regressed mice, 
total non-nodular liver DNA was similar to that observed in 68-72 and 95-week-old dieldrin-
treated mice (Table 64). This similarity indicates that hyperplasia persisted in non-
nodular liver tissue throughout the regression period. Total nodular liver DNA in regres-
sed mice, however, was reduced relative to values observed in dieldrin-treated mice 
(Table 64).' Thus the observed reduction in the size of liver nodules was at least in part 
due to a reduction in the number of cells. The observation that the concentration of DNA. 
in nodular liver tissue of regressed mice was similar to that observed in nodular liver 
tissue of dieldrin-treated mice, suggests that no reduction in the size of nodular liver 
cells occurred during regression and, consequently, it would seem that a reduction in the 
size of liver cells did not contribute to the observed reduction in the size of liver 
nodules. However, liver DNA concentration in non-nodular liver tissue of regressed mice 
was significantly increased (P < 0.05) over values observed in non-nodular liver tissue 
of dieldrin-treated mice (Table 64), which suggests that the average size of non-nodular 
liver cells decreased during regression. This finding is supported by the observation 
that non-nodular liver protein/liver DNA quotients were significantly lower (P < 0.05) in 
regressed mice than in dieldrin-treated mice (Table 65). Liver microsomal protein/liver 
DMA quotients in non-nodular tissues were also slightly, but significantly reduced in 
regressed mice (Table 65). Thus, in contrast to liver cell hyperplasia, liver cell hyper-
trophy appears to be reversible in non-nodular liver tissue of mice exposed to dieldrin. 
The withdrawal of dieldrin from the diet and subsequent metabolic elimination of the 
compound resulted in complete regression of the specific activity of the microsomal mono-
oxygenase system in non-nodular liver tissue (Table 66). Regression also occurred with 
respect to epoxide hydratase, glutathione S-epoxide transferase and UDP-glucuronyl trans-
ferase (Table 66), but the specific activity of these enzymes remained significantly 
higher than those observed in non-dieldrin treated controls (P < 0.01). However, when the 
enzyme activities were expressed per unit non-nodular liver DNA, which reflects the con-
centration of the enzyme(s) per liver cell, regression was virtually complete with respect 
to all
 0f these drug-metaboli2ing enzyme systems (Table 67). In fact, mono-oxygénas e and 
UDP-glucuronyl transferase activity per unit liver DNA were significantly lower (P < 0.01) 
than values observed in non-dieldrin treated controls (Table 67). 
Regression of enzyme activity was also observed in nodular liver tissues but control 
rates were not attained even though no dieldrin could be detected in these tissues (Table 67). 
ced
 hTZZ lndiCate ^  thB dumBes in d ^ - t a b o l i z i n g enzrme activities indu-
by dieldrin are reversible in both non-nodular and nodular liver tissue. However, 
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regression was less complete in nodular liver tissue. 
G-6-Pase-activity was normal in non-nodular liver tissue of regressed mice (Tables 
66 and 67), but remained severely depressed in nodular liver tissue (Tables 66 and 67). 
In dieldrin-treated mice, a reduction of G-6-Pase activity was also observed in non-nodu-
lar liver tissue. It should be kept in mind, however, that separation of non-nodular 
tissue from nodular liver tissue was extremely difficult in these mice and it is likely 
that non-nodular liver tissue contained G-6-Pase deficient nodular liver cells. 
3.6 EFFECT ON SURVIVAL AND INCIDENCE OF LIVER TUMOURS (by courtesy of Miss K.M. Dix) 
S. S. 1 Survival 
Survival in each treatment group is shown in Figure 3. The data were adjusted for 
interim kills. If there were n mice initially in a treatment group and d1 animals had 
died before any animals had been sacrificed, percentage survival S^ was calculated as: 
Q _ 100 (n - di) 
ùi ~ • 
Percentage survival after k animals had been killed and d2 animals had died subsequently 
was calculated as: 
g. . 100 (n - di) :c (n - di) - k - d2 
n (n - dj) - k 
Example: if n = 100 
dx = 20 
d2 = 10 
k = 30 
then Sj = 100 (100 - 20) -
 m 
100 
and s 2 = 100 (100 - 20) x (100 - 20) - 30 - 10 = g0 x_4?_ = 641 
100 (100 - 20) - 30 50 
The principal effect observed was a significant reduction of survival rates of mice ex-
posed to dieldrin (Figure 3). Figure 4, which shows pooled survival rates of the four 
dieldrin treatments and of the four non-dieldrin treatment groups, also serves to demon-
strate this effect. The first liver tumour incidence assessment was carried out after 
65 weeks of exposure. As shown in Figure 3, survival rates at this stage were > 80». in 
all of the eight treatment groups, even though, this investigation revealed that 701 or 
more of the mice exposed to- dieldrin had nodular liver lesions, many of which showed 
massive proportions. Bearing in mind that the first liver tumour was observed in a 43-
week-old dieldrin-treated mouse, it is surprising that survival in the four dieldrin-
37 
SURVIVAL 
(%) ,00 
I ' i ' i 
0 20 40 60 80 100 
diet SSD 
bedding F 
i ' i i i ' i 'i i 
0 20 40 60 80 100 
SSD AGE (WEEKS) 
0 20 40 60 80 100 
diet CD 
bedding F 
100-
80-
60-
40-
20-
0-
H—1 
I . . , 1 
S 
1
 1 i 1 i 1 i 
;\ 
i 
'•, 
l i 1 
s 
U 
0 20 40 60 80 1Ó0 
CD 
S 
Fig. 3. Survival (adjusted for scheduled kills) against time. The experiment was terminated 
after 110 weeks. 0 mg dieldrin.kg-1 diet, -- 10 mg dieldrin.kg-1 diet. 
treatment groups was still > 60'. after 80 weeks of exposure. Fifty percent of the ani-
mals receiving 10 mg dieldrin.kg-1 diet had died by week 86 (ca. 20 months). Fifty per-
cent survival in non-dieldrin treated mice was reached after 94 weeks (ca. 22 months). 
On average, 1/10 dieldrin-treated mice survived 100 weeks (ca. 23 months) compared with 
4/10 non-dieldrin treated mice. 
3.6. 2 Liver tumour incidence 
Liver nodules were classed according to.Walker et al. (1973) as type A: nodular 
growth of solid cords of parenchymal cells classified as benign tumours, and type B: 
papilloform and adenoid growth with cells proliferating m confluent sheets with necrosis 
and xncreased mitoses (Figure 5). Mice with type B liver tumours often had type A growths 
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100 
Fig. 4. Pooled survival rates of dieldrin and non-dieldrin treatments. The experiment was 
terminated after 110 weeks. non-dieldrin treatments, dieldrin treatments (10 mg.kg 
diet). 
as well, but these latter lesions are not included in Column A in the table summarizing 
liver tumour incidence. 
The incidence of liver tumours (Table 68) was analysed for five periods of the study: 
1. up to week 65, 
2. interim kill at week 65, 
3. from week 65 to week 92, 
4
- interim kill at week 92, 
S. from week 92 until end of the study. 
For each of these periods and for each of the liver tumour classifications (type A, 
type B, total) the incidence in groups 2-8 was tested against group 1 (mice maintained 
on semi-synthetic diet and filter paper bedding) using Fisher's exact test (Bradley, 
1968). Significances at the St, H and 0.11 level have been marked accordingly. 
As described above, dieldrin administration to mice resulted in the relatively early 
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appearance of nodular hepatic lesions, the first being observed in a mouse aged approxi-
mately 43 weeks. Longer-term exposure to dieldrin resulted in the development of hepato-
cellular carcinomata. Forty-eight percent of mice with hepatocellular carcinomata ('B' 
type tumours) that died or were killed between 18 months and the termination of the study 
showed lung metastases (Table 69). 
Liver nodules also occurred in some mice from the groups not treated with dieldrin. 
However, these nodules were smaller than those observed in the dieldrin groups being 
usually less than 10 mm in diameter. Two nodules from the non-dieldrin groups showed 
morphological characteristics of hepatocellular carcinomata. No lung metastases were 
observed in non-dieldrin treated mice bearing liver nodules (Table 69). 
Very few nodules were present in the livers of mice in the non-dieldrin groups at 
65 weeks (Table 68). However, the incidence in the corresponding dieldrin-treatment 
groups was very high, even in animals maintained on a purified diet and filter paper 
bedding. At 92 weeks, there was some variation in the incidence of nodular lesions in the 
non-dieldrin treatment groups. Mice on semi-synthetic diet and sawdust bedding showed a 
significantly increased incidence of liver tumours. The relevance of this effect is diffi-
cult to assess in the light of other contrasts between filter paper and sawdust treatments 
in the absence of dieldrin, e.g. treatment CD + F versus treatment CD + S. Thus, conven-
tional diet and sawdust bedding did not exert any obvious influence on the development of 
'spontaneous' tumours in the livers of male CF-1 mice (Table 68). It would appear that, 
even though conventional diet and sawdust contained agents that induced the mouse liver 
microsomal mono-oxygénase system, these agents have no intrinsic tumour-promoting activi-
ty or are present at concentrations below the threshold for overt tumour-promoting action. 
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4 Discussion 
Several mechanisms can be envisaged by which microsomal enzyme inducers, such as 
dieldrin, phenobarbitone, DDT, and a, g and y stereoisomers of HCH, may exert their tu-
mourigenic action in livers of susceptible animal species. 
The tumourigenic action of these compounds could be mediated through direct inter-
action of reactive metabolites with cellular DNA leading to somatic mutations, i.e. altera 
tions in the nucleotide sequence of the DNA genome. This concept assumes that somatic 
mutations are primary events in carcinogenesis. However, there is at present no evidence 
to indicate' that microsomal enzyme inducers such as dieldrin or phenobarbitone possess 
mutagenic activity and/or potential (Wright et al., 1977) and it is considered unlikely 
that these compounds are intrinsically carcinogenic by a direct genotoxic mechanism. 
An alternative mechanism could be that microsomal enzyme inducers exert their tumouri 
genie action in rodent liver by facilitating the action of a potent environmental carcino-
gen. A possible mechanism of action could be that the induction of liver mono-oxygenases 
by microsomal enzyme inducers would render the liver more susceptible to tumour formation. 
The microsomal mono-oxygénas e system has been implicated as a key factor in the generation 
of carcinogenic reactivity from pre-carcinogens (Miller, 1970). This link has led to the 
opinion that an increased capacity of the microsomal mono-oxygénase system is associated 
with increases in the rates of generation of ultimate carcinogens formed from environmen-
tal pre-carcinogens. 
One of the main objectives of this study was to ascertain whether microsomal enzyme 
inducers were present in conventional diet and sawdust bedding and to establish what 
effects such naturally occurring agents may have on the incidence of liver tumours in 
CF-1 mice. The administration of 10 mg dieldrin.kg-i diet to some of the experimental 
groups served as a positive control, i.e. a potent microsomal enzyme inducer with tumouri-
genic properties in CF-1 mice. 
The results of the investigations showed that exposure of mice to dieldrin caused 
a 3-4 fold increase in the activity of p-nitroanisole O-demethylase activity - used as an 
index of mono-oxygenase activity - and a 2-fold increase in the activities of epoxide hy-
dratase and glutathione S-epoxide transferase. UDP-glucuronyl transferase activity was 
increased approximately 1.5-fold in livers of dieldrin-treated mice. 
In the case of non-dieldrin treated mice and using data obtained in mice maintained 
on semi-synthetic diet and filter paper bedding as the baseline, the administration of 
conventional diet to mice and exposure to sawdust bedding, both singly and in combination, 
caused induction of the liver mono-oxygenase system, although this effect was less pro-
nounced than that produced by dieldrin. Other drug-metabolizing enzymes were not or only 
very slightly increased by conventional diet and sawdust bedding 
A high incidence of liver tumours was observed in dieldrin treated mice after 65 
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weeks of exposure, even in mice maintained on a semi-synthetic diet and filter paper 
bedding. In contrast to the effects of dieldrin, conventional diet and sawdust bedding 
failed to enhance the incidence of liver tumours in CF-1 mice. The observation that 
conventional diet and sawdust bedding induce the mono-oxygenase system of mouse liver 
but fail to enhance the incidence of liver tumours indicates that microsomal mono-
oxygenase induction is not invariably associated with enhanced liver tumour formation. 
The hypothesis that activation of the microsomal mono-oxygenase system is associated 
with an increase in the generation of carcinogenic reactivity from precursor carcinogens 
is supported by a positive relationship between the rate of mono-oxygenase catalysed 
metabolism of pre-carcinogens and the mutation rates in bacterial test systems (Czygan 
et al., 1973; Bartsch et al., 1975). However, contradictory results have been obtained 
in animal carcinogenicity tests. For example, the simultaneous application of diethyl-
nitrosamine (DENA) and phénobarbital led to a significant reduction in the frequency of 
liver tumours and to a prolongation of tumour manifestation times (Kunz et al., 1967, 
1969). Identical results were reported using different inducers of the mono-oxygenase sy-
stem, such as 3-MC (Hoch-Ligeti et al., 1968), or PCB (Makiuara et al., 1974). 
In contrast, the combination of DENA with halothane or methoxyfluorane, both of 
which do not induce but rather inhibit the mono-oxygenase system under the experimental 
conditions used, markedly enhanced the development of hepatocellular carcinomas, while 
simultaneously lowering the number of hemangioendotheliomas (Kunz, 1969). 
The results of in vitro and in vivo experiments may be reconciled by observations 
by Kunz et al. (1978). This group showed that at low concentrations of a pre-carcinogen 
substrate (dimethylnitrosamine), phénobarbital pre-treatment decreased, whereas SKF-
52SA increased formaldehyde production and alkylation intensity (covalent binding to pro-
teins). This situation reflects the in vivo situation during animal carcinogenicity 
experiments. In contrast, with high substrate (carcinogen) concentrations, phénobarbital 
Pre-treatment increased both formaldehyde production and alkylation intensity, whereas 
SKF-S25A had the contrary effect. Microbial mutagenicity tests can be carried out with 
non-rate-limiting substrate concentrations, which explains the enhancing effects of 
microsomal enzyme inducers on the mutation rate of carcinogens in such tests. 
The level of possible human exposure to nitrosamines remains substantially below 
the lowest concentrations used in animal experiments. However, induction or inhibition 
of microsomal mono-oxygenase following drug administration may also occur in humans. As 
both the resulting increase and decrease of nitrosamine-mediated alkylation were experi-
mentally found to be increasingly effective the lower the concentration of mtrosamine, 
and as the level of possible human exposure is even lower than the lowest concentration 
**d experimentally, it has been argued by Kunz et al. (1978) that drug-mediated toxifi-
cation or detoxification of the carcinogen in this critical dose range might be of 
considerable importance for humans as well. A major uncertainty about the relevance of 
animal experiments to the human situation is the finding that all modifying effects ot 
drugs on mono-oxygenase activity are highly dependent on sex and species of the anmals 
**d and, in this respect, only little is known about the properties of human mono-
oxygenase. 
In addition to substrate concentration, number of active centres and rate constants, 
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numerous other factors can influence the rates of oxygenation of substrates by the liver 
microsomal mono-oxygénas e system in vivo. These include rates and modes of transport to 
the enzyme, levels and affinities of physiological and foreign substrates, e.g. inducer, 
and activities of enzyme systems which catalyse the subsequent metabolism of the primary 
products of mono-oxygenase action, e.g. epoxide hydratase, UDP-glucuronyl transferase and 
glutathione-S-epoxide transferase. Because of the difficulties in assessing the relative 
contributions of these factors in determining the overall rate of in vivo oxygenation of 
a given substrate, in vivo rate measurements are required to provide perspective to in 
vitro determined rate measurements. 
In the current study, liver tumours were observed in a few animals maintained on 
semi-synthetic diet (SSD) and filter paper bedding (F). This confirms the presence of 
a pre-existing oncogenic factor or susceptibility in this strain of mouse. Although mice 
maintained on SSD and F may not have lived in an entirely carcinogen-free environment, 
it would appear unlikely that 'spontaneous' liver tumours in these animals were caused 
by environmental factors. It is postulated that these tumours are the expression of a 
pre-existing factor which is genetically linked and possibly viral in origin. Experimen-
tal evidence indicates that lymphoid leukosis, lymphosarcomas and leukemias in mice, 
rats and cats, mammary gland carcinomas in mice, certain sarcomas in mice and other tu-
mours are caused by RNA oncogenic viruses (Gross, 1974, 1978). In many cases, these onco-
• genie viruses are transmitted from one generation to another ('vertical transmission' as 
opposed to 'horizontal transmission' of contagious pathogenic agents which spread rapidly 
from- one host to another within the same generation). RNA oncogenic viruses contain a DNA 
polymerase (reverse transcriptase) which catalyses the synthesis of a DNA copy.of the RNA 
genome (Bauer, 1978). This viral DNA becomes a provirus, that is, it establishes permanent 
covalent bonds with the cellular DNA. The demonstration that viral DNA is integrated in 
Z T]S' m C ° n J U C t i 0 n With the f i n d i nS that the provirus is transcribed into messenger 
R M hundreds of generations after the establishment of a transformed clone suggests a 
continumg role of viral gene functions in determining transformation (Bauer, 1978). 
Virus-lxke particles have been observed in 'spontaneous' and phenobarbitone-induced 
ions Tn r C3H miœ CJOneS & BUtler' 1975) bUt itS role in ^ a c t i o n of the le-
f cLvv " I I l n V e S t i S a t e d - R e c - " y . Lapis (1978) observed liver tumours in 30-501 
llfi n Z i been ln0CUlated P ™ * 1 ^ * * MC-29 RNA avian leukosis virus sus-pension. These liver tumours, which develop K K J r. . 
„ H „ , m t o , , ,_ ' œveioped 25-45 days after inoculation with the virus, 
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Z Z t S T ; ^^-f-ability to other avian hosts. Experience with the mouse 
« th f"" the a C t i V a t i ° n ° £ the V i ™ ^ » * occur during the life-
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alter from year to v i r Nervation that the incidence of liver tumours may 
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fallen — g — t y tests have shown that phénobarbital treatment 
tr72::rz^7TaUon resuits mainiy in - in—d—* *~— 
al., 1971, Nishizumi, 1976).
 Similar results have been observed with other 
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microsomal enzyme inducers, such as DDT, BHT, PCBs and a-HCH (Peraino et al., 1971, 1973b, 
1975, 1977; Nishizurai, 1976; Kimura et al., 1976; Schulte-Hermann, 1978). The underlying 
mechanism for the induction of liver tumours in susceptible animal species by microsomal 
enzyme inducers, therefore, seems to be a promoting effect on initiated cells. Kunz et 
al. (1978) observed an increase in pre-neoplastic areas in the liver only with doses of 
phénobarbital sufficient to cause liver enlargement and only during the initial phase of 
drug-mediated cell proliferation. These results strongly suggest that tumour-promoting 
effects by microsomal enzyme inducers are due to the capacity of these compounds to induce 
liver cell hyperplasia. The mechanism of action might thus be the same as can be observed 
when partial hepatectomy is used for promotion of tumour development (Kitigawa, 1971; 
Craddock, 1971; Scherer et al., 1972). The observation that microsomal enzyme inducers, 
such as diphenylhydantoin and amobarbital, which do not cause liver enlargement, show 
no tumour-promoting activity (Peraino et al., 1975) provides additional support for this 
hypothesis. Recent studies by Ohde et al. (1979) have shown that the administration of 
microsomal enzyme inducers, such as a-HCH or cyproterone acetate (CPA), to rats previous-
ly treated with DENA resulted in a dramatically increased rate of proliferation of pre-
neoplastic cells, whilst cell division in the surrounding (normal) parenchyma was much 
less pronounced. It would seem therefore that pre-neoplastic cells are extremely suscepti-
ble to the effects of liver mitogens which may pose considerable difficulties in the 
assessment of safe levels of microsomal enzyme inducers in the human situation. 
The results of the present investigations indicate that dieldrin administration to 
mice caused pronounced generalized liver enlargement, which was due to a combination of 
liver cell hyperplasia and hypertrophy. The occurrence of liver cell hyperplasia was 
evinced by increases in the total DNA content of the liver. Increases in total liver 
Protein/liver DNA quotients, in liver microsomal protein/liver DNA quotients and in liver 
soluble protein/liver DNA quotients on the other hand, were indicative of liver cell 
hypertrophy and of proliferation of hepatocellular SER. However, hyperplasia was shown 
t0
 Play a more prominent role in the overall liver enlargement than hypertrophy. 
In the case of non-dieldrin treated mice and using data obtained in mice maintained 
on semi-synthetic diet and filter paper bedding as the baseline, the administration of 
conventional diet and exposure to sawdust bedding caused only marginal enlargement of the 
liver. There was no evidence for the occurrence of liver cell hyperplasia and any liver 
enlargement was, consequently, due exclusively to hypertrophy. The rationalization that 
enhancement of the incidence of liver tumours in CF-1 mice may be caused by the induction 
of liver cell hyperplasia is, therefore, consistent with the observation that dieldrin 
administration to mice caused pronounced hyperplastic effects followed by the early 
occurrence of liver tumours, whereas conventional diet and sawdust bedding, which did not 
induce liver cell hyperplasia, showed no overt tumour-promoting activity. 
Ihe results obtained with dieldrin in various strains and species (Wright et al., 
1
"2) have led to the suggestion that the induction of liver cell hyperplasia m mouse 
üver could be related to a limited capacity of mouse hepatocytes to respond effectively 
to an increased functional demand for oxidative microsomal enzyme systems. The induction 
°
f
 rat liver mono-oxygenase(s) and epoxide hydratase by dieldrin is more pronounced in 
ra
*s than in mice. Vaino & Parkki (1976) observed a seven-fold increase in the specific 
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activity of liver p-nitroanisole O-demethylase and a five-fold induction of liver epoxide 
hydratase activity in rats exposed by the intraperitoneal route to 10 mg dieldrin.kg-1 
bodyweight for only six days. Rapid and pronounced induction of liver mono-oxygénas e acti-
vity in rats exposed to dieldrin was also observed by Wright et a l . (1972). Metabolic data 
(Hutson, 1976) also indicate that the hydroxylation of dieldrin (which is a major metabo-
lic pathway) is less efficient in mice than in rats and that the concentrations of diel-
drin in liver and other tissues are consequently higher in mice. 
In contrast to results obtained in CF-1 mice, i t has been shown that total liver DNA 
did not increase in rats fed on 200 mg dieldrin.kg"1 diet for up to 28 days (Wright et 
al . , 1972). This finding coupled with the observed increases in liver protein/liver DNA 
quotients in test animals, showed that the increases in relative liver weight in these 
rats were due to liver cell hypertrophy rather than to an increase in the number of 
hepatocytes. The increase in the size of hepatocytes was largely accounted for by in-
creases in microsomal protein and soluble protein (up to 741 of control values). This was 
confirmed by electron microscopic observations that proliferation of SER of rat liver 
cells was pronounced shortly after exposure to dieldrin. 
If the induction of liver cell hyperplasia by microsomal enzyme inducers is related 
to limitations in the capacity of the animal to respond effectively to an increased 
functional demand for drug-metabolizing enzyme systems in liver cel ls , one might assume 
that the most potent microsomal enzyme inducers should induce the greatest degree of 
liver cell proliferation. However, studies in rats with groups of chemically related com-
pounds, e.g. derivatives of BHT (Gilbert et a l . , 1969) and HCH-isomers (Schulte-Hermann, 
1974a) revealed that some of the compounds tested were strong inducers of drug-metaboli-
zing enzymes, but weak inducers of liver cell hyperplasia, in this species. Furthermore, 
when the inducing potentials of chemically unrelated inducers such as phénobarbital, 
«-ICH and DDT were compared, liver enlargement in the rat was not invariably related to 
enzyme induction (Kunz et a l . , 1966a; Koransky et a l . , 1969). I t appears, therefore, 
that liver cell hyperplasia is not a necessary consequence of pronounced induction of 
arug-metabolizing enzyme systems. 
There is also evidence to indicate that the two effects of chemical inducers, i .e . 
c o Z T7gemnt " * i n d U C t i ° n ° f d r uS-m e t*olizing enzyme systems, are not necessarily 
I ^ t r i a Z O l e ' " i n h i b i t ° r ° £ h6me b i o s ^ h e s i s , prevented the phenobarbital-
induced xncrease of cytochrome P-450, but the increase in liver size and proliferation 
n l a l Z t n 0 t T ( R a i S f e U 6 t a l " 1 9 7 0 )- ™ » ° b s ™ - suggests that liver 
x Z R cH ^ r r l e d fr0m m U l t i p l i c a t i- « the heme moiety o the mixed-function 
e S "to i W ° r I J S C h U l t e - H e ™ « ^ suggests that the inductive pathways 
inSr rjssr^rsrrr T " diverge a few hours a£ter 
results: Process. This is evinced by the following experimental 
^ Ä l ^ ~ ^ *' ™ * - -tar, protein S-8 
Wdn D (SO ps
 ke-" h ( T Z m repllCation and can be blocked by a low dose of actino-
7. In contrast L ^ ^ * *" ^  ** h0UrS ^ *• administration of «-HCH-
dietary protein and a ^ n T s e ! C y t ° C h r ° m e P"45° "* ° f ******** do not require 
and are not sensitive to even higher doses of actinomycin D (500 mg.kg'1 
4ft 
bodyweight). 
There are indications of species differences with respect to the induction of liver cell 
hyperplasia by microsomal enzyme inducers (Wright et al., 1972, 1978) but information on 
the susceptibility of the human liver to the effects of these compounds is rather limi-
ted. Results obtained with rhesus monkeys exposed to dieldrin (Wright et al., 1978) and 
the absence of any detectable changes in the livers of humans exposed to high endogenous 
concentrations of dieldrin point to a slow rate of metabolic clearance of dieldrin in 
these primate species and to a low sensitivity of their livers to this compound (Hunter 
& Robinson, 1967; Hunter et al., 1969; Jager, 1970). The dietary intake required for the 
induction of the rhesus monkey liver microsomal mono-oxygenase system was 25-30 yg.kg-1 
bodyweight.day"1, which is approximately 300 times greater than that of the general human 
population in 1966-1967 (Wright et al., 1978). The corresponding threshold concentration in 
the liver was 6 to 7 yg dieldrin.g"1; this concentration would be associated with marked 
microsomal enzyme induction and overt liver enlargement in livers of rats and mice. There 
was no evidence for the occurrence of liver hyperplasia in monkeys fed dieldrin at dietary 
concentrations from 0.01-5 mg.kg"1 for up to 6.5 years (Wright et al., 1978). 
In the case of dieldrin, therefore, it would seem that mouse liver is more susceptible 
to the mitogenic effects of this compound than primate liver. As a result it might be 
argued that the tumour-promoting effect of microsomal enzyme inducers is of secondary 
importance in the human situation, since chronic drug treatment sufficiently high to in-
duce liver cell proliferation in humans might only be conceivable with a few substances. 
Over the past 5 years, however, there has been a surprising increase in the number of 
published reports of patients with liver adenomas, and a close relationship has been 
found with the consumption of oral contraceptives (Sherlock, 1978). In view of the very 
large number of women taking oral contraceptives and the small numbers of primary liver 
tumours that are being reported (Klatskin, 1977), the risk of this complication is not 
very great. However, it has been argued (Sherlock, 1978) that the proportion of women 
who have taken the hormone for more than 5 years is much smaller, and this is when the 
risk usually arises. Furthermore, the observation that pre-neoplastic liver cells are 
more susceptible to the mitogenic effects of microsomal enzyme inducers (Ohde et al., 
1979) than normal hepatocytes indicates that humans with pre-neoplastic liver lesions 
•night be at risk at low levels of exposure to such compounds. _( 
In the present study, chronic exposure of male CF-1 mice to 10 mg dieldrin.kg diet 
resulted in the appearance of liver tumours after approximately 43 weeks. On the basis 
°f previous studies with dieldrin in the CF-1 mouse (Walker et al., 1973), it would seem 
that in utero exposure of mice to the compound reduced the latent period for the develop-
ment
 0f hepatocellular carcinomata (type B tumours). Nearly 50$ of mice with these tu-
mours killed or died between 18 months and the termination of the study after 26 months 
showed lung metastasis. Liver tumours also occurred in some mice in non-dieldrin treatment 
groups. However, these lesions were much smaller than those observed in the dieldrin 
treatment groups being usually less than 1 cm in diameter (compared with 2-5 cm diameter 
of most liver tumours in dieldrin treatments). Two liver tumours from the non-dieldrin 
groups showed morphological characteristics of hepatocellular carcinomata, but no lung 
metastases were observed in any of the non-dieldrin treated animals bearing liver tumours. 
47 
Comparative biochemical investigations in non-nodular and nodular l i ve r t issue from 
dieldrin-treated mice revealed that mono-oxygenase, epoxide hydratase and glutathione 
5-epoxide transferase act ivi t ies were s l igh t ly , but consistently higher in nodular liver 
t issues. Discontinuation of dieldrin administration to 85-week-old mice with l iver tu-
mours resulted in vir tual ly complete regression of enzyme induction in non-nodular liver 
t issue. In contrast, regression of enzyme ac t iv i ty was less complete in nodular liver 
t issue, even though no dieldrin could be detected in the t i s sue . 
The reversibi l i ty experiment also showed that hyperplasia pers i s ted in non-nodular 
liver tissue throughout the regression. Persistence of l iver c e l l hyperplasia during, 
regression was also reported in studies with c-HCH and BHT (Schulte-Hermann e t a l . , 1971). 
Thus, in contrast to the effects on drug-metabolizing enzymes, the induction of l iver cell 
hyperplasia by microsomal enzyme inducers could represent an i r r evers ib le process. 
Liver tumours were found to be deficient in G-6-Pase ac t iv i ty and also showed low 
concentrations of glutathione. G-6-Pase deficiency i s a common feature of pre-neoplastic 
l iver lesions induced by chemical carcinogens, such as DENA (Scherer e t a l . , 1972; 
Scherer & Bmelot, 1975,
 1 9 7 6 ) . m the current study, a s l igh t depression of the specific 
activity of l iver G-6-Pase, i . e . the ac t iv i ty expressed per uni t weight of microsomal 
protein, was also observed in l ivers of die ldr in- t reated mice before the occurrence of 
liver tumours (after 15 weeks of exposure to d ie ld r in ) . However, when the enzyme activity 
• was expressed per unit l iver DNA, which ref lec ts the enzyme concentration per l iver cell , 
no consistent ^ e c t was observed. Depression of l iver G-6-Pase has been observed after 
treatment w i t h a number of hepatotoxic compounds (Feuer e t a l . , 1965). However, the 
results g a i n e d m this study suggest that dieldrin-exposure does not cause any depression 
of hepatocellular G-6-Pase in male CF-1 mice and that the observed trend towards de-
crease
 l n the specific act ivi ty of th i s enzyme, i . e . ac t iv i ty expressed in terms of unit 
weight of microsomal protein, probably ref lects the occurrence of l ive r c e l l hypertrophy 
obular r i r a t e K miCe" ^ h y p e r t r ° ^ « * «*o explain the depression of centri-
Ten bLb " r ^ t 6 ^ l n m S e X P ° S e d t 0 0 t h e r micrOSOmal »*"» Queers, e.g. phénobarbital and BHT (Crampton et a l . , 1977). 
also S e a d r S S ; ° 7 f §1Utathi0ne l n 11Ver t m ° U r S ° b s e ™ d i n t h e P -sen t study could 
) ave Z L t T T 1 " " ° f n e ° P l a S t i C t i S S U e ' F i a l a - d h i s -sociates «™> 
I tt £ c r : t h a t the i n d U C t i ° n ° f P — o p l a s t i c liver lesions is associated 
^ t e ? f r r Y"g ^ t r a n S p eP t i d a s e Cr-GT) in these cells. Orlowski . 
TZoZl r ' T 1 " 6 ' thEt Y-CT " * g l U t a t h i ° n e ™ ^ « d in the transport 
l r p - 1 1 H * ! CGllUlar membrane- " ** been suggested (Fiala et a l . , 1976), 
^^T^^z^^::^rT^to -—both a high 
of glutathione. As a result «, • 1 aCtlvltv' whlc" requires a high turnover 
normal hepatocytes. ' glutathlone concentrations may never approach those of 
tating the expression of pre-exi^ * *" e X P e r i m e n t a l ^ m a l s by facili-
action is «.a, ^  c J L j ^ ^ T . ***"' ^ ^ ™^ danism of 
which the proliferation of pre-exi « t - , 8 U v e r C e U ^ r P 1 ^ * through 
pre existent pre-neoplastic liver lesions may be profoundly 
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increased. 
This ra t ional iza t ion i s consistent with the observation that conventional diet and 
sawdust bedding, which were shown to contain agents that induce the l iver microsomal 
mono-oxygénase system but fai led to induce l iver hyperplasia in the CF-1 mouse, had no 
overt tumour-promoting ac t iv i ty . 
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Summary 
A variety of xenobiotic compounds are known to induce charac te r i s t i c changes in the 
livers of laboratory animals. These changes include l iver enlargement, usually as a ' 
result of cell enlargement (hypertrophy) or ce l l repl icat ion (hyperplasia) , induction 
of drug metabolizing enzymes and proliferat ion of the smooth endoplasmic reticulum (SER). 
Such changes are not usually accompanied by evidence of l iver damage and in such cases 
are reversible upon withdrawal and elimination of the compound. Consequently, most authors 
regard this phenomenon as an adaptive response of the organ to increased functional de-
mands. However, chronic exposure of various s t ra ins of mice to d i e ld r in , phenobarbitone, 
DDT and the a-, g- and y- stereoisomers of hexachlorocyclohexane (HCH, also known as 
benzenehexachloride, BHC) may lead to the development of l iver tumours. 
There is no apparent relationship in chemical s t ructure between these compounds and 
their main common feature i s that they are inducers of the microsomal mono-oxygénas e 
system of mammalian l iver . This has led to the suggestion that a common property of 
microsomal enzyme inducers may be to enhance the incidence of l iver tumours in susceptible 
animal species, possibly as a resu l t of an increased ra te of metabolic ac t ivat ion of 
environmental pre-carcinogens. 
The objective of this study was to ascertain whether microsomal enzyme inducers were 
present m commercial rodent diet and softwood bedding employed rout inely in t h i s labora-
tory and to establish what effects such naturally occurring agents may have on the inci-
dence of l iver tumours in dieldrin-treated (10 mg.kg-i diet) and non-dieldrin t reated CF-1 
mice using animals maintained on semi-synthetic d ie t and f i l t e r paper bedding as controls. 
CF-1 mice were bred and reared on the experimental treatments to ensure continuous 
exposure during both the pre-natal and post-natal periods. 
The administration of dieldrin to CF-1 mice resulted in pronounced generalized l iver 
enlargement due to a combination of hypertrophy and hyperplasia. Hyperplasia was a major 
~ f ' " l n t h e ° b S e r V e d 1 1 V e r « * « * • « » * . m many d ie ldr in- t rea ted mice the 
m e r e l s m iver DNA were nearly proportional to the increases in l ive r weight. 
m e t a b o l ü " ^ ^ * " ^ W " * » * • * * * <he a u c t i o n of drug-
Tc fvSv T T / " 8 ' p-nitr0ani5^ ^ » e t h y l a s e (used as an index of mono-oxygenase 
fe^ivlty 8 l U t a t h i 0 n e S"eP0Xide t r a n S f e r a S e " * U ^ ™ ^ 1 t r a n S ' 
on sel^ZicI-T?idrin t r e a t G d " * " Wd ^ * * °btai-d - -ce maintained 
nvlti I T T "f" P a P 6 r b e d d i n g « *° baSeline> *» administration of 
c a u s e " Lai Z ^ T ^ T t b e d d i n g ' b 0 t h S l n g l y " * ^ — T 
any l iver enlargement would thus p p ^ 'duÎ 7™ "**"* ** ^ ^ "* 
environmental factors did cause indTc on o f \ t , ^ ** ******* ^ 
cause induction of the l iver mono-oxygenase system although 
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this effect was less pronounced than that produced by dieldrin. Other drug-metabolizing 
enzymes were only very slightly increased by conventional diet and sawdust bedding. 
Dieldrin administration to mice resulted in the relatively early appearance of no-
dular hepatic tumours, the first being observed in a mouse aged approximately 43 weeks. 
At 65 weeks, the incidence of liver tumours in the dieldrin treatment groups was very 
high, even in animals maintained on a semi-synthetic diet and filter paper bedding. 
Longer-term exposure to dieldrin resulted in the development of hepatocellular carcinomata. 
Forty-eight percent of mice with hepatocellular carcinomata ('B' type tumours) that died 
or were killed between 18 months and the termination of the study showed lung metastases. 
On the basis of previous studies it would seem that in utero exposure of CF-1 mice 
to dieldrin reduced the latent period for the development of liver tumours. The fact 
that the incidence of liver tumours in dieldrin-treated animals maintained on semi-
synthetic diet and filter paper bedding was similar to that observed in other dieldrin 
treatment groups indicates that it is unlikely that dieldrin exerts its action on mouse 
liver by facilitating or exacerbating the action of a potent environmental carcinogen. 
Liver tumours also occurred in some mice from the groups not treated with dieldrin. 
However, these tumours were much smaller than those observed in the dieldrin groups being 
usually less than 10 mm in diameter. Two tumours from the non-dieldrin groups showed 
morphological characteristics of hepatocellular carcinomata. No lung metastases were 
observed in non-dieldrin treated animals bearing liver tumours. 
Conventional diet and sawdust bedding did not exert any obvious influence on the 
development of 'spontaneous' tumours in the livers of male CF-1 mice and it would seem 
that, even though conventional diet and sawdust contained agents that induced the mouse 
liver microsomal mono-oxygenase system, these agents have no intrinsic tumour-promoting 
activity or are present at concentrations below the threshold for overt tumour-promoting 
action. 
The fact that nodular lesions were observed in a few animals maintained on semi-
synthetic diet and filter paper bedding confirms the presence of a pre-existing oncogenic 
factor or susceptibility in this strain of mouse. This observation, together with evidence 
that dieldrin and its mammalian metabolites possess neither mutagenic activity or potential 
is consistent with the concept that dieldrin acts by facilitating the expression of this 
Pre-existing factor, probably by inducing hyperplasia in mouse liver. This rationalization 
is consistent with the more general concept that tumour-promoting agents act by inducing 
growth (hyperplasia) in their target organs. 
Comparative investigations in non-nodular and nodular liver tissue from the same 
finals revealed that mono-oxygenase, epoxide hydratase and glutathione S-epoxide trans-
ferase activities were slightly, but consistently higher in nodular liver tissue. A 
"*rked depression of G-6-Pase activity and glutathione concentration was observed in no-
dular liver tissue. 
The withdrawal of dieldrin from the diet and subsequent metabolic elimination of 
*e compound resulted in complete regression of the activities of drug-metabolizing 
««»"es in non-nodular liver tissue. Regression of enzyme activity also occurred in no-
d
"lar l i v e r tissue but control rates w e r e not attained even though no dieldrin cculd be 
detected in the tissues. 
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No changes were observed in the total DNA content of non-nodular liver tissue during 
regression which suggests that the induction of liver cell hyperplasia by microsomal 
enzyme inducers may be irreversible. 
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Samenvatting 
Van een groot aantal uiteenlopende lichaamsvreemde stoffen (xenobiotica) is bekend 
dat zij in bepaalde doseringen karakteristieke veranderingen teweeg kunnen brengen in 
levers van proefdieren (zie hoofdstuk 1). Deze veranderingen bestaan gewoonlijk uit lever-
vergroting als gevolg van een combinatie van celvergroting (hypertrofie) en celvermeer-
dering (hyperplasie), inductie van enzymen die een rol spelen bij het metabo-
lisme van lichaamsvreemde stoffen (biotransformatie-enzymen; Engels: drug-metabolizing 
enzymes) alsmede proliferatie van het gladde (Engels: smooth) endoplasmatische reticulum 
laERj. Aanwijzingen voor leverbeschadiging zijn in de meeste gevallen niet waargenomen 
en de resultaten wijzen er tevens op dat de veranderingen zeer waarschijnlijk reversibel 
van aard zijn wanneer de blootstelling van het proefdier aan de lichaamsvreemde stof 
wordt gestopt. Dientengevolge worden deze veranderingen door velen beschouwd als een aan-
passing (adaptatie) van de lever aan een verhoogde funktionele belasting. Recente toxici-
eitsproeven met muizen hebben echter uitgewezen dat blootstelling aan een aantal van 
deze lichaamsvreemde stoffen, zoals DDT, dieldrin, phénobarbital en verschillende stereo-
isomeren van hexachlorocyclohexaan (HCH), aanleiding kunnen geven tot de ontwikkeling van 
levertumoren. 
Er bestaat geen duidelijke samenhang in chemische structuur tussen deze tumorigene 
ichaamsvreemde stoffen. Deze stoffen hebben echter wel met elkaar gemeen dat zij de ac-
tiviteit van microsomale biotransformatie-enzymen en in het bij zonder de activiteit van 
het mono-oxygenasesysteem in de lever verhogen (inductie). Dit heeft geleid tot de hypo-
hese dat de inducerende eigenschappen van deze stoffen van betekenis zouden zijn bij het 
ontstaan van levertumoren in proefdieren. Deze hypothese ontleent steun aan het feit dat 
"transformatie-enzymen een belangrijke rol spelen bij de cellulaire activatie van car-
cinogene reactiviteit ui t pre-carcinogenen. 
Het doel van de in dit proefschrift beschreven studie was te onderzoeken welke in-
deed omgevingsgebonden factoren, n . l . het commerciële proefdierdieet en zaagselbedding, 
en uit
°efenen op het vóórkomen van levertumoren in CF-1 -muizen. Uit de literatuur is 
^ H j k bekend dat deze exogene factoren natuurlijke voorkomende microsomale enzym induc-
eren bevatten. Deze stoffen zouden in analogie met liehaamsweemde microsomale enzym 
Mductoren een verhogend effect kunnen uitoefenen op het vo'o'rkomen van leverturoren in 
^-muizen.
 De effecten van een conventioneel dieet (CD) en van zaagselbedding (S) werden 
™
 d i t onderzoek bestudeerd aan de hand van een controlegroep CF-1-muizen die werden ge-
Voed
 op een semi-synthetisch dieet (SSD) en gehuisvest in kooien met verknipt filtreer-
fPler a l s adding (F). Als positieve controle werd in sommige behandelingsgroepen aan 
'J V ° 5 s e l 10 mg.kg-i van het pesticide dieldrin, een enzym-inducerende stof die tevens 
^voorkomen van levertumoren in CF-1-muizen verhoogt, toegevoegd. CF-1-muizen (manne-
x
* geslacht) werden gefokt conform de experimentele behandelingswij zes, zodat blootstel-
53 
ling plaats vond gedurende de pre- en posi-natale periodes. Hiertoe werden de moederdie-
ren 14 dagen lang op de verschillende behandelingswij zes geplaatst voordat de conceptie 
plaats kon vinden. Het nageslacht verbleef b i j de moederdieren t o t de speentijd (ca. 3 
weken na de geboorte) ; op d i t t i j d s t i p werden de moederdieren en het vrouwelijk nageslacht 
gedood, waarna het mannelijk nageslacht werd gehandhaafd op de gevolgde experimentele be-
handelingswij zes. 
De resultaten van het biochemisch onderzoek (zie hoofdstuk 3) toonden aan dat chro-
nische blootstell ing van CF-1-muizen aan 10 mg d ie ldr in .kg - 1 een leververgroting van 40-
6M veroorzaakte, die gepaard ging met het voorkomen van zowel hypertrofie (= celvergro-
ting) en hyperplasie (= celvermeerdering). Het l aa t s t e fenomeen bleek de belangrijkste 
bijdrage te leveren tot de waargenomen leververgroting. Dit werd afgeleid u i t de verho-
ging van het totale DNA-gehalte van de lever, dat in een groot aantal met dieldrin be-
handelde dieren proportioneel steeg met het levergewicht. In met d ie ldr in behandelde die-
ren ging de vergroting van de lever vergezeld van activitei tsverhogingen van biotransfor-
matie-enzymen. De ac t i v i t e i t van p-ni troanisol O-demethylase, dat werd gemeten als een 
graadmeter van de mono-oxygenaseactiviteit in de lever, was na 15 weken behandeling 3 tot 
4 keer zo hoog in met dieldrin behandelde muizen. Tevens werden 2-voudige verhogingen van 
de ac t iv i t e i t van glutathion S-epoxide transferase en epoxide hydratase waargenomen, ter-
wijl de ac t iv i t e i t van UDP-glucuronyl transferase met een factor 1.5 was gestegen. Induc-
t i e van biotransformatie-enzymen in met dieldr in behandelde dieren werd ook waargenomen 
na langere blootstellingsduur (na 52 en 68-72 weken) en het patroon van de activitei ten-
verhogingen verschilde nie t wezenlijk van dat na 15 weken behandeling. 
Uit het onderzoek i s gebleken dat CD en S slechts een geringe leververgroting ver-
oorzaakten. (<10l). De DNA-metingen leverden geen aanwijzigingen op voor het optreden van 
hypexplasie, zodat de door deze factoren veroorzaakte leververgroting aan hypertrofische 
veranderingen van levercellen moet worden toegeschreven. CD en S veroorzaakten echter 
l e v e r T ! " T d i 8 e V e r h ° g i n g V 3 n ^ a C t i v i t e i t van p-ni t roanisol
 0-demethylase in de 
v e l ï t T T d e r a a n W e Z i g h S i d Vm - d a « « e enzym inductoren in dieet en bedding be-
0-7ZlZr T S V e r 0 0 r Z a a k t e " « * * * van de a c t i v i t e i t van p-ni t roanisol 
it:*Tzz::~Tr rer sterk dan in ™ i z e n die met diewrin werden 
additief
 w , Z , ° 0 r d6Ze factoren veroorzaakte enzym inductie niet 
siutathion ^ r ^ ^ r ; rp bsrraisfr t ie"enzymen 'zoais ^ h y d r a t a s e ' 
ringe mate g e s t i l e e r d e Z e ' o f Î ' ^ ^ ^ > " ^ ^ ° f * ^ * 
reJ2T«2Temlg V a n C F " 1 " m U i Z e n a a n 1 ° m « - d i e l d r i n * " ' voedsel resulteerde 
tJL^vj^r^ïï: :~n in de i- - — - — 
- op SSD en F tot 100, in £
 D " n T ^ " " "*" " ^ f "f 
meeste nodulaire lesies ™ ^ A- ,7 V e r l°° P Van de Proef bleek ^ 
cellulaire car nol Z t l r T ^ ^ < * " * Zich « t e l d e n tot hepato-
- bijna 50, v, £ £ ^ ^ ^ ^ **" ™*" « * * " *' " *" 
dood tussen 78 weken en het eind xxuxaire carcinomata, die stierven of werden ge-
Het vroegtijdig ontstaan van 6 ^  ^ P r ° e f ^ 11° Weken' metastasen hadden in de long. 
de hier beschreven studi. rn , f*™0"31 Z0U verband kunnen houden met het feit dat in 
studie CF-1-muizen reeds in utero werden blootgesteld aan dieldrin. 
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Het feit dat het hoge voorkomen van levertumoren ook werd waargenomen in muizen die op 
SSD en F werden gehandhaafd, duidt erop dat het n ie t waarschijnlijk is dat de tumorigene 
effecten van die ldr in berusten op een versterking van de werking van omgevingsgebonden 
carcinogenen, zoals aflatoxines en/of nitrosamines. 
Levertumoren kwamen eveneens voor in niet met dieldrin behandelde CF-1-muizen. Deze 
tumoren ontstonden op een l a t e r t i j d s t i p dan in met dieldrin behandelde muizen en waren 
tevens geringer in omvang (meestal <0.5 cm tegenover een omvang van 2-5 cm in met diel -
drin behandelde CF-1-muizen}. Slechts in enkele gevallen bestonden er morfologische aan-
wijzingen voor een maligne karakter. Metastasen in de long werden niet waargenomen. Een 
duidelijke invloed van CD en/of S op het vóórkomen van levertumoren in CF-1-muizen kon 
niet worden vastgesteld. Tegen het einde van de proef ontstonden meer levertumoren in 
muizen op SSD en S, dan in muizen die op SSD en F werden gehandhaafd. Een promoverend 
effect van S op het ontstaan van levertumoren in de CF-1-muis kon hieruit niet worden af-
geleid aangezien geen verschi l len werden waargenomen tussen het vóórkomen van levertumoren 
in de behandelingsgroepen CD+F en CD+S. 
Uit deze resul ta ten b l i j k t dat ondanks het fe i t dat CD en S een verhoging van de 
activiteit van het mono-oxygenasesyteem in levers van CF-1-muizen veroorzaken, er van de-
ze factoren geen promoverend effect op het ontstaan van levertumoren uitgaat. In het hui-
dige onderzoek werden levertumoren ook waargenomen in CF-1-muizen op SSD en F. Alhoewel 
ook onder deze experimentele omstandigheden niet kan worden uitgesloten dat blootstelling 
aan exogene carcinogene stoffen plaats vond, l i j k t het niet waarschijnlijk dat dergelijke 
tumoren worden veroorzaakt door exogene factoren. Op grond van de uitkomsten van di t onder-
zoek wordt verondersteld dat het ontstaan van 'spontane' levertumoren het gevolg is van 
de
 expressie van endogeen oncogeen potentiaal dat genetisch is vastgelegd en mogelijker-
wijs in oorsprong wordt veroorzaakt door een viraal genoom. De promoverende invloed van 
microsomale enzyminductoren op het ontstaan van levertumoren zou derhalve kunnen berusten 
°P de versterking van de expressie van pre-existente endogene oncogene factoren. Voor het 
meest waarschijnlijke werkingsmechanisme, n l . versnelling van de groei van pre-neoplasti-
Sche
 o e r c e l l e n a l s gevolg van de hyperplasiogene (mitogene) effecten van microsomale 
enzyminductoren, worden verschillende ondersteunende argumenten genoemd in di t proef-
schrift, waarvan het belangri jkste wellicht i s , dat de mitogene effecten van microsomale 
enzyminductoren in veel s terkere mate tot uitdrukking komen in pre-neoplastische lever-
C 6 l l e n d a n
 in het normale parenchym. 
Vergelijkend onderzoek in non-nodulair en nodulair leverweefsel van met dieldrin be-
d e l d e dieren toonde aan dat de a c t i v i t e i t van verschillende biotransformatie-enzymen 
l e t
* hoger was in nodulair leverweefsel. Een sterke daling werd echter in d i t weefsel waar-
nomen in de a c t i v i t e i t van glucose-6-phosphatase en in de concentratie van glutathion. 
H e t
 stopzetten van de b loo t s t e l l ing van 85 weken oude CF-1-muizen aan dieldrin resulteerde 
f e e n v°Hedige afname van de a c t i v i t e i t van biotransformatie-enzymen in non-nodulair 
e V e i V e e fsel to t het niveau dat in controledieren werd waargenomen. Een minder volledige 
C e s s i e van ensymactiviteit vond plaats in nodulair leverweefsel. Er bleek geen samen-
han8 te bestaan met het in de verschillende weefsels nog aanwezige dieldrinresidu, aange-
; i e» in zowel het non-nodulaire a l s ook in het nodulaire leverweefsel geen dieldrin meer 
*
0n
 »orden aangetoond.. De door die ldr in geïnduceerde leverhyperplasie bleef voortbestaan 
55 
in non-nodulair leverweefsel nadat de b loots te l l ing aan d ie ldr in was stopgezet, hetgeen 
erop wijst dat de inductie van leverhyperplasie door lichaamsvreemde stoffen naar alle 
waarschijnlijkheid nie t reversibel i s . 
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Table 1. Threshold doses for the induction of liver enlargement. Source: 
Schulte-Hermann (1974a). 
Compound 
phénobar-
bital 
pyrethrum 
Ct-HCH 
DDT 
dieldrin 
BHT 
Threshold dose 
30 mg.kg"1 
bodyweight 
85 mg.kg-1 
bodyweight 
25 mg.kg-1 
bodyweight 
10 mg.kg-1 diet 
128 mg.kg-1 
bodyweight 
0.05-1.0 
mg.kg-1 diet 
0.05 mg.kg-1 
bodyweight 
75 mg.kg-1 
bodyweight 
Application 
daily in 
drinking 
water 
daily 
once 
daily 
daily 
daily 
daily 
daily 
Animal species 
mouse 
rat 
rat 
rat 
rat 
rat 
dog 
rat 
References 
Kunz et al., 
1966a 
Springfield 
et al., 1973 
Schulte-Hermann 
et al., 1974b 
Fitzhugh et al., 
1950 
Hoffman et al., 
1970 
Fitzhugh et al., 
1964 
Walker et al., 
1969 
Walker et al., 
1969 
Gilbert & 
Golberg, 1965 
Table 2. Incidence of liver tumours in CF-1 mice fed dieldrin for 132 
weeks. Reference: Walker et al. (1973). 
Dietary 
concentration 
(mg.kg-1) 
males 
0 
0.1 
1.0 
10.0 
females 
0 
0.1 
1.0 
10.0 
Number of 
animals 
288 
124 
111 
176 
297 
90 
87 
148 
% wi 
Type 
16 
22 
23 
37 
13 
23 
31 
37 
th liver 
A1 
tumours 
Type B1 »2 
4 
4 
8 
57 
0 
4 
6 
55 
Total A + B 
20 
26 
31 
94 
13 
27 
37 
92 
1. Liver tumours were classified as Type A fin whirh „„.- u 
ture is basically retained) and TvL I nt £" I p a r e n c h v m a l struc-
is distorted). ecained^ a n d TyP* B (in which parenchymal structure 
2. Mice with Type B tumours frequently showed T„n» A •• 
but these have not been included in Column A. ™ ^ ^ ** W e U ' 
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Table 3. Incidence of liver tumours in male CF-1 mice fed 10 mg diel-
drin.kg l diet for up to 64 weeks and surviving for 104 weeks. Reference: 
Walker et al. (1973). 
Duration 
of feeding 
(weeks) 
0 
2 
4 
8 
16 
32 
64 
Number of 
animals 
18 
13 
10 
10 
11 
10 
13 
Number wi th l i v e r tumours 
Type A1 
2 
2 
0 
3 
4 
4 
6 
Type B1 Total A + B 
2 
2 
1 
4 
4 
4 
( 
( 
( 
( 
( 
( 
11%) 
15%) 
10%) 
40%) 
36%) 
40%) 
13 (100%) 
1. As in Table 2 . 
Table 4 . Inc idence of l i v e r tumours i n 3 s t r a i n s of mice exposed to d i e l d r i n for up 
to 2 y e a r s . Reference : Thorpe & Hunt (1975) . 
St ra in 
CF1 
CFlxLACG 
LACG 
CF1 
CFlxLACG 
LACG 
Sex 
male 
male 
male 
male 
male 
male 
female 
female 
female 
female 
female 
female 
Die t a ry 
concen-
t r a t i o n 
(mg.kg-1) 
0 
10 
0 
10 
0 
10 
0 
10 
0 
10 
0 
10 
Number of 
animals 
45 
30 
45 
30 
45 
29 
44 
29 
43 
30 
45 
31 
Number with liver tumours 
Type 
Ai 
2 
4 
2 
5 
3 
4 
11 
2 
0 
2 
0 
2 
Type 
Bl 
1 
12 
1 
11 
1 
3 
2 
19 
0 
10 
1 
4 
m
Total 
A + B 
3 
16 
3 
16 
4 
7 
13 
21 
0 
12 
1 
6 
% With 
liver 
tumours 
6 
53 
6 
53 
9 
24 
29 
72 
0 
40 
2 
19 
1. As in Table 2. 
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Table 5. Liver tumour incidence in two generations of CF-1 mice (P + Fj) 
exposed to DDT. Reference: Tomatis et al. (1972). 
Treatment Number of mice 
(P + Fl) 
Incidence of liver tumours 
Number 
males 
control 
DDT 2 diet 
DDT 10 mg.kg-i diet 
DDT 50 mg.kg"1 diet 
DDT 250 mg.kg"1 diet 
113 
124 
104 
127 
103 
25 
57 
52 
67 
82 
22 
46 
50 
53 
80 
females 
control 
DDT 2 mg.kg" 
DDT 10 mg.kg" 
DDT 50 mg.kg" 
DDT 250 mg.kg" 
diet 
diet 
diet 
diet 
111 
111 
124 
104 
90 
4 
4 
11 
13 
69 
4 
4 
9 
13 
77 
1. The liver tumour incidence reported in this study is based on the num-
ber of mice surviving at the time of appearance of the first tumour at 
any site in each group (effective number of mice). 
Table 6. Carcinogenicity studies with phenobarbitone in mice. 
Strain 
CF-1 
C3H 
CF-1 
1. The 
Sex 
male 
female 
male 
female 
male 
female 
Duration 
109 
109 
52 
52 
120 
120 
liver tumour 
time that the : first 
Dose 
0 mg.kg"1 
500 mg.kg ! 
0 mg.kg ! 
500 mg.kg ! 
0 mg.kg ! 
500 mg.kg"1 
0 mg.kg ! 
500 mg.kg"1 
0 
0.05% in 
diet 
diet 
diet 
diet 
diet 
diet 
diet 
diet 
drinking water 
0 
0.05% in 
drinking water 
incidence in this study 
tumour was observed. 
Number of 
45 
30 
44 
28 
37 
36 
39 
29 
44 
98 
47 
73 
was based 
Liver 
Number 
11 
24 
10 
21 
25 
35 
5 
29 
12 
77 
0 
45 
on the 
tumour inc 
% 
24 
80 
23 
75 
68 
97 
13 
100 
271 
7R1 
_1 
62 
number of 
idence Reference 
Thorpe & 
Walker 
(1973) 
Peraino et 
al. (1973a) 
Ponomarkov 
et al. 
(1976) 
survivors at the 
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Table 7. Carcinogenicity studies with hexachlorocyclohexane (HCH) in mice. 
Strain Sex 
dd 
dd 
male 
male 
CF-1 male 
female 
Dose Duration Number of Incidence of Reference 
(mg.kg 1 diet) (weeks) mice liver tumours 
0 
6.6 HCH1 
66.0 HCH1 
666.0 HCH1 
0 
100 ex-HCH 
250 a-HCH 
500 a-HCH 
100 ß-HCH 
250 0-HCH 
500 ß-HCH 
100 y-HCH 
250 Y-HCH 
500 Y-HCH 
100 6-HCH 
250 6-HCH 
500 &-HCH 
o 
200 6-HCH 
400 Y-HCH 
0 
200 ß-HCH 
400 Y-HCH 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
24 
110 
110 
110 
110 
110 
110 
14 
20 
20 
20 
20 
20 
38 
20 
20 
20 
20 
20 
20 
20 
20 
20 
20 
45 
30 
29 
44 
30 
29 
Number 
0 
0 
0 
20 
0 
0 
30 
20 
0 
0 
0 
0 
0 
0 
0 
0 
0 
11 
22 
27 
10 
13 
20 
% 
-
-
-
100 
-
-
79 
100 
-
-
-
— 
— 
— 
— 
— 
— 
24 
73 
93 
23 
43 
69 
Nagasaki et al. 
(1971, 1972) 
Ito et al. 
(1973) 
Thorpe S Walker 
(1973) 
1. Technical HCH, the composition of which was: 66.6% a 
Y-isomer, 6.3% S-isomer and 0.6% others. 
-isomer, 11.3% g-isomer, 15.2% 
Table 8. The incidence of liver nodules in male and female 
Wistar rats exposed to DDT or phenobarbitone-sodium (Ph-Na) 
for up to 152 weeks. Reference: Rossi et al. (1977). 
Treatment Initial number 
of animals1 
Total number of animals 
with liver nodules 
number % 
males 
DDT 500 mg.kg-1 (2 26 
Ph-Na 500 mg.l -1 0 22 
females 
DDT 500 mg.kg-1 (2 27 
Ph-Na 500 mg.l -1 (3 28 
9 
13 
15 
9 
34.6 
59.0 
55.5 
32.1 
1. Survivors at time first liver nodule was observed in each 
group. 
2
- In the diet. 
3
- In the drinking water. 
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Table 9. Carcinogenicity studies with dieldrin in the rat. 
Strain Sex Duration 
(weeks) 
Osborne males 104 
Mendel and 
females2 
CFE males 104 
females 104 
Osborne males 110-111 
Mendel 
females 110-111 
Fisher males 104-105 
344 
females 104-105 
1. Examined histologically. 
2. Equally divided by sex. 
Dietary 
concentra-
tion (mg.kg-1.) 
0 
0.5 
2 
10 
50 
100 
150 
0 
0.1 
1.0 
10.0 
0 
0.1 
1.0 
10.0 
0 
29 
65 
0 
29 
65 
0 
2 
10 
50 
0 
2 
10 
50 
Number of 
animals1 
17 
22 
23 
18 
20 
18 
11 
43 
23 
23 
23 
43 
23 
23 
23 
10 
46 
50 
10 
47 
48 
24 
24 
24 
24 
24 
24 
24 
24 
Total 
with 
animals 
tumours 
number % 
3 
8 
8 
4 
4 
3 
0 
12 
6 
5 
8 
19 
15 
14 
12 
5 
24 
22 
7 
39 
27 
24 
23 
24 
23 
17 
17 
16 
14 
18 
36 
35 
22 
20 
17 
-
28 
26 
22 
35 
44 
65 
61 
52 
50 
52 
44 
70 
83 
56 
100 
96 
100 
96 
71 
71 
67 
58 
Remarks on 
liver 
lesions 
enlarged 
centrilobu-
lar cells in 
dieldrin-
treated rats, 
no liver 
cell tumours 
three fema-
les on 10 
mg dieldrin. 
kg-1 and one 
control fe-
male showed 
focal hyper-
plasia for-
ming micros-
copic hyper-
plastic nodu-
les 
low incidence 
of neoplastic 
lesions with 
no apparent 
increased 
frequency 
for treated 
groups over 
controls 
two control 
males and 
four males 
on 50 mg diel-
drin . kg-1 
showed no-
dular hyper-
plasia which 
was classi-
fied as a 
non-neoplas-
tic lesion 
Reference 
Fitzhugh 
et al. 
(1964) 
Walker 
et al. 
(1969) 
NCI 
(1978a) 
NCI 
(1978b) 
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Table 10. Liver tumour inc idence i n male Wistar r a t s t r e a t e d with HCH. 
Reference: I t o e t a l . (1975) . 
HCH-isomer 
ot 
a 
a 
a 
a 
a 
e 
e $ 
Y 
Y 
control 
Dietary 
concentration (mg. kg-1) 
1 500 
1 000 
1 000 
1 000 
500 
500 
1 000 
500 
500 
500 
500 
Duration 
(weeks) 
72 
72 
48 
24 
48 
24 
24 
48 
24 
48 
24 
72 
Liver tumours 
Nodular 
hyperplasia 
10/13 
12/16 
5/12 
0/8 
0/5 
0/6 
0/6 
0/5 
0/8 
0/8 
0/6 
0/8 
(77%) 
(75%) 
(42%) 
-
-
-
-
-
-
-
-
-
Hepatocellular 
carcinomata 
3/13 
1/16 
0/12 
0/8 
0/5 
0/6 
0/6 
0/5 
0/8 
0/8 
0/6 
0/8 
(23%) 
( 6%) 
-
-
-
-
-
-
-
-
-
-
Table 11. Extent of b ind ing of d i e l d r i n or i t s me tabo l i t e s to l i v e r 
DNA. Reference: Wright e t a l . (1977) . 
Species 
(strain) 
d é s i n t é g r a t i o n s . 
- 1 ™ „ - l 
D i e l d r i n 
min" 1 .mg" 1 DNA pg equxv.mg" DNA 
molecule 
equiv. 109 
nuc leo t ide 
u n i t s - 1 
Rat (CFE) 
Mouse (CF-1) 
Mouse (LACG) 
0.614 
0.232 
0.053 
1.92 
0.724 
0.163 
1.52 
0.58 
0.13 
Individual animals in each group of 10 rats or mice received a 
single i.p. injection of \lkC\ -dieldrin in dimethylsulphoxide 
(0.1 ml') equivalent to 14.5 uCi (370 ug.kg-1 bodyweight) for the 
rats and 1.45 uCi (400 pg.kg-1 bodyweight) for the two mouse 
strains. The animals were killed by decapitation exactly 3 hours 
!ater. The livers were pooled according to species and strain. 
Table 12. Experimental treatments. SSD = 
semi-synthetic diet; CD = conventional diet; 
F
 • filter paper; S = sawdust. 
Diet 
SSD 
SSD 
SSD 
SSD 
CD 
CD 
CD 
CD 
Bedding 
F 
S 
F 
S 
F 
S 
F 
S 
Dieldrin 
(mg.kg-1 diet) 
0 
0 
10 
10 
0 
0 
10 
10 
63 
1 
2 
3 
4 
5 
6 
7 
8 
SSD 
SSD 
SSD 
SSD 
CD 
CD 
CD 
CD 
F 
S 
F 
S 
F 
S 
F 
S 
0 
0 
10 
10 
0 
0 
10 
10 
Table 13. Treatment groups sizes after weaning. 
Diet Bedding Dieldrin Treatment size 
(mg.kg-1 diet) 
85 
60 
79 
47 
93 
113 
100 
64 
Total 614 
Abbreviations as in Table 12. 
Table 14. Composition per 100 g of Laboratory Animal Diet 
no. 2. Based on information supplied by the manufacturer. 
Chemical composition 
moisture 8 g 
ether extract 4.5 g 
crude protein 21.5 g 
crude fibre 2.7 g 
• total digestible nutrients 78 g 
Vitamin and mineral composition 
lysine 1.1 g 
methionine 0.39 g 
calcium 0.9 g 
phosphorus 0.8 g 
vitamin A 1100 i.u. 
vitamin D3 120 i.u. 
a-tocopherol (E) 2.4 i.u. 
vitamin K3 1.0 mg 
riboflavin (B2) 0.7 mg 
pyridoxine (added) (Bê) 0.1 mg 
pantothenic acid 1.7 mg 
nicotinic acid (niacin) 8.0 mg 
folic acid 0.02 mg 
choline chloride (added) 45,0 mg 
cyanocobalamin (B12) 1.5 ug 
manganese 6.5 mg 
iron 10.0 mg 
iodine 0.05 mg 
copper 2.0 mg 
zinc 4.0 mg 
cobalt 0.1 mg 
digestible energy: 14.3 kJ.g-1 
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Table 15. Composition of semi-synthetic diet (per 100 g). 
protein 
carbohydrates 
fat 
vitamins 
casein 
corn starch 
potato starch 
sucrose 
corn oil 
thiamine (Bi ) 
riboflavine (B2) 
pyridoxine-HCl (Bg) 
nicotinic acid (niacin) 
calcium pantothenate 
biotin (H) 
menapthone (K3) 
a-tocopherol (E) 
vitamin D3' 
vitamin A 
cyanocobalamin (B12) 
choline chloride 
minerals calcium citrate 
potassium dihydrogen 
phosphate 
magnesium carbonate 
magnesium sulphate.7 H20 
manganous sulphate.4 H20 
zinc carbonate 
ammonium ferric 
citrate 
copper sulphate 
sodium fluoride 
potassium iodate 
calcium hydrogen 
or thophosphate 
calcium carbonate 
sodium chloride 
23.6 g 
46.7 g 
10.0 g 
5.0 g 
10.0 g 
0.4 
0.5 
0.6 
1.0 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
i.u. 
i.u. 
i.u. 
1 
0 
0 
7 
100 
500 
2 
100 mg 
47.6 mg 
1.36 g 
141 mg 
338 mg 
18.4 mg 
4.0 mg 
45.0 mg 
2.6 mg 
0.5 mg 
0.3 mg 
1.05 g 
910 mg 
700 mg 
Metabolizable energy (calculated): 18.3 kJ.g" •1 
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Table 16. Bodyweight1»2. The results are expressed in g. 
Treatments Exposure time (weeks) 
diet bedding dieldrin n3 15 n 52 n 68-72 n 92 
(mg.kg-1 diet) 
4 34.2±0.8"* 4 39.9±4.5 3 38.2± 1.7 6 42.8±7.2 
4 35.4±J,9 6 41.4±3.0 8 38.5± 4.5 
4 35.1±0.6 5 40.6±7.5 3 42.7± 4.1 6 37.4±5.2 
4 33.8±1.9 6 41.6±5.0 5 46.8±5.1* 
4 39.lil.7** 4 42.2±6.5 2 45.4;39.0 6 44.7±2.9 
4 36.4±1.8 6 46.6±5.0* 6 42.8±5.1 
4 35.8±4.1 5 44.9±4.1 2 46.8;50.3** 6 40.3±5.8 
4 37.8±1.7** 6 46.8±4.2* 4 41.2± 1.8 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg 
dieldrin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
SSD 
SSD 
CD 
CD 
F 
S 
F 
S 
0 
10 
0 
10 
0 
10 
0 
10 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
15 
n.s. 
n.s. 
n.s. 
n.s. 
52 
n.s. 
n.s. 
n.s. 
n.s. 
68-72 
n.s. 
n.s. 
n.s. 
n.s. 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 18. Liver DNA concentration (non-nodular tissue)1'2. The results are expressed in 
mg liver DNA.g-1 liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
dieldrin 
(mg.kg-1 
0 
10 
0 
10 
0 
10 
0 
10 
diet) 
Exp 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
osure time (weeks) 
15 
3.0310.211* 
2.50±0.15** 
2.76±0.19 
2.28±0.05*** 
2.70±0.15* 
2.60±0.13* 
2.60±0.20* 
2.47±0.32* 
n 
4 
6 
5 
6 
4 
6 
5 
6 
52 
2.59i0.26 
2.39±0.22 
2.59±0.11 
2.53±0.09 
2.59±0.28 
2.82±0.34 
2.58±0.I4 
2.28±0.27 
n 
3 
8 
3 
5 
2 
6 
2 
4 
68-72 
2.62±0.09 
2.73±0.15 
2.79±0.06* 
2.41±0.1I* 
2.83;3.00* 
2.59±0.14 
3.05;2.85* 
2.53±0.19 
n 
6 
6 
6 
6 
92 
2.66±0.13 
3.00±0.21** 
2.59±0.17 
2.77±0.32 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg dieldi 
kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
15 
** 
** 
n.s. 
n.s. 
52 
n.s. 
n.s. 
n.s. 
* 
68-72 
n.s. 
** 
* 
* 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 19. Tota l l i v e r DNA in non-nodular l i v e r s 1 ' 2 . The r e s u l t s a r e expressed i n mg l i v e r 
DNA. 100 g _ 1 bodyweight. 
Treatments Exposure time (weeks) 
diet bedding d i e l d r i n n 3 15 n 52 n 68-72 n 92 
(mg.kg 1 d i e t ) 
4 12.8+0.5h 4 10.4+0.6 3 1 2 . 7 + 1 . 3 6 11.1+0.7 
4 16.1+0.9*** 6 15.3+2.3** 5 2 4 . 0 + 3 . 4 * * 
4 12.6+0.6 5 10.9+0.7 3 1 1 . 3 + 0 . 7 6 15.3+1.9** 
4 16.4+0.7*** 4 19.7+4.7** 1 23.4 
4 13.0+0.5 4 12.3+1.3* 2 11.6;18.5 6 10.7+0.7 
4 17.1+1.0*** 4 18.4+3.6** 2 23 .4 ;22 .1 
4 12.5+1.0 5 12.7+0.9** 2 12.9;12.4 6 14.4+2.2 
4 17.1+2.5* 4 18.3+4.4** 
SSD 
SSD 
CD 
CD 
F 
S 
F 
S 
0 
10 
0 
10 
0 
10 
0 
10 
* 
Abbreviations as in Table 12. . . 
1. Significance of the difference between treatment and control mean (=SSD + F + 0 mg dieldrin. 
kg"1): *p<0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD
 + F : 0 mg.kg--1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD
 + F : 0 mg.kg-1 v 10 mg.kg-1 
CD
 + S : 0 mg.kg-1 v 10 mg.kg-1 
15 52 68-72 
*** *** ** 
*** ** 
*** * 
* * 
* P < 0.05; **p < 0.01;***p < 0.001; n.s.: not significant 
(P > 0.05). 
3. Number of individual observations. 
4. Mean +_ standard deviation. 
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Table 22. Liver microsomal protein (non-nodular tissue)1'2. The results are expressed in 
mg protein.g-1 liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S ' 
dieldrin 
(mg.kg-1 
0 
10 
0 
10 
0 
10 
0 
10 
diet) 
Exp< 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
Dsure time (weeks) 
15 
98.5± 4.81* 
93.1± 2.6 
94.0± 6.6 
101.3±_ 7.2 
99.0± 4.4 
107.1± 8.0 
97.3±11.3 
104.3+12.7 
n 
4 
6 
5 
6 
4 
6 
5 
6 
52 
84.2±5.8 
87.4±3.8 
82.5±2.3 
88.6±6.9 
83.7±3.3 
94.6±1.9** 
87.7±6.5 
91.5±5.0 
n 
2 
8 
3 
5 
2 
6 
2 
4 
68-72 
96.8; 91.8 
94.5± 7.5 
84.5i 15.4 
85.Oi 6.4 
99.2; 114.7 
93.8± 8.0 
99.3; 81.8 
92.3±. 9.9 
n 
6 
6 
6 
6 
92 
75, 
75, 
81, 
86, 
,1±10.3 
,6i 7.2 
,5± 5.3 
,6± 6.9: 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg diel-
drin. kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
15 
n.s. 
n.s. 
n.s. 
n.s. 
52 
n.s. 
n.s. 
*** 
n.s. 
68-72 
n.s. 
n.s. 
n.s. 
n.s. 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 23. Liver s o l u b l e p r o t e i n (non-nodular t i s s u e ) 1 » 2 . The r e s u l t s a r e expressed in 
mg p r o t e i n . g - 1 l i v e r . 
Treatments Exposure time (weeks) 
diet bedding d i e l d r i n 
(mg.kg - 1 d i e t ) 
SSD F 0 
10 
SSD S 0 
10 
CD F 0 
10 
CD S 0 
10 
Abbreviations as i n Table 12. 
' •S ign i f i cance of t he d i f f e r e n c e between t rea tment and cont ro l mean (= SSD + F + 0 mg d i e l -
drin . k g - 1 ) : *p < 0 . 0 5 ; **p < 0 . 0 1 ; ***p < 0 .001 . 
2. Dieldrin ve r sus n o n - d i e l d r i n s t a t i s t i c a l a n a l y s i s : 
Exposure time (weeks) 
0 mg.kg-1 v 10 mg.kg- 1 
0 mg.kg- 1 v 10 mg.kg- 1 
0 mg.kg- 1 v 10 mg.kg- 1 
0 mg.kg- 1 v 10 mg.kg- 1 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
15 
71.4±2.01( 
69.4±4.0 
70.8+1.8 
70.3±4.8 
69.0±1.2 
66.1±2.1 
66.6±6.0 
69.6+1.6 
n 
4 
5 
4 
5 
4 
5 
5 
5 
52 
59.7±3.1 
61.7±2.9 
63.2±2.9 
63.9±1.5 
61.2±3.0 
63.2±3.8 
60.4±2.5 
61.7±3.3 
n 
2 
6 
3 
5 
2 
4 
2 
4 
68-72 
61.8;62.9 
66.4± 6.5 
65.3± 1.8 
60.5± 2.0 
80.3;81.0* 
66.6i 4.3 
66.3;68.1 
67.0± 3.9 
n 
6 
6 
6 
6 
92 
63.5±7.4 
65.9±7.5 
65.8±4.4 
66.3±4.1 
15 
n.s. 
n.s. 
n.s. 
n.s. 
52 
n.s. 
n.s. 
n.s. 
n.s. 
68-72 
n.s. 
n.s. 
** 
n.s. 
. . - , **p < 0 . 0 1 ; ***p < 0 . 0 0 1 ; n . s . : not s i g n i f i c a n t 
(P > 0 .05) . 
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Table 24. Total liver protein/liver DNA quotients (non-nodular tissue)1» .2 
Treatments 
diet bedding dieldrin 
(mg.kg-1 diet) 
SSD F 0 
10 
SSD S 0 
10 
CD F 0 
10 
CD S 0 
10 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
15 
75.5+3.41» 
90.4±6.2** 
82.3±2.5* 
93.4±2.8*** 
83.9±3.0* 
85.4±8.9 
80.8±3.8 
92.2±6.9**, 
n 
4 
6 
5 
6 
4 
6 
5 
6 
52 
81.6± 5.6 
88.2± 6.8 
79.8± 1.8 
81.2±. 4.6 
81.8±_ 9.4 
81.6± 9.8 
78.9i 2.0 
90.3±13.6 
n 
2 
8 
3 
5 
2 
6 
2 
4. 
68-72 
78.6;80.9 
77.9±. 3.5 
78.7± 0.8 
81.6±. 6.8 
86.7;85.6* 
80.li 6.0 
79.5;79.4 
83.5± 1.8 
n 
6 
6 
6 
6 
92 
75. 
68, 
78, 
78, 
,5±6, 
,0±8, 
,9±6, 
,9+7, 
,7 
,3 
,4 
,6 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg diel-
drin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
15 
** 
*** 
n.s. 
* 
52 
n.s. 
n.s. 
n.s. 
n.s. 
68-72 
n.s. 
n.s. 
n.s. 
n.s. 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
3. Number of individual observations. 
4. Mean +- standard deviation. 
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Table 25. Liver microsomal p r o t e i n / l i v e r DNA q u o t i e n t s (non-nodular t i s s u e ) » . 
Treatments Exposure time (weeks) 
diet bedding d i e l d r i n n 3 15 n 52 n 68-72 n 92 
(mg.kg - 1 d i e t ) 
SSD
 F 0 4 32.8±3.7£f 4 33.1±3.2 2 35 .6 ;35 .6 6 28.4±4.8 
10 4 37.3±1.4 6 36.9*3.4 8 34.7± 2.3 
SSD
 S 0 4 34.2±3.2 5 31.9±1.5 3 3 0 . 3 ± 5 . 1 6 25.3±3.9 
10 4 44.4±3.3** 6 35.8±3.2 4 35.4± 3.6 
CD
 F 0 4 36.7±1.4 4 32.7*3.7 2 35 .0 ;38 .2 6 33.2*4.4 
10 4 41 .6±4 .1* 6 35.5±4.2 6 36 .4* 4.0 
CD
 S 0 4 37.5*4.6 5 34.0±2.5 2 32 .6 ;28 .7 6 31.6*4.0 
10 4 41.4*5.2* 6 41.1*4.7* 
Abbreviations as i n Table 12. 
'• S ignif icance of the d i f f e r e n c e between t rea tment and con t ro l mean (= SSD + F + 0 mg d i e l -
d r i n . k g " 1 ) : *p < 0 . 0 5 ; **p < 0 . 0 1 ; ***p < 0 .001) . 
2. Die ldr in ve r su s n o n - d i e l d r i n s t a t i s t i c a l a n a l y s i s : 
Exposure time (weeks) 
SSD + F : 0 mg.kg- 1 v 10 mg.kg- 1 
SSD + S : 0 mg.kg- 1 v 10 mg.kg-1 
CD + F : 0 mg.kg- 1 v 10 mg.kg- 1 
CD
 + S : 0 mg.kg- 1 v 10 mg.kg- 1 
15 
n . s . 
** 
n . s . 
n . s . 
52 
n . s . 
* 
n . s . 
* 
68-72 
n . s . 
n . s . 
n . s . 
n . s . 
*P < 0 .05; **p < 0 . 0 1 ; ***p < 0 . 0 0 1 ; n . s . : not s i g n i f i c a n t 
(P > 0 .05 ) . 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 26. Liver soluble protein/liver DNA_quotients (non-nodular tissue)1»2. 
Treatments Exposure time (weeks) 
diet bedding dieldrin n3 15 n 52 n 68-72 n 92 
(mg.kg-1 diet) 
SSD F 0 4 24.7±2.14 4 23.4±1.6 2 22.7;24.4 6 24.0±3.0 
10 4 28.5±1.7* 5 26.2±2.3 6 24.6± 2.7 
SSD S 0 4 26.7±0.4 4 24.3±1.4 3 23.4± 0.6 6 22.0±2.6 
10 4 30.8±2.2** 5 25.5±1.3 5 25.2± 1.3 
CD F 0 4 26.0±1.7 4 23.9±2.6 2 28.4;27.0* 6 25.1±1.5 
10 4 25.2±1.8 5 23.9±2.2 4 26.1± 1.4 
CD S 0 4 26.2±1.6 5 23.4±1.1 2 21.7;23.9 6 24.2±3.2 
10 4 29.0±0.8** 5 27.6±4.7 4 26.5± 0.5** 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg diel-
drin. kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
15 52 68-72 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 * n.s. n.s. 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 ** n.s. n.s. 
CD t F : 0 mg.kg-1 v 10 mg.kg-1 n.s. n.s. n.s. 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 * n.s. ** 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p < 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 30. Liver UDP-glucuronyl transferase specific activity (non-nodular tissue)1^2. The 
results are expressed in nmol p-nitrophenol conjugated.mg-1 microsomal protein.min l . 
Treatments Exposure time (weeks) 
diet bedding 
SSD 
SSD 
CD 
CD 
dieldrin 
(mg.kg-1 diet) 
0 
10 
0 
10 
0 
10 
0 
10 
15 
1.08±0.13 , ( 
1.60±0.16* 
1.18±0.28 
1.59±0.04** 
1.41±0.19 
1.65±0.02*' 
1.16±0.40 
1.66±0.03*" 
n 52 n 68-72 
1.61±0.13 
2.17±0.19** 
1.70±0.16 
1.99±0.10** 
1.70±0.17 
1.89±0.12* 
1.63±0.05 
2.08±0.10** 
I . 7 4 ; 1 . 8 6 
2.50±0.31* 
1 .52; I .14* 
2.27±0.14 
1.53;1.54 
2.37±0.48 
1.87;1.16 
2.54±0.50 
n 92 
6 1.48±0.10 
6 1.35±0.26 
6 l'.48±0.12 
6 1.47±0.19 
Abbreviations as in Table 12. 
1. Significance of the'difference between treatment and control mean (= SSD + F + 0 
drin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not signifi-
cant (p > 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
diel-
15 
** 
n . s . 
n . s . 
n . s . 
52 
** 
* 
n . s . 
*** 
68-72 
* 
*** 
n . s . 
n . s . 
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Table 34. Liver UDP-glucuronyl transferase activity per unit DNA (non-nodular tissue)1»2. 
The results are expressed in nmol p-nitrophenol conjugated.mg-1 liver DNA.min-1. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
die ldrin 
(mg.kg-1 
0 
10 
0 
10 
0 
10 
0 
10 
diet) 
Exposure time (weeks) 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
15 
32.8± 5.01* 
60.3± 8.1** 
41.3±I1.9 
73.2±. 4.4*** 
51.5± 5.0* 
65.4± 1.7*** 
43.1± 9.4 
67.6± 9.9** 
n 
3 
5 
4 
5 
3 
5 
4 
5 
52 
52.6± 5.6 
77.5±12.4* 
52.9i 2.7 
69.5± 8.7* 
54.0± 9.0 
68.9± 9.6* 
56.4± 3.9 
86.2±13.0** 
n 
2 
8 
2 
5 
2 
6 
2 
4 
68-72 
63.3;61.9 
87.2±15.8 
47.8;45.7** 
80.5±10.9 
53.6;58.9 
92.6±24.3 
60.9;33.3 
94.5±25.4 
n 
6 
6 
6 
6 
92 
41.6±5.3 
33.9±6.7! 
45.8±2.0 
46.5±8.5 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg diel-
drin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
15 
** 
** 
** 
* 
52 
* 
* 
n.s. 
** 
68-72 
n.s. 
** 
n.s. 
n.s. 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 36. Liver glucose-6-phosphatase activity per unit DNA (non-nodular tissue)1»2. 
The results are expressed in yg at P^.mg 1 liver DNA.min-1. 
Treatments Exposure time (weeks) 
diet bedding dieldrin 
(mg.kg-1 diet) 
SSD F 0 
10 
SSD S 0 
10 
CD F 0 
10 
CD S 0 
10 
n^ 
4 
4 
4 
4 
4 
4 
4 
4 
15 
8.6±0.51( 
9.2±0.8 
8.6±0.8 
9.2±0.4 
9.7±0.3 
9.3±0.9 
9.9±0.7 
9.7±1.1 
n 
4 
6 
5 
6 
4 
6 
5 
6 
52 
8.1±0.7 
7.5±1.0 
7.8±0.6 
7.0±1.5 
8.5±1.3 
6.8±1.2 
8.6+.1.4 
7.9±1.0 
n 
2 
8 
3 
5 
2 
6 
2 
4 
68-72 
8.9; 9.3 
7.9±. 1.0 
8.3± 1.7 
6.0± 1.0** 
9.2;10.4 
8.4±. 0.8 
7.4; 8.6 
7.8± 0.5 
n 
6 
6 
6 
6 
92 
7.7±0. 
5.1±0, 
8.9+1. 
8.7±1 
,9 
5*** 
.2 
.4 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean (= SSD + F + 0 mg diel-
drin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
15 
n.s. 
n.s. 
n.s. 
n.s. 
52 
n.s. 
n.s. 
n.s. 
n.s. 
68-72 
n.s. 
* 
n.s. 
n.s. 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not significant 
(p > 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 37. L iver g l u t a t h i o n e c o n c e n t r a t i o n (non-nodular t i s s u e ) 1 » 2 . The 
resul t s a r e expressed i n u m o l . g - 1 l i v e r . 
Treatments Exposure time (weeks) 
diet bedding d i e l d r i n 
(mg.kg - 1 d i e t ) 
SSD F 0 
10 
SSD S 0 
10 
CD F 0 
10 
CD S 0 
10 
n 3 
4 
4 
4 
4 
4 
4 
4 
4 
52 
9.9±0.2 l t 
10.2±0.5 
10.5±0.5 
10.1±0.7 
9.9+0.5 
9.8±0.7 
10.6±0.3 
10.3±0.3 
n 
3 
8 
2 
5 
2 
6 
2 
4 
68-72 
10.5± 0.2 
10.9± 0.9 
11.8± 0.2 
11.1± 1.2 
9 . 9 ; 9.3 
9.9± 0.4 
10 .2 ;10 .5 
10.3± 0.6 
n 
6 
6 
6 
6 
92 
10, 
10, 
10, 
11. 
,9±0, 
,7±0. 
,9±0. 
,2±0. 
,5 
,8 
,2 
,6 
Abbreviations as i n Table 12. 
1. S igni f icance of t he d i f f e r e n c e between t reatment and con t ro l mean 
(= SSD + F + 0 mg d i e l d r i n . k g - 1 ) : *p < 0 .05 ; **p < 0 . 0 1 ; ***p < 0 .001 . 
2. Die ld r in v e r s u s n o n - d i e l d r i n s t a t i s t i c a l a n a l y s i s : 
Exposure time (weeks) 
n. 
n, 
n. 
n. 
, s . 
, s . 
, s . 
, s . 
n . s . 
n . s . 
n . s . 
n . s . 
52 68-72 
SSD + F : 0 mg.kg- 1 v 10 mg.kg- 1 
SSD + s : 0 mg.kg- 1 v 10 mg.kg- 1 
CD + F : 0 mg.kg- 1 v 10 mg.kg- 1 
CD
 + S : 0 mg.kg- 1 v 10 mg.kg- 1 
*P < 0 .05 ; **p < 0 . 0 1 ; ***p < 0 . 0 0 1 ; n . s . : not 
s ign i f i can t (p > 0 . 0 5 ) . 
3. Number of i n d i v i d u a l o b s e r v a t i o n s . 
*• Mean ± s t andard d e v i a t i o n . 
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Table 38. Liver glutathione concentration per unit DNA (non-nodular 
tissue)1»2. The results are expressed in umol.mg-1 liver DNA. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
dieldrin 
(mg.kg-1 
0 
10 
0 
10 
0 
10 
0 
10 
diet) 
Exp 
n3 
4 
4 
4 
4 
4 
4 
4 
4 
osure time 
52 
4.1*0.3"* 
4.1±0.3 
4.2±0.2 
4.1±0.4 
4.0±0.5 
3.8±0.5 
4.0±0.1 
4.5±0.8 
(weeks) 
n 
3 
8 
2 
5 
2 
6 
2 
4 
68-72 
4.0±0.1 
4.0±0.5 
4.1;4.4 
4.6±0.4 
3.3;3.3 
3.9±0.3 
3.8;4.0 
4.1±0.3 
n 
6 
6 
6 
6 
92 
4.1±0.2 
3.6±0.3** 
4.2±0.3 
4.1±0.4 
Abbreviations as in Table 12. 
1. Significance of the difference between treatment and control mean 
(= SSD + F + 0 mg dieldrin.kg-1): *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Dieldrin versus non-dieldrin statistical analysis: 
Exposure time (weeks) 
52 68-72 
SSD + F : 0 mg.kg-1 v 10 mg.kg-1 
SSD + S : 0 mg.kg-1 v 10 mg.kg-1 
CD + F : 0 mg.kg-1 v 10 mg.kg-1 
CD + S : 0 mg.kg-1 v 10 mg.kg-1 
n. 
n, 
n, 
n< 
s. 
.s. 
.s. 
.s. 
n.s. 
n.s. 
n.s. 
n.s. 
*p < 0.05; **p < 0.01; ***p < 0.001; n.s.: not 
significant (p > 0.05). 
3. Number of individual observations. 
4. Mean ± standard deviation. 
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Table 42. DNA concentration in non-nodular and nodular liver tissue of dieldrin-
treated CF-1 mice. The results are expressed in mg.g"1 liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
1. *p < 0.05; 
dieldrin 
(mg.kg" 
10 
10 
10 
10 
**p < 0. 
-l 
01 
diet) 
; n.s. 
Exposure 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
liver 
tissue 
2.75 
2.74 
2.84 
2.62 
2.49 
2.30 
2.36 
2.46 
2.57 
3.04 
3.04 
2.43 
2.67 
2.50 
2.80 
2.32 
2.42 
2.77 
2.38 
2.59 
2.38 
Nodular 
tissue 
2.47 
2.87 
2.37 
2.23 
2.56 
2.43 
2.41 
2.13 
2.11 
2.52 
3.01 
2.37 
2.35 
2.24 
2.46 
2.30 
2.62 
2.42 
2.52 
2.57 
2.47 
: not significant (p > 0.05), 
Percentage 
decrease(-) 
in nodular 
liver tissue 
-10.2 
4.7 
-16.5 
-14.9 
2.8 
5.7 
2.1 
-13.4 
-17.9 
-17.1 
- 1.0 
- 2.5 
-12.0 
-10.4 
-12.1 
- 0.9 
8.3 
-12.6 
5.9 
- 0.8 
3.8 
Significance1 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 43. Total protein concentration in non-nodular and nodular liver tissue of diel-
drin-treated CF-1 mice. The results are expressed in mg protein.g liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD s 
Abbreviations 
1. *P < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in Table 
**p < 0.01; 
12. 
n.s, 
Exposure 
time 
(weevs) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
219.6 
204.7 
219.6 
211.8 
190.1 
200.5 
203.7 
179.6 
193.6 
210.0 
223.4 
216.1 
197.9 
213.4 
209.5 
200.5 
220.7 
230.8 
204.0 
210.5 
199.1 
, ; not significant 
Nodular 
liver 
tissue 
223.6 
211.5 
204.9 
215.7 
174.8 
186.6 
188.4 
195.5 
152.4 
199.7 
208.2 
208.9 
198.4 
187.4 
198.4 
188.4 
202.4 
203.7 
221.6 
209.6 
196.0 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
1.8 
3.3 
- 6.7 
1.8 
- 8.0 
- 6.9 
- 7.5 
3.3 
-21.3 
- 4.9 
- 6.8 
- 3.3 
0.3 
-12.2 
- 5.3 
- 6.0 
- 8.3 
-11.7 
8.6 
- 0.4 
- 1.6 
• 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
— 
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Table 44. Microsomal protein concentration in non-nodular and nodular liver tissue of 
dieldrin-treated CF-1 mice. The results are expressed in mg protein.g-1 liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in Table 12. 
**p < 0.01; n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
94.8 
84.1 
98.8 
94.0 
82.7 
92.5 
81.5 
75.9 
87.4 
97.3 
92.7 
107.2 
94.0 
82.5 
95.8 
86.9 
98.4 
104.0 
97.8 
90.3 
81.0 
: not significant 
Nodular 
liver 
tissue 
75.9 
86.8 
76.6 
102.7 
72.3 
83.2 
76.0 
73.8 
64.7 
80.8 
89.2 
69.8 
86.1 
68.9 
91.8 
79.8 
88.4 
96.6 
101.7 
99.1 
90.2 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-19.9 
3.2 
-22.5 
9.3 
-12.6 
-10.1 
- 6.7 
- 2.8 
-26.0 
-17.0 
- 3.8 
-34.9 
- 8.4 
-16.5 
- 4.2 
- 8.2 
-10.2 
- 7.1 
4.0 
9.7 
11.4 
• 
Significance1 
non—no du1ar 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
94 
Table 45. Soluble protein concentration in non-nodular and nodular l iver t issue of 
dieldrin-treated CF-1 mice. The resul t s are expressed in mg protein.g - 1 l iver . 
Treatments 
diet bedding die ldr in 
(mg.kg-1 diet) 
Exposure Non- Nodular 
time nodular liver 
(weeks) liver tissue 
tissue 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
Significance 
non-nodular 
versus nodu-
lar liver 
tissue 
SSD F 10 
SSD S 10 
CD F 
CD s 
10 
10 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
72.3 
65.6 
62.7 
59.0 
58.7 
57.3 
67.8 
65.8 
65.8 
56.0 
71.4 
63.4 
69.1 
64.0 
73.9 
59.2 
60.5 
63.0 
61.3 
58.1 
63.3 
63.4 
61.2 
65.6 
68.6 
68.7 
60.4 
65.2 
2.2 
- 9.8 
- 3.5 
6.8 
4.4 
1.4 
- 6.6 
- 3.6 
- 7.0 
17.1 
- 3.9 
8.4 
-12.6 
1.9 
Abbreviations as in Table 12 
«KiLions as in xaDie iz . 
P < 0.05; **p < 0.01; n . s . : not significant (p > 0.05). 
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Table 46. Total protein/DNA quotients in non-nodular and nodular liver tissue of diel-
drin-treated CF-1 mice. 
Treatments 
diet bedding dieldrin 
(mg.kg-1 
SSD F 10 
SSD S 10 
CD F 10 
CD S 10 
Abbreviations as in 
1. *p < 0.05; **p < 
Tabli 
0.01 
diet) 
e 12. 
; n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non- Nodular 
nodular liver 
liver 
tissue 
79.8 
74.7 
77.3 
85.1 
81.9 
87.2 
86.3 
73.0 
75.3 
69.0 
93.1 
88.9 
74.1 
85.4 
74.8 
82.8 
103.1 
83.3 
85.7 
81.3 
83.6 
: not significant 
tissue 
90.5 
73.7 
86.5 
84.3 
78.4 
76.8 
78.2 
87.1 
80.2 
65.7 
82.6 
88.1 
84.4 
83.7 
80.7 
83.5 
93.3 
84.2 
87.9 
81.6 
79.4 
(p > 0.05), 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
13.4 
- 1.3 
11.9 
- 0.9 
- 4.3 
-11.9 
- 9.4 
19.3 
6.5 
- 4.8 
-11.3 
- 0.9 
13.9 
- 2.0 
- 7.9 
1.5 
- 9.5 
1.1 
2.6 
0.4 
- 5.0 
• 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 47. Microsomal protein/DNA quotients in non-nodular and nodular liver tissue of 
dieldrin-treated CF-1 mice. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD s 
Abbreviations 
'• *P < 0.05; 
dieldrin 
(mg.kg-1 
10 
10 
10 
10 
as in 
**P< 
Tabl 
0.01 
diet) 
e 12. 
; n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
: not sign 
Non- Nodular 
nodular liver 
liver tissue 
tissue 
34.4 
30.7 
34.8 
37.8 
35.6 
40.2 
34.5 
30.8 
34.0 
32.0 
38.6 
44.1 
35.2 
33.0 
34.2 
35.9 
46.0 
37.5 
41.1 
34.9 
34.0 
ificant 
30.7 
30.2 
32.3 
40.1 
32.4 
32.6 
31.5 
34.6 
34.0 
29.6 
35.4 
29.5 
36.6 
30.8 
37.3 
30.5 
40.7 
39.9 
42.2 
38.6 
36.5 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-10.8 
- 1.6 
- 7.2 
6.1 
- 9.0 
-18.9 
- 8.7 
12.3 
0 
- 7.5 
- 8.3 
-33.1 
4.0 
- 6.7 
9.1 
-15.0 
-11.5 
6.4 
2.7 
10.6 
7.4 
Significance1 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s, 
n.s. 
n.s. 
n.s. 
* 
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Table 48. Soluble protein/DNA quotients in non-nodular and nodular liver tissue of diel-
drin-treated CF-1 mice. 
Treatments 
diet bedding dieldrin 
(mg.kg-1 diet) 
SSD F 10 
SSD S 10 
CD F 
CD S 
10 
10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
26.3 
26.3 
27.3 
25.0 
23.9 
24.4 
22.3 
27.1 
24.6 
23.1 
25.8 
26.6 
26.7 
26.9 
Nodular 
liver 
tissue 
29.9 
23.1 
24.9 
26.1 
28.8 
28.0 
20.8 
26.8 
26.0 
25.0 
28.3 
28.5 
23.5 
26.4 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
13.7 
-12.2 
- 8.8 
4.4 
20.5 
14.8 
- 6.7 
- 1.1 
5.7 
8.2 
9.7 
7.1 
-12.0 
- 1.9 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
Abbreviations as in Table 12. 
1. *p < 0.05; **p < 0.01; n.s.: not significant (p > 0.05). 
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Table 49. p-Nitroanisole O-demethylase specific act ivi ty in non-nodular and nodular l i -
ver tissue of d ie ldr in- t rea ted CF-1 mice. The results are expressed in nmol p-n i t ro-
phenol formed.mg-1 microsomal protein.min - 1 . 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
dieldrin 
(mg.kg-1 
10 
10 
10 
10 
diet) 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
3.94 
5.56 
6.57 
5.52 
4.15 
5.76 
5.10 
5.75 
6.10 
3.59 
3.05 
5.53 
3.09 
5.13 
4.63 
4.38 
3.18 
5.83 
4.11 
5.48 
4.48 
Nodular 
liver 
tissue 
6.76 
7.84 
8.18 
6.65 
5.85 
6.33 
7.00 
7.35 
8.66 
5.13 
5.90 
8.14 
6.32 
8.37 
6.87 
5.57 
6.07 
8.35 
7.39 
8.29 
7.03 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
71.6 
41.0 
24.5 
20.5 
41.0 
9.9 
37.3 
27.8 
42.0 
42.9 
93.4 
47.2 
104.5 
63.2 
48.4 
27.2 
90.9 
43.2 
79.8 
51.3 
56.9 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
* 
n.s. 
* 
n.s. 
** 
n.s. 
** 
Abbreviations as in Table 12. 
1. *p < 0.05; **p < 0.01; n . s . not significant (p > 0.05). 
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Table 50. Epoxide hydratase specific activity in non-nodular and nodular liver tissue 
of dieldrin-treated CF-1 mice. The results are expressed in nmol styrene glycol formed. 
mg"1 microsomal protein.min- . 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in 
**P< 
Table 
0.01; 
12. 
n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
3.22 
3.59 
3.32 
4.94 
4.65 
4.40 
4.30 
5.10 
4.70 
2.64 
3.51 
4.05 
5.56 
2.42 
2.02 
4.70 
4.37 
: not significant 
Nodular 
liver 
tissue 
4.72 
6.09 
5.38 
5.10 
7.73 
6.20 
6.40 
5.80 
5.05 
3.90 
5.76 
6.39 
5.91 
5.14 
4.91 
5.90 
5.55 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
46.6 
69.6 
62.0 
3.2 
66.2 
40.9 
48.8 
13.7 
7.4 
47.7 
64.1 
57.8 
6.3 
112.4 
143.1 
25.5 
27.0 
• 
Significance1 
versus nodu-
lar liver 
tissue. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 51. Glutathione S-epoxide transferase specific activity in non-nodular and nodu-
lar liver t issue of d ie ldr in- t rea ted CF-1 mice. The results are expressed in nmol con-
jugated styrene oxide.mg-* soluble protein.min . 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
'• *P < 0 .05 ; 
die ldr in 
(mg.kg-1 
10 
10 
10 
10 
as in 
**P < 
Tabl 
0.01 
diet) 
e 12. 
; n . s . 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non- Nodular 
nodular liver 
l iver tissue 
t issue 
0.441 
0.682 
0.613 
0.531 
0.755 
0.678 
0.495 
0.656 
0.506 
0.678 
0.773 
0.700 
0.605 
0.612 
: not significant 
0.559 
0.940 
0.790 
0.788 
0.799 
0.834 
0.705 
0.801 
0.619 
0.860 
0.918 
0.831 
0.706 
0.682 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
26.8 
37.8 
28.9 
48.4 
5.8 
23.0 
42.4 
22.1 
22.3 
26.8 
18.8 
18.7 
16.7 
11.4 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
* 
n . s . 
** 
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Table 52. UDP-glucuronyl transferase specific activity in non-nodular and nodular liver 
tissue of dieldrin-treated CF-1 mice. The results are expressed in nmol conjugated p-
nitrophenol.mg-1 microsomal protein.min-1. 
Treatments 
diet bedding dieldrin 
(mg.kg-1 diet) 
SSD F 
SSD S 
CD F 
CD S 
10 
10 
10 
10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
2.68 
1.86 
2.46 
2.10 
2.41 
2.32 
2.15 
2.38 
1.72 
2.19 
1.96 
2.74 
1.94 
2.06 
3.03 
2.88 
2.24 
1.99 
Nodular 
liver 
tissue 
1.40 
2.46 
1.73 
2.36 
2.73 
2.66 
1.55 
1.91 
2.08 
1.88 
2.77 
1.96 
2.68 
2.42 
2.80 
1.72 
1.86 
2.59 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-47.8 
32.3 
-29.7 
12.4 
13.3 
14.7 
-27.9 
-19.7 
20.9 
-14.2 
41.3 
-28.5 
38.1 
17.5 
- 7.6 
-40.3 
-17.0 
30.2 
Significance 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
Abbreviations as in Table 12. 
1. 0.05; p < 0.01; n.s.: not significant (p > 0.05). 
102 
Table 53 . p - N i t r o a n i s o l e O-demethylase a c t i v i t y per u n i t DNA in non-nodular and 
nodular l i v e r t i s s u e of d i e l d r i n - t r e a t e d CF-1 mice. The r e s u l t s a r e expressed i n 
nmol p - n i t r o p h e n o l formed.mg_1 l i v e r DNA.min-1. 
Treatment 
d ie t bedding d i e l d r i n 
(mg.kg - 1 d i e t ) 
SSD F 
SSD S 
CD F 
CD S 
10 
10 
10 
10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
120.9 
193.4 
226.5 
208.4 
147.9 
177.7 
173.4 
231.2 
210.7 
114.9 
117.8 
243.3 
105.7 
180.6 
204.2 
157.3 
144.2 
203.3 
139.9 
205.7 
184.1 
Nodular 
liver 
tissue 
204.4 
253.4 
251.4 
266.8 
189,7 
219.3 
297.7 
251.7 
273.1 
136.4 
208.8 
250.4 
235.8 
306.7 
202.3 
169.7 
247.3 
322.0 
300.9 
330.9 
296.6 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
69.1 
31.0 
11.0 
28.0 
28.3 
23.4 
71.7 
8.9 
29.6 
18.7 
77.2 
2.9 
123.1 
69.8 
- 0.9 
7.9 
71.5 
58.4 
115.1 
60.9 
61.1 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
** 
Abbreviat ions as i n Table 12. . 
1. *p < 0 . 0 5 ; **p < 0 . 0 1 ; n . s . : not s i g n i f i c a n t (p > U .us ; . 
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Table 54. Epoxide hydratase activity per unit DNA in non-nodular and nodular liver 
tissue of dieldrin-treated CF-1 mice. The results are expressed in nmol styrene glycol 
formed.mg"1 liver DNA.min-1. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in 
**p < 
Table 
0.01; 
12. 
n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
111.0 
110.2 
115.5 
186.5 
165.7 
177.0 
148.5 
157.3 
159.8 
84.5 
135.6 
142.5 
183.5 
86.9 
92.2 
163.9 
148.7 
: not significant 
Nodular 
liver 
tissue 
145.0 
184.2 
173.9 
204.6 
250.6 
212.3 
201.8 
201.3 
171.9 
103.7 
203.9 
234.1 
181.8 
156.5 
200.0 
227.5 
202.7 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
30.6 
67.2 
50.6 
9.7 
51.2 
19.9 
35.9 
28.0 
7.6 
22.7 
50.4 
64.3 
- 0.9 
80.1 
116.9 
38.8 
36.3 
. 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
* 
n.s. 
* 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 55. G l u t a t h i o n e S-epoxide t r a n s f e r a s e a c t i v i t y per u n i t DNA in non-nodular and 
nodular l i v e r t i s s u e of d i e l d r i n - t r e a t e d CF-1 mice. The r e s u l t s a r e expressed in 
ymol conjugated s t y r e n e oxide .mg _ 1 l i v e r DNA.min-1. 
Treatments 
d i e t bedding d i e l d r i n 
(mg.kg - 1 d i e t ) 
SSD F 10 
SSD S 10 
CD F 
CD S 
10 
10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
11.6 
18.0 
16.7 
13.3 
18.0 
16.5 
11.0 
17.8 
12.5 
15.7 
19.9 
18.6 
16.1 
16.5 
Nodular 
liver 
tissue 
16.7 
21.7 
19.7 
20.6 
23.0 
21.0 
14.7 
21.4 
16.1 
21.5 
26.0 
23.7 
16.6 
18.0 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
44.0 
20.5 
18.0 
54.9 
27.8 
27.3 
33.6 
20.2 
28.8 
36.9 
30.7 
27.4 
3.1 
9.1 
Significance,1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
Abbreviat ions as i n Table 12. 
1. *p < 0 . 0 5 ; **p < 0 . 0 1 ; n . s . : no t s i g n i f i c a n t (p > 0 .05 ) . 
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Table 56. UDP-glucuronyl transferase activity per unit DNA in non-nodular and nodular 
liver tissue of dieldrin-treated CF-1 mice. The results are expressed in nmol conjugated 
p-nitrophenol.mg-1 liver DNA.min-1. 
Treatments 
diet bedding dieldrin 
(mg.kg l diet) 
SSD F 
SSD S 
CD F 
CD S 
10 
10 
10 
10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
57.1 
85.6 
92.4 
79.3 
66.3 
80.9 
96.9 
80.1 
55.1 
120.6 
66.4 
69.0 
96.6 
74.0 
78.1 
67.7 
113.8 
118.4 
Nodular 
liver 
tissue 
74.4 
55.9 
43.0 
94.7 
53.7 
81.2 
93.5 
93.9 
55.3 
60.3 
91.8 
101.5 
55.4 
73.7 
71.7 
105.5 
111.8 
72.6 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
30.3 
-34.7 
-53.5 
19.4 
19.0 
0.4 
- 3.5 
4.7 
0.4 
-50.0 
38.3 
47.1 
-42.7 
- 0.4 
- 8.2 
55.8 
- 1.8 
-38.7 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
Abbreviations as in Table 12. 
1. *p < 0.05; **p < 0.01; n.s.: not significant (p > 0.05). 
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Table 57. Glucose-6-phosphatase specific activity in non-nodular and nodular liver 
tissue of dieldrin-treated CF-1 mice. The results are expressed in ug at P^.mg-1 
microsomal protein.min-1. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in 
**p < 
Table 
0.01; 
12. 
n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
0.189 
0.249 
0.242 
0.150 
0.157 
0.168 
0.154 
0.164 
0.166 
0.183 
0.156 
0.188 
0.198 
0.221 
0.258 
0.199 
0.186 
0.201 
0.207 
0.212 
0.223 
: not significant 
Nodular 
• liver 
tissue 
0.109 
0.089 
0.083 
0.075 
0.108 
0.102 
0.068 
0.092 
0.067 
0.094 
0.089 
0.091 
0.098 
0.070 
0.094 
0.095 
0.103 
0.078 
0.085 
0.101 
0.078 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-42.3 
-64.3 
-65.7 
-50.0 
-31.2 
-39.3 
-55.8 
-43.9 
-59.6 
-48.6 
-42.9 
-51.6 
-50.5 
-68.3 
-63.6 
-52.3 
-44.6 
-61.2 
-58.9 
-52.4 
-65.0 
• 
Significance1 
versus nodu-
lar liver 
tissue 
* 
n.s. 
** 
n.s. 
** 
n.s. 
** 
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Table 58. Glucose-6-phosphatase activity per unit DNA in non-nodular and nodular liver 
tissue of dieldrin-treated CF-1 mice. The results are expressed in yg at Pj.mg-1 liver 
DNA.min-1. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in 
**p < 
Table 
0.01; 
12. 
n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
6.5 
7.6 
8.4 
5.7 
5.6 
6.7 
5.3 
5.1 
5.6 
5.9 
6.0 
7.3 
8.1 
9.7 
8.8 
7.1 
8.5 
7.5 
8.5 
7.4 
7.6 
: not significant 
Nodular 
liver 
tissue 
3.4 
2.7 
2.7 
3.0 
3.5 
3.5 
2.1 
3.2 
2.8 
2.5 
3.1 
2.7 
3.6 
2.1 
3.5 
2.9 
4.2 
3.1 
3.4 
3.9 
2.9 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-47.7 
-64.5 
-67.9 
-47.4 
-37.5 
-47.8 
-60.4 
-37.3 
-50.0 
-57.6 
-48.3 
-63.0 
-55.6 
-78.4 
-60.2 
-59.2 
-50.6 
-58.7 
-60.0 
-47.3 
-61.8 
• 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
* 
n.s. 
** 
n.s. 
** 
** 
** 
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Table 59. Glutathione concentration in non-nodular and nodular liver tissue of dieldrin-
treated CF-1 mice. The results are expressed in umol.g-1 liver. 
Treatments 
diet bedding dieldrin 
(mg.kg-1 
SSD F 10 
SSD S 10 
CD F 10 
CD S 10 
Abbreviations as in 
1. *p < 0.05; **p < 
Tabl 
0.01 
diet) 
e 12. 
; n.s. 
Exposure 
time 
(weeks) 
68-72 
68-72 
52 
68-72 
68-72 
Kon- Nodular 
nodular liver 
liver tissue 
tissue 
10.5 
11.0 
9.9 
12.8 
10.7 
10.8 
10.1 
10.7 
10.4 
9.1 
10.1 
10.0 
10.2 
9.9 
11.2 
10.0 
: not significant 
5.2 
7.7 
5.5 
6.4 
5.4 
5.4 
5.1 
6.0 
6.7 
7.8 
5.7 
7.0 
5.7 
7.3 
7.0 
6.3 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-50.5 
-30.0 
-44.4 
-50.0 
-49.5 
-50.0 
-49.5 
-43.9 
-35.6 
-14.3 
-43.6 
-30.0 
-44.1 
-26.3 
-37.5 
-37.0 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
* 
** 
* 
** 
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Table 60. Glutathione/DNA quotients in non-nodular and nodular liver tissue of dieldrin-
treated CF-1 mice. The results are expressed in pmol.mg-1 liver DNA. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dield Irin 
(mg.kg l diet) 
10 
10 
10 
10 
as in 
**P< 
Table 
0.01; 
12. 
n.s. 
Exposure 
time 
(weeks) 
68-72 
68-72 
52 
68-72 
68-72 
Non-
nodular 
liver 
tissue 
3.8 
4.0 
3.5 
5.2 
4.2 
4.7 
4.4 
3.5 
4.3 
3.8 
4.0 
3.6 
3.7 
4.2 
4.3 
4.2 
: not significant 
Nodular 
• liver 
tissue 
2.1 
2.7 
2.3 
3.0 
2.8 
3.0 
2.4 
2.0 
2.8 
3.3 
2.5 
2.8 
2.3 
2.9 
2.7 
2.6 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
-44.7 
-32.5 
-34.3 
-42.3 
-33.3 
-36.2 
-45.5 
-42.9 
-34.9 
-13.2 
-37.5 
-22.2 
-37.8 
-31.0 
-37.2 
-38.1 
• 
Significance1 
versus nodu-
lar liver 
tissue 
** 
** 
* 
«* 
110 
Table 61. Dieldrin concentration in non-nodular and nodular liver tissue of dieldrin-
treated CF-1 mice. The results are expressed in ug dieldrin.g_1 liver. 
Treatments 
diet bedding 
SSD F 
SSD S 
CD F 
CD S 
Abbreviations 
1. *p < 0.05; 
dieldrin 
(mg.kg-1 diet) 
10 
10 
10 
10 
as in Table 12. 
**p < 0.01; n.s. 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
10.8 
6.2 
10.0 
8.3 
6.4 
6.3 
5.3 
14.8 
7.6 
9.3 
5.7 
12.7 
6.8 
9.1 
5.3 
9.0 
10.2 
6.8 
14.6 
11.0 
4.8 
: not significant 
Nodular 
liver 
tissue 
10.9 
7.9 
10.5 
11.0 
6.9 
8.7 
7.7 
11.6 
8.2 
9.9 
7.1 
14.6 
8.0 
9.2 
6.1 
6.3 
10.2 
6.9 
11.8 
9.9 
6.2 
(p > 0.05) 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
0.9 
27.4 
5.0 
32.5 
7.8 
38.1 
45.3 
-21.6 
7.9 
6.5 
24.6 
15.0 
17.6 
2.0 
15.1 
-30.0 
0 
1.5 
-19.2 
-10.0 
29.2 
• 
Significance' 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
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Table 62. Dieldrin/DNA quotients in non-nodular and nodular liver tissue of dieldrin-
treated CF-1 mice. The results are expressed in ug dieldrin.mg-1 liver DNA. 
Treatments 
diet bedding dieldrin 
SSD F 
SSD S 
(mg.kg"1 diet) 
10 
10 
CD F 10 
CD S 10 
Exposure 
time 
(weeks) 
68-72 
52 
68-72 
52 
68-72 
52 
68-72 
Non-
nodular 
liver 
tissue 
3.9 
2.3 
3.5 
3.3 
2.4 
2.7 
2.2 
6.0 
3.0 
3.1 
2.4 
5.2 
2.5 
3.6 
1-9 
3.7 
4.4 
2.5 
6.2 
4.2 
2.0 
Nodular 
liver 
tissue 
4.4 
2.7 
4.4 
4.3 
3.1 
3.6 
3.2 
5.4 
4.3 
3.2 
2.8 
6.2 
3.4 
4.1 
2.5 
2.4 
4.4 
2.8 
4.7 
3.8 
2.5 
Percentage 
increase/ 
decrease(-) 
in nodular 
liver tissue 
12.8 
17.4 
25.7 
30.3 
29.2 
33.3 
45.5 
-10.0 
43.3 
3.2 
16.7 
19.2 
36.0 
13.9 
31.6 
-35.1 
0 
12.0 
-24.2 
- 9.5 
25.0 
Significance1 
non-nodular 
versus nodu-
lar liver 
tissue 
n.s. 
n.s. 
n.s. 
n.s. 
* 
n.s. 
n.s. 
Abbreviations as in Table 12. 
1. *p < 0.05; **p < 0.01; n.s.: not significant (p > 0.05). 
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Table 68. Liver tumour incidence1. 
Diet 
Bedding 
SSD 
F 
CD 
F 
Dieldrin (mg.kg-1 diet) 10 10 10 10 
Time 
period 
(weeks) 
0-
65 
66-
90-
92-
0-
65 
90 
92 
110 
110 
Classification 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
X liver tumours 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
% liver tumours 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
X liver tumours 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
Total number of mice 
No. mice with liver 
'A' tumour(s)2 
No. mice with liver 
'B' tumour(s) 
Total liver tumours 
% liver tumours 
3 
0 
0 
0 
15 
2 
0 
2 
13.3 
10 
0 
0 
0 
-
21 
0 
1 
1 
4.8 
6 
0 
0 
0 
55 
2 
1 
3 
5.5 
2 
0 
0 
0 
15 
1 
0 
1 
6.7 
183 
6 
0 
6 
33.3 
11 
4* 
0 
4* 
36.4 
1 
1 
0 
1 
47 
12 
0 
12 
25.5 
5 
0 
0 
0 
15 
7 
4 
i . * * * 
73.3 
6 
1 
I** 
c** 
83.3 
5 
2 
3 
c** 
31 
10 
11 
21 
67.7 
5 
1 
1 
2 
12 
10*** 
2 
1 o # * # 
100 
2 
2** 
0 
2** 
100 
19 
13 
3 
16 
84.2 
8 
0 
0 
0 
15 
0 
0 
0 
-
17 
1 
0 
1 
5.9 
21 
2 
0 
2 
9.5 
7 
1 
0 
1 
68 
4 
0 
4 
5.9 
7 
0 
0 
0 
15 
0 
0 
0 
-
25 
0 
1 
1 
4.0 
29 
5 
0 
5 
17.2 
6 
0 
0 
0 
82 
5 
1 
6 
7.3 
10 
2 
4 
6 
16 
9* 
4 
]3*** 
81.3 
213 
10* 
11** 
21*** 
100 
4 
2 
2 
4** 
51 
23 
21 
44 
86.3 
3 
0 
1 
1 
16 
7 
5* 
1 o^*# 
75.0 
13 
4 
9** 
13*** 
100 
6 
2 
4 
6** 
38 
13 
19 
32 
84.2 
1. Significance of the difference between control (SSD + F + 0 mg dieldrin.kg-1) 
and treatments: *p < 0.05; **p < 0.01; ***p < 0.001. 
2. Animals which also showed type 'B' liver tumours are not included in the 'A' column. 
3. Interim kills were made in this group during this time period. 
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